

ACCESS ICPE ABSTRACTS ON
YOUR MOBILE DEVICE




www.abstracts2view.com/ispe

- Online only Abstract Supplement
- Free WiFi is provided for you to access this tool

Join the conversation
#ICPEtaipei

30th Final Program ICPE

INTERNATIONAL CONFERENCE ON
PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT



OCT 24-27, 2014

TAIPEI INTERNATIONAL CONVENTION CENTER
TAIPEI, TAIWAN

Jointly Sponsored by:



International Society for
Pharmacoepidemiology



Institute of Clinical Pharmacy &
Pharmaceutical Sciences, National
Cheng Kung University



The Pharmaceutical
Society of Taiwan



National Taiwan
University

Board of Directors & Volunteer Leaders

30th ICPE

INTERNATIONAL CONFERENCE ON
PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT

ISPE BOARD OF DIRECTORS

Officers

Til Stürmer, FISPE, *President*
John D Seeger, FISPE, *President-Elect*
Stella Blackburn, FISPE, *Immediate Past President*
Kate Lapane, FISPE, *Vice President Finance*
Alison Bourke, FISPE, *Vice President Finance-Elect*
Mark H Epstein, *Executive Secretary*

Directors

Morten Andersen	Marie Lindquist
Ariel E Arias	June Raine
Rhonda L Bohn, FISPE	Sabine Straus
Jennifer B Christian, FISPE	Suzanne L West, FISPE
Edeltraut Garbe	Wei Zhou
Tobias Gerhard, FISPE	Stanley A Edlavitch, <i>Lifetime Emeritus</i>
Wan-Ting Huang	
Yea-Huei Kao Yang, FISPE	

2014 ICPE SCIENTIFIC PROGRAM COMMITTEE

Soko Setoguchi, FISPE, *Chair*

Core Program Committee

Hisham Aljadhey	Kiyoshi Kubota, FISPE
Morten Andersen	Kate Lapane, FISPE
Frank Andersohn	Frank May, FISPE
Stella Blackburn, FISPE	Yola Moride, FISPE
Gillian Caughey	BJ Park, FISPE
K Arnold Chan, FISPE	Susana Perez-Gutthann, FISPE
Natasha Chen	Lisa Pont
Nam-Kyong Choi	Mary E Ritchey
Jennifer B Christian, FISPE	Patricia Saddier
Corinne de Vries, FISPE	Nancy C Santanello, FISPE
Mark H Epstein	John D Seeger, FISPE
Tobias Gerhard, FISPE	Paul Stang, FISPE
Andrew Gilbert	Michael Steinbach
Partha Gurumurthy	Til Stürmer, FISPE
Jason Hsu	Veronika Wirtz
Krista Huybrechts	Wei Zhou
Andrew Jerdonek	
Yea-Huei Kao Yang, FISPE	

CHAIRS/CO-CHAIRS & LIAISONS

Committees

Archivist..... Hugh Tilson, FISPE
Bylaws & Policies..... Stella Blackburn, FISPE
Frank May, FISPE
Development Susan Oliveria, FISPE
Syd Philips
Education Frank Andersohn
Tobias Gerhard, FISPE
Fellowship & Awards..... Stella Blackburn, FISPE
Finance..... Kate Lapane, FISPE
Global Development..... Kiyoshi Kubota, FISPE
K Arnold Chan, FISPE
Management Oversight Stella Blackburn, FISPE
Membership Vincent Lo Re III, FISPE
Jasmanda Wu
Nominating Stella Blackburn, FISPE
Public Policy & Ethics..... Jesper Hallas, FISPE
Yola Moride, FISPE
Publications & Communications..... Annlouise Assaf, FISPE
Scholarship Frank May, FISPE
Scientific Program (2014) Soko Setoguchi, FISPE
Strategic Planning John D Seeger, FISPE

Councils

Academic..... Irene Petersen
Government/Regulatory..... Gunilla Sjölin-Forsberg
Sabine Straus
Industry/Service Providers Susan Oliveria, FISPE
Student Linda Wijlaars
Jason Guertin

Special Interest Groups

Adherence Robert Gross
Asian Pharmacoepidemiology Network (AsPEN) Kiyoshi Kubota, FISPE
Yea-Huei Kao Yang, FISPE
Benefit Risk Assessment, Communication & Evaluation (BRACE)..... Ken Hornbuckle
Paul Coplan
Peter Mol
Biologics Veronique Kugener
Jane Porter
Comparative Effectiveness Research (CER) Aisling Caffrey
Mary Panaccio
Nicole Gatto
Databases..... Helga Gardarsdottir
David Miller

Volunteer Leaders & Committees

Drug Utilization Research	Lisa Pont Katja Taxis
Medical Device	Michael Steinbuch Michael Matheny
Medicines In Pregnancy	Jennifer Reefius Carol Louik
Molecular Epi/Biomarkers/ Pharmacogenetics	Bruce Carleton Wei Zhou Geoff Liu
Pediatrics	Rachel Sobel Tamar Lasky
Vaccines	Robert Chen, FISPE

Liaisons

CIOMS	Sabine Straus
ENCePP	Yola Moride, FISPE
US FDA	Judy Staffa

Regional Chapters

FarmacoEpiEnRed- Spanish Chapter	Ana Afonso Sandra Lopez Leon Elisa Martin-Merino
Gulf Region	Hisham Aljadhey
Latin America	Carlos E Duran Marcela Jirón Veronika Wirtz

Student Chapters

- ▶ Bloomberg School of Public Health, Center for Drug Safety and Effectiveness (CDSE), Johns Hopkins University
- ▶ College of Pharmacy, University of Cincinnati
- ▶ Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ▶ Harvard School of Public Health
- ▶ Health Outcomes and Pharmacy Practice, The University of Texas at Austin
- ▶ JSS University, Mysore
- ▶ Leslie Dan Faculty of Pharmacy, University of Toronto
- ▶ Pharmaceutical Health Services Research, University of Maryland Baltimore
- ▶ PhD Program for Clinical Pharmacy & Pharmaceutical Sciences, National Cheng Kung University
- ▶ Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- ▶ Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island

2014 LOCAL HOST COMMITTEE

Yea-Huei Kao Yang, FISPE, <i>Chair</i>	Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University
K Arnold Chan, FISPE	Department of Medical Research, National Taiwan University Hospital
I-Shou Chang	National Health Research Institutes, Taiwan
Jing-ding Huang	Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University
Wan-Ting Huang	Centers for Disease Control, Taiwan
Weng-Foung Huang	Institute of Hospital and Health Care Administration, National Yang-Ming University
Jaw Jou Kang	Institute of Toxicology, College of Medicine, National Taiwan University
Fang-Chen Lee	The Pharmaceutical Society of Taiwan
Kueiyu Lee	National Health Research Institutes, Taiwan
Li-Ling Liu	Food and Drug Administration, Ministry of Health and Welfare, Taiwan
Tsuimin Tsai	Taiwan Drug Relief Foundation
Chun-Yu Wang	Taiwan Society of Health-System Pharmacists
Ming-Kung Yeh	Food and Drug Administration, Ministry of Health and Welfare, Taiwan

DEVELOPMENT COMMITTEE

Susan Oliveria, FISPE, <i>Chair</i>	Janet Hardy
Syd Phillips, <i>Co-Chair</i>	Andrew Jerdonek
Dimitri Bennett	Susan Jick
Rhonda L Bohn, FISPE	Kirk Midkiff
Andrzej Czarnecki, FISPE	Jeanne J Nelson
Mark Cziraky	Cynthia O'Malley
Mark H Epstein	Nancy Santanello, FISPE
Nick Everage	Marianne Ulcickas Yood, FISPE
Melissa Fowler	Jasmanda Wu
Joshua Gagne	

ISPE Supporters

ORGANIZATIONAL & INSTITUTIONAL MEMBERS

Pharmaceuticals

- ▶ F. Hoffmann-LaRoche AG
- ▶ GlaxoSmithKline
- ▶ Sanofi-Aventis

Service Providers

- ▶ RTI Health Solutions

Government/Regulatory Agency

- ▶ Department of Epidemiology, Lazio Regional Health Service, Italy

Academic Programs

- ▶ Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health, USA
- ▶ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy, USA

- ▶ Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania, USA
- ▶ Charles University in Prague, Faculty of Pharmacy, Czech Republic
- ▶ Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, USA
- ▶ Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital & Harvard Medical School, USA
- ▶ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University, UK
- ▶ Harvard School of Public Health, USA
- ▶ London School of Hygiene and Tropical Medicine, UK
- ▶ McGill Pharmacoepidemiology Research Unit, McGill University, Canada
- ▶ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- ▶ Russian National Society of Evidence-Based Pharmacotherapy, Russia
- ▶ Rutgers Pharmacoepidemiology
- ▶ Slone Epidemiology Center, Boston University, USA
- ▶ University of Cincinnati, College of Pharmacy, USA
- ▶ University of Rhode Island, USA

ANNUAL CAMPAIGN as of September 22, 2014

The Society expresses its sincere appreciation to the following supporters listed below for their contributions in honor of the 30th Annual Meeting (ICPE).

Jerome Avorn, FISPE
Hsu-Chih Chien
Joshua J Gagne
Jessica Jalbert
Xinyue Liu

Kazeem Ad Oshikoya
Mary E Ritchey
Daniel Weibel
Almut Winterstein, FISPE
Ian Chi K Wong

Fe-Lin Wu
Hui Feng Yun
Wei Zhou

In this Program

30th ICPE Agenda

Thursday, October 23	10
Friday, October 24.....	16
Saturday, October 25	24
Sunday, October 26.....	34
Monday, October 27	44

30th ICPE Posters

Poster Guidelines	52
Poster Session A	53
Poster Session B	62
Poster Session C.....	70

Indexes

Abstract Index	79
Advertisers Index	89

Abstract Reviewers

Heshu Abdullah-Koolmees
Iosief Abraha
John Acquavella
Michael Adena
Syed Rizwanuddin Ahmad, FISPE
Jesse Alderson
M. Sanni Ali
Hisham Aljadhey
Waad Alkathiri
Celline Almeida
Thamir Alshammari
Elizabeth Andrews, FISPE
Eirini Apostolidou
Kwame Appenteng
Alejandro Arana, FISPE
Ariel Arias
Ali Artaman
Darren Ashcroft
Alex Asimwe
Elodie Aubrun
Shahram Bahmanyar
Yan Bai
Swapu Banerjee
Kiran Bapatla
Laurence Baril
Gillian Bartlett-Esqulant
Brian Bateman
Claudia Becker
Dimitri Bennett
Leona Bessonova
Timothy Beukelman
Gouri Shankar Bhattacharyya
Carles Blanch
Michael Blum
Cheryl Blume
William Blumentals
Mariette Boerstael
Rhonda L Bohn, FISPE
Jaclyn Bosco
Nancy Brandenburg
Kimberly Brodovicz
Cheryl Broussard
Emily Brouwer
Johanita Burger
Katsiaryna Bykov
Gloria Caldwell
Ronald Cantrell
Wendy Castillo
Gillian Caughey
Mariadas Gracias Braga Ceccato
Julie Chandler
Chia-Hsuei Chang
Robert Chen, FISPE
Yong Chen
Natasha Chen
Wendy Cheng
Victoria Chia
Nam-Kyong Choi
Jennifer B Christian, FISPE
Christian F Christiansen
Cecilia Chung
Catherine Cohet
Lyn Colvin
Suellen Curkendall
Andrzej Czarnecki, FISPE

Kourtney Davis
Marieke DeBruin
Rachael DiSantostefano
David Dore
Lorena Dos Santos Antola
Susan Dos Reis
Brian Dreyfus
Liubov Drozdova
Cecile Droz-Perroteau
Wenmin Du
Sascha Dublin
Mei Sheng Duh
Stephan Dunning
Tomasz Dyszynski
Stanley Edlavitch
Conference Chair Emeritus
Soha Elmorsy
Gang Fang
Soulmaz Fazelifarsani
Germano Ferreira
Pili Ferrer
Daniel Fife, FISPE
Kristian Filion
Robert Flynn
Annie Fourrier-Reglat
Jessica Franklin
Jon Fryzek
Kari Furu
Genevieve Gabb
Joshua Gagne
David Gagnon
Kunal Gandhi
Alfonso Garcia-Pando
Helga Gardarsdóttir
Christiane Gasse
Stewart Geary
Tobias Gerhard, FISPE
Andrew Gilbert, FISPE
Alicia Gilsenan
Rosa Gini
Cynthia Girman
Gunnar Gislason
Earl Goehring, Jr.
Cheong Hian Goh
Michael Greenberg
Carlos Grijalva
Robert Gross
Luke Grzeskowiak
Line Guenette
Sinem Ezgi Gulmez
Dianlin Guo
Jennifer Guo
Partha Gurumurthy
Lia Gutierrez
Katrina Wilcox Hagberg
Staffan Hagg
Eelko Hak
Gillian Hall, FISPE
Jesper Hallas, FISPE
Christian Hampp
Jian Han
Abraham Hartzema, FISPE
Abdul Haseeb
Kevin Haynes, FISPE
Rohini Hernandez

Sonia Hernandez-Diaz, FISPE
Richard Hill
Jason Hsu
Wan-Ting Huang
Nancy Huang
Krista Huybrechts
Luisa Ibanez
Amalia Issa
Michael Jackson
Karina Jalomo
Ricardo Jimenez
Marcela Jiron
Catherine Johannes
Judith Jones, FISPE
Meghan Jones
Michele Jonsson Funk
Lisa Kalisch Ellett
Aaron Kamaau
Yea-Huei KaoYang, FISPE
James Kaye
Katherine Kelley
Judy Kelly
Michael Kelsch
Myoung Kim
Victor Kiri
Olaf Klungel
Ole Koehler
Oleksii Korzh
Xiuqing Kou
Antonis Kousoulis
Edeltraut Kroeger
Kiyoshi Kubota, FISPE
Natalia Kutishenko
Chao-Lun Lai
Kari S Lankinen
Kate Lapane, FISPE
Tamar Lasky
Jung Lee
Yvonne Lee
Charles Leonard
Mitchell Levine, FISPE
Michael Lewis, FISPE
Lin Li
Hu Li
Nancy Lin
Mei-Shu Lin
Marie Lindquist
Zhiwen Liu
Yanfang Liu
Shusen Liu
Vincent Lo Re, III, FISPE
Luciane Lopes
Sandra Lopez Leon
Jeanne Loughlin
Jennifer Lund
Marina Machado
Isla Mackenzie
Anke-Hilse Maitland-vander Zee
Jacqueline Major
Charles Makin
Edmond Malka
Ronac Mamtani
Andrea Margulis
Sergey Martsevich
Linus Masese

Frank May, FISPE
Annie McNeill
Eric Meadows
Mikhail Menis
Shannon Michels
Kirk Midkiff
Katie Miller
David Miller
Daniel Mines
Allen Mitchell, FISPE
Peter Mol
Yola Moride, FISPE
Kathleen Mortimer
Mohammad Movahedi
Kumar Mukherjee
Jerald Mullersman
Linda Mundy
Erwan Muroles Rouzic
Pavel Napalkov
Jennifer Nelson
Jeanne Nelson
C Ineke Neutel, FISPE
Steve Niemcryk
Niklas Noren
Fredrik Nyberg
Denise Oleske
Catherine Panozzo
Byung-Joo Park, FISPE
Elisabetta Patorno
Jayanton Patumanond
Michael Peng
Susana Perez-Gutthann, FISPE
Payam Peymani
Cynthia Phillips
Simone Pinheiro
Manel Pladevall Vila
Estel Plana Hortonedá
Lisa Pont
Ivan Pradipta
Nicole Pratt
Dima Qato
Scott Quinlan
Adepu Ramesh
Mauricio Ramos-Coss
Jennita Reefhuis
Bishnu Regmi
Adriano Reis
Christel Renoux
Nuria Riera
Mary Beth Ritchey
Elena Rivero, FISPE
Daniel Rosenberg
Elizabeth Roughead
Christianne Roumie
Christopher Rowan
Leo Russo
Katarzyna Sablinska
Susan Sacks, FISPE
Patricia Saddier
Catherine Saltus
Yared Santa-Ana-Tellez
Nancy Santanello, FISPE
Shadi Sarahroodi
Ameet Sarpatwari
Tania Schink

Abstract Reviewers (Cont.)

Niklas Schmedt
Fred Schneiweiss
Martijn Schuemie
Renate Schulze-Rath
Glen Schumock
Harry Seifert
Soko Setoguchi, FISPE
Natalia Shcherbakova
Meredith Smith
Henrik Toft Sorensen
Montserrat Soriano Gabarro
Patrick Souverein
J Michael Sprafka
Gayathri Sridhar
Judy Staffa
Paul Stang, FISPE

Kristina Star
Kathryn Starzyk
Michael Steinman
Monika Stender
Til Stürmer, FISPE
Martina Teichert
Veena Thyagarajan
Jennifer Tjia
Darren Toh
Sylvie Tomczyk
Marie Tournier
Thierry Trenque
Gianluca Trifirò
Ilse Truter
Florence Tubach

Jamal Uddin
Carla Van Bennekom
Patricia van den Bemt
Stephen Van Den Eeden
Lionel Van Holle
Cristina Varas-Lorenzo
Zdravko Vassilev
Helle Wallach Kildemoes
Shirley Wang
Meng-Ting Wang
Liu Wei
Winifred Werther
Suzanne West, FISPE
Bjorn Wettermark
James Wilson

Amanda Wilson
Lesley Wise
Jasmanda Hsiao-Hui Wu
Chuntao Wu
Wanning Xu
Fei Xue
Wai Ping Yau
Xiaofei Ye
Melissa Yong
Zhong Yuan
Emre Yucel
Jie Zhang
Wei Zhou



SAVE THE DATES

ISPE 2015 Mid-Year Meeting

April 12-14, 2015

in conjunction with the

5th Bordeaux

Pharmacoepi Festival

April 14-16, 2015

Bordeaux, France

Student abstracts for oral presentation at the ISPE Mid-Year Meeting will be solicited and scholarships will be provided to individuals whose abstracts are accepted. **Deadline: November 14, 2014.**

Visit pharmacoepi.org for updated symposium details. You may also contact ISPE at +1.301.718.6500 or ISPE@paimgmt.com.

2016 Meetings

ISPE Mid-Year Meeting

- April 10-12, 2016
Royal Sonesta Harbor Court Baltimore
Baltimore, Maryland

32nd ICPE

- August 25-28, 2016
The Convention Center Dublin
Dublin, Ireland

ICPE Exhibitors & Supporters

ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped the Society enhance the scientific program content and increase attendance at the 30th ICPE.

MERCI *Thank you* DANKE *igracias* TACK
謝謝 감사합니다 ありがとう

EXHIBITORS

- ▶ Analysis Group
- ▶ Anolinx LLC
- ▶ Boehringer Ingelheim GmbH
- ▶ Clinical Practice Research Datalink
- ▶ Degge Group and DGI, LLC
- ▶ Eu2P Programme
- ▶ IMS Health GmbH & Co OHG
- ▶ IPSOS Healthcare
- ▶ Japan Medical Data Center
- ▶ Kantar Health
- ▶ Medical Data Vision Co., Ltd.
- ▶ Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.
- ▶ National Taiwan University Health Data Research Center
- ▶ Optum
- ▶ Quintiles
- ▶ RTI Health Solutions
- ▶ Springer-Verlag GmbH
- ▶ Truven Health Analytics
- ▶ Uppsala Monitoring Centre

ACADEMIC SUPPORTERS

- ▶ Department of Pharmaceutical Outcomes and Policy, University of Florida
- ▶ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University, UK
- ▶ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ▶ Rutgers Pharmacoepidemiology
- ▶ University of Illinois at Chicago

BADGES

All attendees at the 2014 ICPE must wear their badges to all events. A badge will be needed for admission to a conference-related function, such as the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and Gala Dinner. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., guests.

Badge Legend ■ Student ■ New Member ■ One-Day Admission

ANNUAL MEETING SPONSORS

Titanium

- ▶ Ministry of Science and Technology, Taiwan
- ▶ Bureau of Foreign Trade, Taiwan Ministry of Economic Affairs

Platinum

- ▶ National Health Research Institutes, Taiwan
- ▶ The Pharmaceutical Society of Taiwan
- ▶ Taiwan Food and Drug Administration
- ▶ Wiley Publications

Gold

- ▶ Amgen
- ▶ Anolinx
- ▶ Bayer HealthCare
- ▶ Boehringer Ingelheim GmbH
- ▶ Clinical Practice Research Datalink
- ▶ Degge Group and DGI, LLC
- ▶ IMS Health
- ▶ Kantar Health
- ▶ Medical Data Vision Co., Ltd.
- ▶ Merck & Co., Inc., Whitehouse Station, NJ, USA
- ▶ Optum
- ▶ Pfizer
- ▶ Quintiles
- ▶ RTI Health Solutions
- ▶ Takeda
- ▶ Truven Health Analytics

Silver

- ▶ Biogen Idec
- ▶ Celgene
- ▶ Department of Information and Tourism, Taipei City Government
- ▶ Eli Lilly and Company
- ▶ Procter & Gamble

Bronze

- ▶ CSD THIN–Medical Research
- ▶ HealthCore Inc.
- ▶ Ipsos Healthcare
- ▶ UBC
- ▶ Uppsala Monitoring Centre

as of September 22, 2014

Meeting At-A-Glance

THURSDAY, OCTOBER 23, 2014

* Banquet Hall, Plenary Hall, South Lounge, and North Lounge are on the 3rd Floor.

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:30am - 6:00pm Registration Open Main Entrance Lobby												
7:45am - 5:00pm Speakers' Ready Room 105												
8:30am - 12:30pm Educational Sessions Intro. to Pharmacoepidemiology (Chinese) 101A Intro. to Drug Utilization (Chinese) 101C Pharmacogenetics (1) – Introduction 101D Practical Skills in Protocol Writing & Computer Programming 101B Intro. to Pharmacoepidemiology 201ABC					12:30 - 2:00pm Lunch on Your Own		2:00 - 6:00pm Educational Sessions Practical Skills in Protocol Writing & Computer Programming (Chinese) 101A Intermediate Pharmacoepidemiology 201ABC Pharmacogenetics (2) – Intermediate 101D Pharmacovigilance 101C Intro. to Drug Utilization Research 101B			6:30pm - ? Students/Young Professionals Meet & Greet Meet at Southern Entrance of TICC at 6:20pm		
9:00am - 5:00pm ISPE Board of Directors Meeting 401												

FRIDAY, OCTOBER 24, 2014

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:30am - 6:00pm Registration Open Main Entrance Lobby												
7:30am - 5:00pm Speakers' Ready Room 105												
8:30am - 12:30pm Educational Sessions General/Asian Databases 201D Registry/Prospective Cohort 201E Comparative Effectiveness Research 201ABC Device Epidemiology 201E					12:30 - 2:00pm Lunch on Your Own		2:00 - 6:00pm Educational Sessions Advanced Topics in Pharmacoepidemiology 201ABC Advanced Topics in Drug Utilization Research 201D Non-Database Pharmacoepidemiology 201F Advanced Topics in Pharmacoepidemiology (Chinese) 201E Pharmacovigilance (Chinese) 103			6:00 - 7:30pm Welcome Reception Academic/ International Chapter Showcase Banquet Hall*		

SATURDAY, OCTOBER 25, 2014

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm							
7:00am - 6:00pm Registration Open Main Entrance Lobby			10:00-10:30am Break/ Posters/ Exhibits 101/Main Entrance Lobby		12:15-1:15pm Spotlight Poster Sessions 101		3:00-3:30pm Break/ Posters/ Exhibits 101/ Main Entrance Lobby			6:30 - 7:30pm Special Interest Groups (SIGs)									
7:00am - 5:00pm Speakers' Ready Room 105			10:30am - Noon Concurrent Sessions All About Statins 201BC Biologics Bouillabaisse 201AF Continuing the Discussion on Antipsychotic Safety 201DE Improving Strength and Balance 4 th Floor VIP The Good, the Bad, and the Ugly of Anti-Infectives 103 Women's Health 102		Noon - 1:30pm Lunch/ Poster Session A/ Roundtable Discussions Banquet Hall* ISPE Committee/ Council Meetings Development South Lounge, 3 rd Fl. Fellowship & Awards South Lounge, 3 rd Fl. Finance South Lounge, 3 rd Fl. Public Policy South Lounge, 3 rd Fl. Student Council North Lounge, 3 rd Fl.		1:30 - 3:00pm Concurrent Sessions Antibiotics and Other Exposures in Pregnancy 102 Cancer Care Continuum 201DE CER and Safety in CV TX/Care 201BC Pseudorandom Exposures 4 th Floor VIP Understanding Antidepressant Use and Safety 103 Watch Closely 201AF			3:30 - 5:00pm Plenary Session Plenary Hall, 3 rd Floor <i>Development in Pharmaco-epidemiological Methods: Current Status and Future Direction</i>		5:00 - 6:30pm Symposia & Workshops A Guide to Guidelines 201DE Academic Detailing 103 Biospecimens From Asia in Pharmacoepi. Research 4 th Floor VIP Challenges in Risk Minimization Evaluation 102 Gender Differences in Pharmacoepi. 201BC Impact of Methodological Choices on Findings from Pharm. Studies Plenary Hall, 3 rd Fl.) The New ISPE Vaccine Special Interest Group 201AF		6:00 - 7:30pm Adherence 201DE AsPEN 201BC Biologics Elegance Lounge BRACE 102 Comparative Effectiveness Research North Lounge* Databases 103 Drug Utilization/ HSR 4 th Floor VIP Medical Devices Elegance Lounge Medications in Pregnancy 201AF Molecular Epi. South Lounge* Pediatrics Elegance Lounge Vaccines Elegance Lounge		7:30 - 9:00pm PDS Editorial Board (By invitation) 202		7:30pm - ? Students/Young Professionals Night Out --SOLD OUT	
7:00-8:00am Poster Session A Set-Up 101/Main Entrance Lobby		8:00am - 6:00pm Exhibits/Posters 101/Main Entrance Lobby 8:00 - 8:30am Welcome Plenary Hall, 3 rd Floor Soko Setoguchi Yea-Huei Kao Yang Til Stürmer		8:30 - 10:00am Keynote Session Plenary Hall, 3 rd Floor <i>Pharmacoepidemiology--The Next 30 Years</i>															

Meeting At-A-Glance

SUNDAY, OCTOBER 26, 2014

* Banquet Hall, Plenary Hall, South Lounge, and North Lounge are on the 3rd Floor.

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 6:00pm Registration Open Main Entrance Lobby												
7:00am - 5:00pm Speakers' Ready Room 105												
7:00-8:00am Poster Session B Set-Up 101/Main Entrance Lobby	8:00am - 6:00pm Exhibits/Posters 101/Main Entrance Lobby			11:45am-12:45pm Spotlight Poster Sessions 101		4:00-4:30pm Break/Posters/Exhibits 101/Main Entrance Lobby			4:30 - 6:00pm Symposia & Workshops		6:00 - 7:00pm Council Meetings	
	8:00 - 9:30am Concurrent Sessions		10:00 - 11:30am Concurrent Sessions		11:30am- 1:00pm Lunch/ Poster Session B/ Roundtable Discussions Banquet Hall*		1:00 - 2:30pm Plenary Session Plenary Hall, 3 rd Floor <i>Using Patient-Centered Information in Pharmacoepidemiology: A Global Perspective</i>		2:30 - 4:00pm Annual Meeting of ISPE Members & Awards Ceremony Plenary Hall*		7:30 - 10:30pm Gala Dinner at the Grand Hotel* Buses will shuttle between TICC and the Grand Hotel.	
	Antidepressants During Pregnancy and Diverse Outcomes 103		Diverse Topics in Pediatric Populations 103		ISPE Committee Meetings				Adherence to Drug Treatment: A Practical Look at Complex Measurement Issues 201DE		Academic 201DE	
	Diabetes and Cancers: The Double Whammy 201BC		Don't Go Breaking My Heart 201BC		Bylaws and Policies Banquet Hall*				Databases in China: Are We Ready Yet? 201AF		Government/Regulatory 201AF	
	Equity, Elderly & Ecclecticism 201AF		How Sick We Are 102		Education South Lounge, 3 rd Fl.				Challenges in Implementing Findings of Regulatory Science 103		Industry/Service Provider 201BC	
	How Thin Is Your Blood 201DE		Not All Diabetes Are Alike: Issues of Diagnosis 201DE		Global Development North Lounge, 3 rd Fl.				Guidelines and Recommendations for Comparative Effectiveness Research (CER) Methods Plenary Hall			
	Sticks and Stones May Break My Bones 102		PS or What???		Membership South Lounge, 3 rd Fl.				Leveraging Electronic Health Data For Medical Device Epidemiology 102			
	Well Adjusted by Design 4 th Floor VIP		To Use or Not to Use Psychotropic Medications 201AF		Publications South Lounge, 3 rd Fl.				Primary Data Collection in Pharmacoepi. 201BC			
									Tracking Adverse Drug Reactions in Social Media 4 th Floor VIP			

MONDAY, OCTOBER 27, 2014

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 4:00pm Registration Open Main Entrance Lobby												
7:00am - 3:30pm Speakers' Ready Room 105												
7:00-8:00am Poster Session C Set-Up 101/Main Entrance Lobby	8:00am - 1:45pm Exhibits/Posters 101/Main Entrance Lobby			10:30am - Noon Symposia & Workshops		12:15-1:15pm Spotlight Poster Sessions 101			3:15 - 4:45pm Symposia & Workshops		4:45 - 5:30pm The Final Word:	
	8:30 - 10:00am Concurrent Sessions		Comparative and Clinical Effectiveness Studies 201BC		1:30 - 3:00pm Concurrent Sessions		3:00-3:15pm Break		The Common Data Model: 201DE		• Poster Walk Awards	
	Kids Up and Down and All Around 103		Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharm. 402		From Epilepsy to Dementia 201BC				Comparisons in Pharmacoepi: 4 th Floor VIP		• 2015 Meetings	
	On or Off Course 201BC		Drugs and Devices 201DE		Gain on Pain 201AF				How to Bridge the Gap Between Requirements of Regulatory Health Technology Assessment Authorities for Post Authorization Studies? 103		Adjournment 4 th Floor VIP	
	Steroids With a Twist! 201DE		HOT, HOT, HOT, Getting HOTTER? Climate Change and Pharmacoepi. 102		Probably a Good Link 201DE				Multi-National Pharmacoepi. Studies in Asia 201BC			
	Strings Making Sense (SMS) Harvesting Data 201AF		How Do We Overcome Challenges of Diverse Views in Multi-Disciplinary Collaboration on CER? 4 th Floor VIP		The Answer Is Not Clear 4 th Floor VIP				Special Issues in Pharmacovigilance in Emerging Countries Elegance Lounge			
	Translating Policy into Practice 102		Improving the Science of Regulatory Decision-Making 201AF		World War V: Vaccines and Viruses 102				The Patients' Voice in the Heart of BRACE 201AF			
	Treatment of Diabetes: Is It Safe Enough? 4 th Floor VIP		International Collaboration on Pharmacogenomics in Epidemiology Research 103		For Better or for Worse 103				Using Pharmaceutical Data for Evaluating Medicines Policy and Informing Quality Use of Medicines 102			

7:30am–6:00pm

Registration
(Main Entrance
Lobby)

7:45am–5:00pm

**Speakers’
Ready Room**
(105)

9:00–5:00pm

**ISPE Board of
Directors Meeting**
(401)

(Open to ISPE members;
notify ISPE staff if you
would like to attend.)

PRE-CONFERENCE EDUCATIONAL SESSIONS *(Registration required)*

8:30am–12:30pm

Introduction to Pharmacoepidemiology (Chinese) (101A)

Content

- To introduce the basic concepts of cohort study in the field of pharmacoepidemiology, including study design, structure and statistical analysis. A brief introduction of time-dependent variables and propensity score is also included.
- To introduce the basic concepts of case-control studies in the field of pharmacoepidemiology, including study design, structure and statistical analysis. Some empirical studies will be included.
- Introduction of confounding and bias and how to address them in cohort studies.
- To introduce the type of confounding and bias in case-control studies such as selection bias, information bias and measurement bias. Additionally, give some examples to introduce how to deal with confounding and bias in case-control studies.

Educational Objectives

- To understand the concepts and design of two frequently adopted study designs in the field of pharmacoepidemiology: cohort and case-control study.

- To understand the concept of confounding and bias and the methods to avoid confounding and bias in cohort studies.
- To understand what kind of confounding and bias need to be dealt with in case-control studies.

Course Faculty/Presentations

Tzu-Chieh (Jay) Lin, Institute of Pharmacy and Pharmaceutical Science, National Cheng Kung University, *Cohort Studies*

Fei-Yuan (Sharon) Hsiao, Graduate Institute of Clinical Pharmacy, National Taiwan University, *Case-Control Studies*

Chi-Chuan (Emma) Wang, School of Pharmacy, National Taiwan University, *Confounding and Bias in Cohort Studies*

Ching-Lan (Rebecca) Cheng, Institute of Pharmacy and Pharmaceutical Science, National Cheng Kung University, *Confounding and Bias in Case-control Studies*

Introduction to Drug Utilization Research (Chinese) (101C)

Content

- The educational session consists of presentations providing an overview of drug utilization research and presenting essential methods.
- The theoretical framework will be described and the practical application of different methods will be illustrated using selected examples.
- Interpretation of study results taking into account limitations of data sources and methods will be addressed.
- Additional perspectives covered are the importance of drug utilization research for public health and implications for policy decisions.
- Interaction with participants will be encouraged; e.g., by presenting short questions to be considered by the audience, and by giving time for questions and answers during and at the end of presentations.

Educational Objectives

- To provide an overview of drug utilization research within the context of pharmacoepidemiology, health services research and public health.
- To describe fundamental principles for classifying and quantifying drug use and to provide an understanding of the methodological challenges.
- To motivate researchers to cooperate on the collection of a minimum dataset of consistent and reliable data in their country or region, in terms

- of volume, expenditures and quality of drug use, facilitating international cross-national comparisons.
- To give an applied overview of methods useful for evaluating interventions, in particular in drug policy research.

Course Faculty/Presentations

Wei Zhou, Merck Research Laboratories & Guest Professor, Xiamen University, *Introduction and Overview of Drug Utilization Research*

Yong Chen, Merck Research Laboratories, Merck & Co., Inc., *Data Analytics and Observational Methods*

Chung-Hsuan Wu, Department of Pharmacy, Taipei Medical University, *Quantitative Research Methods for Individual Based Drug Use Pattern and Medication Adherence Research*

Jason C Hsu, Department of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, *Using Pharmaceutical Policy and Regulatory Science Methods for Drug Utilization Research*

PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30am–12:30pm

Pharmacogenetics (1) - Introduction (101D)

Content

This highly interactive course is intended to involve participants in:

- A dynamic didactic experience of the foundational principles of pharmacogenomics.
- An appreciation for the different methods used in pharmacogenomics research.
- Examination of real world examples of pharmacogenomic epidemiology.
- Application of methodology to designing pharmacogenomic epidemiology studies.
- Interpretation of the data found in the pharmacogenomic epidemiology literature, and understanding wider implications of the results.

Educational Objectives

- To understand the genetic and pharmacogenomic terminology and how cellular and molecular biology informs pharmacogenomic studies at the level of analysis.
- To better understand the study design and methodologic approaches, their strengths and weakness used in pharmacogenomic epidemiology.
- To understand the latest statistical approaches used in pharmacogenomics studies.
- To understand the role that pharmacogenomics can play in pharmacovigilance.
- To understand how pharmacogenomics relates to the current focus of personalized medicine.
- To have an overview of clinical utility of pharmacogenomics and associated regulatory issues as well as policy-relevant research, including policy and ethics relevant to the Asia-Pacific region.

Course Faculty/Presentations

Geoffrey Liu, University of Toronto, *The Convergence of Pharmacoepidemiology and Pharmacogenomics and Analytical Issues involving genetics using the GWAS study design*

David Pulford, GSK, *Overview of Pharmacogenomics and Methods*

Bruce Carleton, University of British Columbia and Canadian Pharmacogenomics Network for Drug Safety, *Challenges and Opportunities of Pharmacogenomics in Drug Risk Assessment*



Kantar Health provides a broad range of epidemiology information and custom analysis.

Our multi-client epidemiology offers span multiple geographies for a wide variety of indications.

CancerMPact® Patient Metrics: 30+ tumors across 7 countries, plus coverage of 10 tumors in expanded markets

Epi Database®: up to 190 indications across 13 countries

National Health and Wellness Survey: 165 indications across 10 countries, including new data for 2013



ZEG Berlin (Center for Epidemiology and Health Research), a Kantar Health company, provides expertise in pharmacoepidemiology with a focus on drug safety and risk management and minimization. ZEG specializes in large multinational observational/active surveillance studies.

If you would like us to act as catalysts for you, contact us at www.kantarhealth.com/contactus.

www.kantarhealth.com

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

8:30am –12:30pm

Practical Skills in Protocol Writing and Computer Programming (101B)

Content

Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when executing the studies. This highly interactive course will engage participants in the following topics:

1. Pre-specifying study components in a protocol, including design, analysis, conduct, and reporting of the study, along with a science-based rationale for the choices pertaining to these components.
2. Translating elements of the study protocol into SAS programming.

Educational Objectives

- To introduce a framework for translating study questions into a clear and detailed protocol supported by a rational thought process that is tailored to available data for pharmacoepidemiologic studies using electronic healthcare data.
- To execute the protocols of pharmacoepidemiologic studies into SAS programming.
- To develop the skills to document and report pharmacoepidemiologic studies using electronic healthcare data in a transparent and reproducible way.

Course Faculty/Presentations

Chih-Ying (Natasha) Chen, *Comparator Selection, Power and Feasibility of the Study, Analytical Plans and Handling of Confounders and Effect Modifications*
Christian Hampp, *Study Design, Data Sources Selection, Inclusion/Exclusion Criteria of Study Population*
Jessica Jalbert, Weill Cornell Medical College, *Exposure Definition and Ascertainment, Outcome Definition, Ascertainment and Validity*
Nicole Pratt, University of South Australia, *From Protocol to SAS Programming*
Soko Setoguchi, FISPE, Duke Clinical Research Institute, *From Protocol to SAS Programming*

Introduction to Pharmacoepidemiology (201ABC)

Content

This half-day course will provide participants with a short introduction to the basic principles and concepts of pharmacoepidemiology. The course includes lectures on cohort studies, case-control studies and bias & confounding.

Educational Objectives

- Explain common study designs used in pharmacoepidemiology and appreciate their strengths and weaknesses.
- Describe the key steps in the design and analysis of cohort and case-control studies
- Understand major types of biases that threaten the validity of pharmacoepidemiologic research (confounding, selection bias, measurement bias).

Course Faculty/Presentations

Almut Winterstein, FISPE, University of Florida, *Cohort Studies*
Sonia Hernández-Díaz, FISPE, Harvard School of Public Health, *Case-Control Studies*
Tobias Gerhard, FISPE, Rutgers University, *Bias & Confounding*

12:30–2:00pm

Lunch on Your Own

2:00–6:00pm

Practical Skills in Protocol Writing and Computer Programming (Chinese) (101A)

Content

Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when executing the studies. This highly interactive course will engage participants in the following topics:

- Pre-specifying study components in a protocol, including design, analysis, conduct, and reporting of the study, along with a science-based rationale for the choices pertaining to these components.
- Translating elements of the study protocol into SAS programming.

Educational Objectives

- To introduce a framework for translating study questions into a clear and detailed protocol supported by a rational thought process that is tailored to available data for pharmacoepidemiologic studies using electronic healthcare data.
- To execute the protocols of pharmacoepidemiologic studies into SAS programming.
- To develop the skills to document and report pharmacoepidemiologic studies using electronic healthcare data in a transparent and reproducible way.

Course Faculty/Presentations

Yaa-Hui Dong, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital
Chien-Ning Hsu, Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital and School of Pharmacy, Kaohsiung Medical University
Fang-Ju Lin, Pharmerit International
Yi-Hsin Yang, School of Pharmacy, Kaohsiung Medical University
Chih-Ying Chen



**Improve your
probability
*of success***

**Superior
delivery**

**Connecting
insights**

**Better
outcomes**

Contact us

US Direct: +1 973 850 7571

www.quintiles.com

RWLPR@quintiles.com

Real-world insights are driving healthcare decisions on safety, efficacy, effectiveness and value. To develop the evidence you need to satisfy diverse stakeholders, start by integrating therapeutic expertise, real-world data and powerful analytics technology. Harness post-approval research to maximize value, contain costs and drive better outcomes.

Learn how at www.quintiles.com/RWLPR

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

2:00–6:00pm

Intermediate Pharmacoepidemiology (201ABC)

Content

Covariates that may confound or modify a result are often poorly measured or not measured at all. The result is pharmacoepidemiologic studies that seem to contradict one another. Most critiques of observational research rest on unmeasured covariates. This course will classify the options for dealing with unmeasured covariates in study design and analysis, and present examples of self-controlled case series and matched designs, propensity-balancing and proxy-variable designs, and instrumental variable analyses.

Educational Objectives:

- Recognize when missing covariate data threatens the inferences from an observational study.
- Know study designs and analytic strategies that reduce distortions due to missing covariates.

- Develop an intellectual framework for understanding novel problems that involving missing covariates.

Course Faculty/Presentations

Alexander M Walker, FISPE, World Health Information Science Consultants

- *Confounding by Indication as a Motivating Example of Missing Covariates*
- *Self-Controlled Case Series and Matching*
- *Propensity Scores as a Technique for Controlling for Confounder Through Proxy Measures*
- *Instrumental Variables*

Pharmacogenetics (2) – Intermediate (101D)

Content

This highly interactive course is intended to involve participants in:

- A dynamic didactic experience of the foundational principles of pharmacogenomics.
- An appreciation for the different methods used in pharmacogenomics research.
- Examination of real world examples of pharmacogenomic epidemiology.
- Application of methodology to designing pharmacogenomic epidemiology studies.
- Interpretation of the data found in the pharmacogenomic epidemiology literature, and understanding wider implications of the results.

Educational Objectives:

- To understand the genetic and pharmacogenomic terminology and how cellular and molecular biology informs pharmacogenomic studies at the level of analysis.
- To better understand the study design and methodologic approaches, their strengths and weakness used in pharmacogenomic epidemiology.
- To understand the latest statistical approaches used in pharmacogenomics studies.
- To understand the role that pharmacogenomics can play in pharmacovigilance.
- To understand how pharmacogenomics relates to the current focus of personalized medicine.

- To have an overview of clinical utility of pharmacogenomics and associated regulatory issues as well as policy-relevant research, including policy and ethics relevant to the Asia-Pacific region.

Course Faculty/Presentations

Wei Zhou, Merck Research Laboratories, *Data Sources and Biobanks in the Asia-Pacific Region*

Rayjean Hung, Mount Sinai Lunenfeld Research Institute, *High Dimensionality Methods in Genomic Analyses*

Paul Boutros, Ontario Institute for Cancer Research, *Bioinformatics: A Tool for Pharmacogenetics and Pharmacoepidemiology*

Amalia M Issa, University of the Sciences, *Pharmacogenomic Health Policy in the Asian Context*

Daniel Fu-Chang Tsai, National Taiwan University College of Medicine, *Pharmacogenomic Health Policy in the Asian Context*

Pharmacovigilance (101C)

Content

This half-day course will introduce participants to the principles of surveillance in pharmacovigilance with a focus on quantitative aspects. The course will cover classical pharmacovigilance signal detection using spontaneous adverse event reports, quantitative signal detection methods for electronic medical record and claims data, and international initiatives, including the EU-ADR project, and the US FDA's Mini-Sentinel program, aimed at using routinely collected electronic healthcare data to conduct signal detection and prospective medical product safety monitoring. The course will involve lectures with ample opportunities for questions and discussion.

Educational Objectives:

Upon completing this course, participants will be able to:

- Explain the need for pharmacovigilance and its component activities with a focus on safety surveillance.
- Describe the potential data sources (e.g., spontaneous reports, claims, electronic medical records, etc.) for safety surveillance in pharmacovigilance.
- Understand the array of basic analytic methods for pharmacovigilance in spontaneous adverse events reports and signal detection and active monitoring in electronic healthcare databases.

- Recognize the limitations of each data source and approach and how they complement each other.

Course Faculty/Presentations

Ian Wong, The University of Hong Kong, *Introduction to Pharmacovigilance and Spontaneous Adverse Event Reporting*

Andrew Bate, Pfizer Ltd, UK, *Multiple Data Streams for Safety Surveillance: Leveraging Real World Data Sources*

Gianluca Trifirò, Erasmus University Medical Center & University of Messina, Italy, *Electronic Medical Records and Claims Data for Drug Safety Signal Detection: Lessons Learned from the EU-ADR Project*

Joshua Gagne, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, *Semi-Automated, Distributed, Prospective Medical Product Safety Monitoring*

AGENDA Thursday, October 23

2:00–6:00pm

Introduction to Drug Utilization Research (101B)

Content

- The educational session consists of presentations providing an overview of drug utilization research and presenting essential methods.
- The theoretical framework will be described and the practical application of different methods will be illustrated using selected examples.
- Interpretation of study results taking into account limitations of data sources and methods will be addressed.
- Additional perspectives covered are the importance of drug utilization research for public health and implications for policy decisions.
- Interaction with participants will be encouraged, e.g. by presenting short questions to be considered by the audience, and by giving time for questions and answers during and at the end of presentations.

Educational Objectives:

- To provide an overview of Drug Utilization Research within the context of Pharmacoepidemiology, Health Services Research and Public Health.
- To describe fundamental principles for classifying and quantifying drug use and to provide an understanding of the methodological challenges.

- To motivate researchers to cooperate on the collection of a minimum dataset of consistent and reliable data in their country or region, in terms of volume, expenditures and quality of drug use, facilitating international cross-national comparisons.
- To explain the process of developing and validating prescribing quality indicator.
- To give an applied overview of methods useful for evaluating interventions, in particular in drug policy research (time series analysis).

Course Faculty/Presentations

Lisa Pont, The University of Sydney, *Drug Utilization Research*
Hege Salveson, Blix, *ATC/DDD: Introductory Methods*
Morton Andersen, *Implementation Research*
Andrew Gilbert

6:30pm

Student/Young Professionals Meet and Greet

Open to all Students
and Young Professionals

- Students can meet at the Southern Entrance of TICC at 6:20pm to arrange transportation and ride-share.

Value through Innovation



Even with more than 129 years of experience, we remain intensely curious. For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company, today operating with 142 affiliates. Research is our driving force. And we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. With more than 47,428 employees worldwide and a track record built up in more than 129 years, we are continuously dedicated to improving the outlook for a healthier life.

Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com



PRE-CONFERENCE EDUCATIONAL SESSIONS *(Registration required)*

7:30am–6:00pm

Registration
(Main Entrance
Lobby)

7:30am–5:00pm

**Speakers’
Ready Room**
(105)

8:30am–12:30pm

General/Asian Databases (201D)

Content

This highly interactive workshop will involve participants in the following topics:

- Examine the use of database resources in pharmacoepidemiology research.
- Define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource, workshop will strengthen the concepts discussed through participant interaction.
- Review the details of data resources available within Asia.
- Develop the skills to validate outcome measures in pharmacoepidemiology resources.
- Discuss privacy and confidentiality concerns within data resources.

Educational Objectives

- To review the Guidelines for Good Database Selection and use in Pharmacoepidemiology Research.

- To gain an understanding of available pharmacoepidemiology resources with a focus on Asian data resources.
- To develop the skills to select an appropriate resource to conduct pharmacoepidemiology research.
- To learn techniques to identify a study population and validate outcome measures.
- To examine privacy and confidentiality concerns.

Course Faculty/Presentations

Gillian Hall, FISPE, *Overview of Database Use in Pharmacoepidemiology*

Kiyoshi Kubota, FISPE, University of Tokyo, *Asian Data Resources*

Kevin Haynes, FISPE, HealthCore Inc., *Selection of Databases for Pharmacoepidemiology Research*

Brian Sauer, University of Utah, *Privacy and Confidentiality*

Vincent Lo Re III, FISPE, Perelman School of Medicine, University of Pennsylvania, *Validation of Outcomes*

Registry/Prospective Cohort (201E)

Content

Designing studies to meet various stakeholder needs, including multi-purpose registries; practical considerations & challenges including collecting data from clinicians and direct-to-patient, informed consent, adverse event reporting, expectations with regard to missing data; intro to network building.

Educational Objectives

- A pregnancy registry is a non-randomized prospective cohort of women exposed to a biopharmaceutical product who are enrolled early in gestation and followed throughout pregnancy or longer.
- The frequency of maternal and infant outcomes among exposed is compared with that among a reference group.
- A valid reference group needs to have comparable gestational age at enrollment and time of follow up, outcome definition and ascertainment methods, and distribution of baseline risk factors.

- The objective of this talk is to describe distinctive methodological aspects of pregnancy registries including delayed entry, missing data, selection of comparison groups and statistical power.
- The impact of these methodological issues on the interpretation of registry findings will be discussed using real examples.

Course Faculty/Presentations

Nancy A Dreyer, Quintiles Real-World & Late Phase Research, *Registries for Safety, Effectiveness & Value: Designing Practical Studies Fit for Purpose; and Assuring Quality*

Sonia Hernandez-Diaz, Pharmacoepidemiology Program, Department of Epidemiology, Harvard School of Public Health, *Pregnancy Registries: Methodological Points and Real-World Examples*

Saad Shakir and Deborah Layton, Drug Safety Research Unit, Portsmouth University, *Interactive Group Session about Risk Management*

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

8:30am–12:30pm

Comparative Effectiveness Research: Methodologic Challenges of Newly Marketed Medical Products (201ABC)

This course explains the methodologic challenges of conducting comparative effectiveness studies for newly marketed medical products. The faculty will describe potential biases in observational research that are particularly salient when comparing the effectiveness of new medical products – including biases related to exposure misclassification and channeling – and will discuss other limitations to research in the early marketing period, such as sparse data for confounding adjustment. To illustrate these issues, the speakers will present case studies from past and ongoing comparative effectiveness research. The course covers solutions for these challenges – including confounder summary scores (i.e., propensity scores and disease risk scores), time-based instrumental variable analyses, sequential analyses, and distributed data networks – as well as practical limitations to implementing these solutions.

Educational Objectives

Upon completing this course, participants will be able to:

- Recognize the need for comparative effectiveness information for new medical products and the potential sources of such evidence.
- Understand how the patient, provider and healthcare system characteristics can create confounding and other biases in comparative effectiveness studies of newly marketed medications.

- Appreciate the potential solutions for overcoming the challenges of generating comparative effectiveness evidence for newly marketed products and the limitations of these solutions.

Course Faculty/Presentations

Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, USA

Michele Jonsson-Funk, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA

Cynthia Girman, Comparative & Outcomes Evidence, Center for Observational & Real-world Evidence, Merck Sharp & Dohme, USA

Jeremy Rassen, Aetion, Inc., USA

Successful Journeys Start with Great Maps

UBC continues to power global patient access and product safety strategies with real-world evidence gathering and analysis

Value Demonstration

Safety & Risk Management

Database Analytics Automation

Connect with us during our ICPE poster sessions:

Registry: Its Use in Real-World Data Collection

Pan Yi, Dieck G, Stemhagen A

Post Authorization Safety Studies (PASS): Application of Prospective Observational Study Methodology

Pan, Yi, Walton A, Dieck G

Post Authorization Safety Studies (PASS): Application of Retrospective Chart Review Methodology

Stein D, Pan Yi, Payne KA



INFORMED DECISIONS • OPTIMIZED CARE

ubc.com

©2014 Express Scripts Holding Company. All Rights Reserved.

PRE-CONFERENCE EDUCATIONAL SESSIONS *(Registration required)*

8:30am–12:30pm

Device Epidemiology (201E)

Content

Topics will cover several different types of medical devices and international initiatives for evaluating performance of these devices. Special attention will be paid to the “how-to” aspects of conducting valid medical device safety and effectiveness epidemiology research including identifying devices, conducting surveillance, selecting comparator groups, special considerations for confounding and bias, studying long-term outcomes, and using appropriate data sources and advanced methodologies.

Educational Objectives

- Define medical devices and differentiate between devices and drugs.
- Describe special considerations which must be taken into account when conducting medical device epidemiology research and how to address these considerations.
- List data sources appropriate for surveillance of different types of medical devices and their strengths and limitations.
- Describe biases that may be introduced in a study depending on how devices and comparator groups are selected and identified.
- Enumerate considerations for evaluating long-term safety and effectiveness of medical devices.
- Describe regulatory, reimbursement, and greater healthcare environment for use of medical devices and how it differs between US, Europe and Asia as well as how it differs from drugs.
- Recount real-world examples of medical device epidemiology, in the context of comparative effectiveness research.

Faculty/Presentations:

Michael Matheny, Vanderbilt University Medical Center, *Medical Device Surveillance: Basic Statistical Considerations and Scaling to Large Data*

Nicole Pratt, School of Pharmacy and Medical Sciences, University of Adelaide, *Surveillance of Medical Devices within Registries*

Maria Inacio, Kaiser Permanente, *Data Sources for Medical Device Epidemiology*

Theodore Lystig, Medtronic, *Advanced Topics in Medical Device Epidemiology*

Mary E Ritchey, Procter & Gamble

Danica Marinac-Dabic, US Food and Drug Administration, *In Depth Example: Translational Epidemiology for Arthroplasty Devices*


Jessica Jalbert, LA-SER, *Comparative Effectiveness Research and Medical Devices in the Healthcare Environment*

12:30–2:00pm

Lunch on Your Own

New Member Luncheon (3F Banquet Hall)

-By Invitation



OUR WORK IS SOMEONE'S HOPE. JOIN US.

Merck, established in 1891, is a global, research-driven pharmaceutical company dedicated to putting patients first. This philosophy was first articulated by George Merck and still guides us today. Join us and experience our culture first-hand – one of strong ethics and integrity, diversified experiences and a resounding passion for improving human health. As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.

MRL Epidemiology, founded by Dr. Harry Guess in 1985 – Improving research to assess patient outcomes. Our mission is the scientific study of disease, endpoints and patient outcomes to evaluate benefits and the risks of our products. At Merck, we pride ourselves on meeting patient expectations – leveraging the most complete data and a strong cohesive effort to make the products that make life better.

We provide epidemiologic and outcomes research for all Merck drugs and vaccines. Using existing information, database analyses and conducting epidemiology studies across the globe, we characterize disease natural history for new therapeutic areas, assist in clinical trial design based on the epidemiology of the disease, develop and validate patient-reported outcomes, link biomarkers to outcomes and help understand the safety and effectiveness of our products pre- and post-launch. Our team is an active member of clinical development, safety/risk management and outcomes research teams. We are part of a global center of excellence in observational research–CORE (Center for Observational and Real-World Evidence). MRL Epidemiology also includes European Research Units and an Asia Pacific Unit based in China.

Join us and participate in our investigative design and interpretation that enables us to bring life-enhancing products to market.

Visit www.merck.com/careers to find out how.



PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

2:00–6:00pm

Advanced Topics in Pharmacoepidemiology (201ABC)

Course Faculty/Presentations

Juhaeri Juhaeri, Sanofi, *Benefit-Risk Assessment, Communication and Evaluation (BRACE) throughout the Life Cycle of Therapeutic Products*
Robert Reynolds, FISPE, Pfizer, *Risk Management/Risk Minimization*

Kenneth J Rothman, FISPE, RTI Health Solutions,
The Unimportance of Representativeness
Saad Shakir, Drug Safety Research Unit

Advanced Topics in Drug Utilization Research (201D)

Content

This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel. The session will involve participants in the

- Use of drug utilization information from administrative health data to improve medicines use.
- Development of Prescribing Quality Indicators.
- Methods for identifying and managing problems with medicines use in practice.
- Methods for evaluating the effect of clinical or policy interventions.
- Interpretation of the evaluation data and dissemination of results.

Educational Objectives

- To gain an advanced understanding of planning, implementation and evaluation requirements for an effective quality use of medicines intervention.
- To develop a sophisticated understanding of the importance of project planning processes to the effectiveness of interventions.
- To develop an appreciation of the significance of this work to knowledge transfer at the patient care practice and policy change levels of the health system.

Course Faculty/Presentations

Libby Roughead, University of South Australia,
Methods for Identifying and Managing Problems with Medicines Use in Practice
Petra Denig, University Medical Center Groningen,
Developing Valid Prescribing Quality Indicators
Nicole Pratt, University of South Australia, *Evaluating Drug Utilization Interventions: Analysis Methods*
Jerry Avorn, FISPE, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, *Evaluating Practice or Policy*

Non-Database Pharmacoepidemiology (201F)

Content

- Basic theory and practical tips in conducting pharmacoepidemiologic studies when large databases are not available.
- Common study design used to collect data through observation, medical records or questionnaires.
- Strengths and limitations of working without large databases.
- Case studies illustrating the use of different study designs to answer relevant questions about safety and utilization of medicines in primary and secondary care settings.

Educational Objectives

- To develop the skills to develop pharmacoepidemiologic studies without large databases.
- To discuss strengths and limitations of different study designs and data collection methods.
- To identify strategies to improve quality and reliability of pharmacoepidemiological studies conducted without large databases.

Course Faculty/Presentations

Kiyoshi Kubota, FISPE, NPO Drug Safety Research Unit Japan
Annie Fourrier-Reglat, University Bordeaux, France
Hisham Aljadhey, College of Pharmacy, King Saud University
Lisa Pont, The University of Sydney

Raising the Standard in Pharmacoepidemiology



For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop compelling results for our clients across North America, Europe, and emerging markets.

Drawing on our expertise in pharmacoepidemiology, we assist our clients with:

- Peri-approval safety studies for IND and NDA submissions and post-approval commitment
 - Observational pharmacoepidemiology studies (claims analysis + chart review, EMR data analysis)
 - Prospective drug safety surveillance
 - Drug safety monitoring boards
- Pharmacovigilance and spontaneous report analyses
- Clinical trial data analysis and meta-analysis for drug safety endpoints
- PMR/PMS and PASS studies
- Strategic responses to drug safety concerns raised by the U.S. and ex-U.S. regulatory agencies
- Design and evaluation of the effectiveness of REMS programs
- Advanced methods in causal inference (ex, marginal structural models, mediation analysis, high-dimensional propensity score matching)
- Comparative effectiveness research
- Quality of life instrument development and validation
- Mass tort pharmaceutical liability litigation

PRE-CONFERENCE EDUCATIONAL SESSIONS *(Registration required)*

2:00–6:00pm

Advanced Topics in Pharmacoepidemiology (Chinese) (201E)

Content

The educational session covers four advanced topics in pharmacoepidemiology for post-marketing evaluation of medical products, including:

- Safety signal detection and refinement: relevant methods and data sources.
- Comparative safety and effectiveness research: trade-offs between different studies designs and advanced methods for reducing the biases that can distort estimates of non-randomized research.
- Benefit-risk assessment: relevant tools and characterization of uncertainties, case study from recent regulatory history, and the challenge and future development of benefit risk assessment.
- Unmeasured confounders: application of propensity score calibration in pharmacoepidemiologic studies.

Educational Objectives

- To provide an overview of post-marketing safety signal detection and refinement for medical products.
- To understand challenges and proposed methodological solutions in non-randomized research.
- To give a conceptual work with several examples and the way forwarding to benefit-risk assessment of medical products.
- To describe how to use external information to control for unmeasured confounders in the main study with propensity score calibration.

Course Faculty/Presentations

K Arnold Chan, FISPE, National Taiwan University College of Medicine, *Post-Marketing Safety Signal Detection and Refinement for Medical Products*

Edward Chia-Cheng Lai, Duke Clinical Research Institute & National Cheng-Kung University College of Medicine, *Comparative Safety and Effectiveness Research- Challenges and Proposed Solutions*

Chia-Hsien Chang, Takeda Pharmaceutical Company, Limited, *Benefit and Risk Assessment of Medical Product: What Can We Learn From Healthcare Databases?*

Jin-Liern Hong, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, *Adjustments for Unmeasured Confounders with External Information using Propensity Score Calibration*

Clinical Practice Research Datalink



Gold sponsor

WE'RE PROUD TO BE SPONSORING ISPE'S FIRST INTERNATIONAL CONFERENCE IN ASIA

Visit our stand to learn how our increased data population and real-time feasibility tools are adding more dimensions to our data.

Medicines and Healthcare Products Regulatory Agency

NHS
National Institute for Health Research

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

2:00–6:00pm

Pharmacovigilance (Chinese) (103)

Content

- An overview of principles, hot topics, research scopes and essential methods regarding pharmacovigilance with a focus on quantitative aspects.
- The latest US FDA pharmacovigilance practice.
- Classical pharmacovigilance signal detection using multiple data streams for safety surveillance.
- Spontaneous adverse event reports.
- Quantitative signal detection methods for electronic medical record and claims data.
- US FDA's Mini-Sentinel program.
- Evaluation methods and examples for drug safety surveillance policies.

Educational Objectives

Upon completing this course, participants will be able to:

- Explain the need for pharmacovigilance and its component activities with a focus on safety surveillance.
- Describe the potential data sources (e.g., spontaneous reports, electronic medical records, claims etc.) for safety surveillance in pharmacovigilance.
- Understand the array of basic and advanced analytic methods for pharmacovigilance in spontaneous adverse events reports and signal detection and active monitoring in electronic healthcare databases.
- Know how to use quantitative regulatory science methods to evaluate the impacts of pharmacovigilance policies.

Course Faculty/Presentations

- Min Chu Chen**, US Food & Drug Administration, *Introduction to the Latest US FDA Pharmacovigilance Practice and Multiple Data Streams for Safety Surveillance*
- Cliff Ke**, Taiwan Drug Relief Foundation, *Spontaneous ADR Reporting in Taiwan: Lessons Learned and the Future Perspective*
- Sengwee Darren Toh**, Harvard Medical School & Harvard Pilgrim Health Care Institute, *Large Electronic Healthcare Databases for Medical Product Safety Surveillance: The US FDA Mini-Sentinel Project*
- Jason C Hsu**, Department of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Taiwan, *Pharmaceutical Policy and Regulatory Science Research Methods for Evaluation of Drug Safety Surveillance Policies*

6:00–7:30pm

Welcome Reception/Academic Showcase/ International Chapter Showcase (Banquet Hall, 3rd Floor)

- **Yea-Huei Kao Yang**, FISPE, Chair, 2014 Local Host Committee
- **Soko Setoguchi**, FISPE, Chair, 2014 Scientific Program Committee
- **Til Stürmer**, FISPE, ISPE President

ACADEMIC SHOWCASE/INTERNATIONAL CHAPTER PARTICIPANTS (as of September 1, 2014)

- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University, UK
- Gulf Region Chapter
- Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- University of Florida, Department of Pharmaceutical Outcomes and Policy
- University of Illinois at Chicago





31st ICPE CALL for ABSTRACTS

Abstracts Due: February 16, 2015

Meeting info: pharmacoepi.org



You are Invited to Submit an Abstract

ISPE invites you to submit an abstract for an oral/poster presentation, workshop or symposium at the 31st ICPE in Boston, MA USA. This pre-eminent conference on pharmacoepidemiology will be an invaluable scientific experience and will allow you to experience Boston's dynamic and lively personality.

Guidelines For Submissions

Abstract Submission Deadline

FEBRUARY 16, 2015

The deadline for receipt of all abstracts is **February 16, 2015**. Please visit pharmacoepi.org, for submission guidelines. The online submission site will be operational by mid-December 2014.

Questions about abstract submissions and technical issues should be directed to Coe Truman at c4support@coetruman.com or by telephone +1.507.403.2305. Note, submissions will not be accepted until the online submission site is open in **December 2014**.

Reviewing/Registration

The ISPE Scientific Program Committee will review all abstracts in **April 2015**. All submitters will be notified by email in early **June 2015**. All presenters and panelists (workshop/symposia) *must* register to attend the 2015 ICPE.

Scholarships & Student Awards

Abstract Submission Deadline

MARCH 4, 2015

ISPE will award a limited number of scholarships to help defray conference expenses. Information will be posted on pharmacoepi.org

ISPE will grant several student awards to recognize and encourage student excellence in pharmacoepidemiology. The Scientific Program Committee oversees the selection of awards, which will be presented at the 2015 ICPE Annual Meeting of ISPE Members & Awards Ceremony.

Sponsorships, Exhibits & Academic Showcase

ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their products and services with attendees. A Conference Sponsorship & Exhibitor Prospectus will be posted on pharmacoepi.org/meetings/31ICPE.

SAVE THE DATES!

August 23-26, 2015
Hynes Convention Center
Boston, MA USA

Please visit
pharmacoepi.org/meetings/31ICPE
for updated conference information.



AGENDA *Saturday, October 25*

7:00am-6:00pm

Registration (Main Entrance Lobby)

7:00am-5:00pm

Speakers' Ready Room (105)

7:00-8:00am

Poster Session A Set-up
(101/Main Entrance Lobby)

8:00am-6:00pm

Exhibits/Posters
(101/Main Entrance Lobby)

8:00-8:30am

WELCOME (Plenary Hall, 3rd Floor)

- ▶ **Soko Setoguchi, FISPE**
Chair, 2014 Scientific Program Committee
- ▶ **Yea-Huei Kao Yang, FISPE**
Chair, 2014 Local Host Committee
- ▶ **Til Stürmer, FISPE**
ISPE President

8:30-10:00am

KEYNOTE SESSION (Plenary Hall, 3rd Floor)

Pharmacoepidemiology – The Next 30 Years
From Where Have We Come, Where Are We Going in the Next 30 Years?

Faculty:

- ▶ **Byung-Joo Park, FISPE**, Korean Institute of Drug Safety & Risk Management
- ▶ **Judith K Jones, FISPE**, The Degge Group, Ltd.
- ▶ **Hubert GM Leufkens, FISPE**, Utrecht Institute of Pharmaceutical Sciences, Dutch Medicines Evaluation Board

Moderators:

- ▶ **Frank May, FISPE**, Drug & Therapeutics Information Service
- ▶ **Susana Perez-Gutthann, FISPE**, RTI Health Solutions

Thirty years have passed since the first annual scientific meeting of the International Society for Pharmacoepidemiology. An intrepid group of epidemiologists, clinicians and mathematicians from North America and Europe came together in the mid-1980's, focused primarily on the problematic field of medicine safety.

Much has changed in the intervening years. Inevitably effectiveness of medicines, (as a corollary to medicine safety) quickly came sharply into focus in the early years, and the science soon attracted deep interest of drug regulators and academics, as well as scientists in safety departments of the pharmaceutical industry. Rather more recently practitioners from clinical disciplines have been attracted to the science because of its focus on benefits and harms of medicines, as well as the way it naturally extends perspectives gained from controlled trials to more fully illuminate clinical experience in evidence-based medicine.

Methods of observational research in therapeutic strategies have radically evolved in the past 30 years. These improvements in methods have occurred in parallel with the rise of large datasets and their relative accessibility for systematic investigation. As a matter of policy ISPE has avoided deeper entanglement in the still-evolving economic sciences, which have become associated with estimates of relative value of different therapeutic approaches.

At this moment of generational-change in the development of pharmacoepidemiology during ISPE's 30th annual scientific meeting, this keynote session will focus on the next 30 years of the field's development.

Three eminent speakers will address possible futures for pharmacoepidemiology in this session. These speakers, all of whom have been eminent researchers and thinkers in our field, represent the globe's three principal regions, the Americas, Europe/Africa and Asia. They will draw on their own past experiences, as well observations of the development of our science up until 2014 so that they can predict future directions for pharmacoepidemiology, and its likely position at the next generational transition in 2044.

10:00-10:30am

Break/Posters/Exhibits
(101/Main Entrance Lobby)

10:30am-Noon CONCURRENT ORAL PRESENTATION SESSIONS

All About Statins (201BC)

Moderators: Robert Glynn & Ching-Lan Cheng

10:30am

- Effect of Statin Use on Acute Kidney Injury Following Elective Cardiothoracic Surgery: A Population Cohort Study in Denmark [1]
J Bradley Layton, Malene K Hansen, Carl-Johan Jakobsen, Jan J Andreasen, Vibeke E Hjortdal, Bodil S Rasmussen, Abhijit V Kshirsagar, Ross J Simpson, Christian F Christiansen. (United States)

10:45am

- Perioperative Utilization of Statins in Patients Undergoing Intermediate to High Risk Non-Cardiac Surgery [2]
Elisabetta Patorno, Shirley Wang, Sebastian Schneeweiss, Jun Liu, Brian Bateman. (United States)

11:00am

- Pattern of Risks of Rheumatoid Arthritis among Patients Using Statins: A Cohort Study with the Clinical Practice Research Datalink [3]
Hilda J De Jong, Jan Willem Cohen Tervaert, Arief Lalmohamed, Frank De Vries, Rob J Vandebriel, Henk Van Loveren, Olaf H Klungel, Tjeerd Van Staa. (Canada)

11:15am

- Statin Use and Cholesterol Levels among US Adults with Age-Related Macular Degeneration (AMD): Findings from the 2005-2008 National Health and Nutrition Examination Survey (NHANES) [4]
R A Cantrell, C I Kiu Weber, P Delmar, M Gleeson, Q Doan. (United States)

11:30am

- Statin Initiation in a Closed Cohort of U.S. Women over Two Decades [5]
Tracy L Kinsey, Til Stürmer, Robert J Glynn. (United States)

11:45am

- Pharmacoeconomic and In Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonylureas with Fibrates and Statins [6]
Hedi Schelleman, Xu Han, Colleen M Brensinger, Sara K Quinney, Warren B Bilke, David A Flockhart, Lang Li, Sean Hennessy. (United States)

Biologics Bouillabaisse (201AF)

Moderators: David Miller & Cheryl Enger

10:30am

- Does a Risk Management Plan Increase Safety Monitoring for the Use of Tumor Necrosis Factor-alpha Inhibitors? [7]
Meng-Ju Chan, Chien-Ning Hsu, Yen-Hsia Wen, Yu-Chin Lily Wang. (Taiwan)

10:45am

- Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis from the Perspective of the Taiwanese Healthcare System [8]
Ching-Chi Chi, Shu-Hui Wang. (Taiwan)

11:00am

- Regional Differences in Utilisation of Biologicals in Portugal [9]
Joelle M Hoebert, Sofia Oliveira-Martins, Hubert GM Leufkens, José Cabrita, Helder Mota-Filipe, Patrick C Souverein. (Netherlands)

11:15am

- Risk of Incident Heart Failure among Established Rheumatic Arthritis Patients Treated with TNF-alpha Inhibitors in Taiwan [10]
Tzu-Chieh Lin, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)

11:30am

- Development of an Algorithm to Identify Denosumab 60 Milligram Users in Health Insurance Claims Data [11]
Veena Thyagarajan, Fei Xue, Betsey Gardstein, Kathleen Skerry, Cathy W Critchlow, Cheryl Enger. (United States)

11:45am

- Payer-Level Differences in the Response to Regulatory Actions Regarding Bevacizumab [12]
Stacie B Dusetzina, Aaron N Winn, Haiden A Huskamp, G Caleb Alexander, Nancy L Keating. (United States)

Continuing the Discussion on Antipsychotic Safety (201DE)

Moderators: Alejandro Arana, FISPE & John Jackson

10:30am

- Antipsychotics and Mortality: Adjusting for Mortality Risk Scores to Address Confounding by Terminal Illness [13]
Yoonyoung Park, Jessica Franklin, Sebastian Schneeweiss, Raisa Levin, Stephen Crystal, Tobias Gerhard, Krista Huybrechts. (United States)

10:45am

- Mediators of the Causal Pathway to Mortality in Older Adults Who Use Antipsychotics [14]
John W Jackson, Tyler J VanderWeele, Deborah Blacker, Sebastian Schneeweiss. (United States)

11:00am

- Concomitant Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) during Antipsychotic Treatment in Incident Cases of Schizophrenia and Risk of 1-Year Psychiatric Hospitalizations [15]
Ole Koehler, Ole Mors, Liselotte Petersen, Christiane Gasse. Denmark)

11:15am

- Incidence of Weight Gain with Seroquel XL™ in Primary Care in England: Results from an Observation Post-Marketing Cohort Study [16]
Deborah Layton, Miranda Davies, Vicki Osborne, Saad AW Shakir. (United Kingdom)

11:30am

- Detecting Potential Adverse Reactions of Sulpiride in Schizophrenic Patients by Prescription Sequence Symmetry Analysis [17]
Edward Chia-Cheng Lai, Jyun-Hong Chen, Cheng-Yang Hsieh, Swu-Jane Lin, Yea-Huei Kao Yang (Taiwan)

11:45am

- Course and Outcome of Clozapine Treatment in Patients with Incident Schizophrenia in Denmark [18]
Christiane Gasse, Aske Astrup, Henrik Støvring, Theresa Wimberley. (Denmark)

10:30am-Noon CONCURRENT ORAL PRESENTATION SESSIONS

Improving Strength and Balance (4th Floor VIP)

Moderators: Olaf Klungel & Ian Douglas

10:30am

- Improving Empirical Variable Selection in Propensity-Score Models with High-Dimensional Covariate Space Using Healthcare Databases [19]
Sebastian Schneeweiss, Wesley Eddings, Robert J Glyn, Jessica M Franklin. (United States)

10:45am

- Penalized Regression for Fitting High Dimensional Propensity Score Models in Small Samples [20]
Carl de Moor, Ed Malka. (United States)

11:00am

- Improving Propensity Scoring through Machine Learning [21]
John A Rigg, Huma Lodhi, John Gregson, Joseph Kim. (United Kingdom)

11:15am

- Propensity Score Matching and Unmeasured Covariate Imbalance: A Simulation Study [22]
M Sanni Ali, Rolf HH Groenwold, Svetlana V Belitser, Arno W Hoes, A de Boer, Olaf H Klungel. (Netherlands)

11:30am

- Use of Propensity Score Methodology to Assess Comparability of Treatment Groups in a Registry Program [23]
Kenneth J Rothman, Menno V Huisman, Gregory YH Lip, Hans-Christoph Diener, Sergio J Dubner, Chang-Sheng Ma, Kristina Zint, Christine Teutsch, Nils Schoof, Miney Paquette, Eva Kleine, Dorothee B Bartels, Jonathan Halperin. (United States)

11:45am

- Applying High Dimensional Propensity Score (HDPS) in a Exploratory Data Analysis with a US Claims Database for Recent Medicinal Products [24]
Bing Cai, Sundaresan Murugesan, Jamie Geier, Andrew Bate. (United States)

The Good, the Bad, and the Ugly of Anti-Infectives (103)

Moderators: Florence Wang & Suzanne West, FISPE

10:30am

- Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection [25]
Dana D Byrne, Craig W Newcomb, Dena M Carbonari, Melissa S Nezamzadeh, Kimberly BF Leidl, Maximilian Herlim, Yu-Xiao Yang, Sean Hennessy, Jay R Kostman, Mary B Leonard, Russell Localio, Vincent Lo Re III. (United States)

10:45am

- Antiretroviral Adherence among Patients Enrolled in an AIDS Drug Assistance Program [26]
Jenna Parrett, Alice C Thornton, Emily S Brouwer. (United States)

11:00am

- Adherence to Antiretroviral Drugs and Its Determinants among Human Immunodeficiency Virus(HIV) Patients Attending HIV Clinic in a Teaching Hospital in Nigeria [27]
Chioma Stella Ejekam, Adebayo Temitayo Onajole, Charles C Okany, OA Lesi, ES Oridota. (Nigeria)

11:15am

- Predictors of Receiving Guideline Recommended Antiretroviral Treatment: Type of Provider Influences the Provision of Optimum HIV Treatment [28]
Emily S Brouwer, Sarah Wixson, Daniela C Moga. (United States)

11:30am

- Seasonal Variation in Penicillin Use in Brazil and Mexico: An Analysis of the Impact of Over-the-Counter Regulations [29]
Yared Santa-Ana-Tellez, Aukje K Mantel-Teeuwisse, Hubert GM Leufkens, Vronika J Wirtz. (Netherlands)

11:45am

- The Effects of Obesity on the Comparative Effectiveness of Linezolid and Vancomycin in MRSA Pneumonia [30]
Aisling R Caffrey, Eunsun Noh, Haley J Morrill, Kerry L LaPlante. (United States)

Women's Health (102)

Moderators: Michele Jonsson-Funk & Jennita Reefhuis

10:30am

- Use of Triptans and Risk of Hemorrhagic Stroke in Women [31]
Klaus K Andersen, Christian Dehlendorff, Charlotte Skriver, Søren Friis, Tom S Olsen. (Denmark)

10:45am

- Women's Perception of Risks in Pregnancy [32]
Irene Petersen, Rachel McCrea, Angela Lupattelli, Michael Twigg, Hedvig Nordeng. (United Kingdom)

11:00am

- Procedure-Related Issues Associated with the Nexplanon Contraceptive Implant: Interim Results from the Nexplanon Observational Risk Assessment Study (NORA) [33]
Suzanne Reed, Klaas Heinemann. (Germany)

11:15am

- Unwanted Pregnancies in Women Using Intrauterine Devices: Final Results from the EURAS-IUD Study [34]
Klaas Heinemann, Sabine Moehner, Thai Do Minh. (Germany)

11:30am

- Rates of Opioid-Managed Pelvic Pain after Sterilization by Implanted Device vs. Tubal Ligation, U.S. 2005-2011 [35]
Mitchell M Conover, Jennifer M Wu, Alan C Kinlaw, Jennifer O Howell, Michele Jonsson Funk. (United States)

11:45am

- Persistent Opioid Use Following Cesarean Delivery: Patterns and Predictors among Opioid Naïve Women [36]
Brian T Bateman, Jessica M Franklin, Katsiaryna Bykov, Krista F Huybrechts, Michael A Fischer, Niteesh K Choudhry. (United States)

AGENDA Saturday, October 25

Noon -1:30pm

Lunch/Poster Session A/Roundtable Discussions (Banquet Hall, 3rd Floor)

Roundtable Discussions

To foster the ability of the more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Saturday and Sunday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange and networking. Seating is limited; first-come, first-served.

- **Ulf Bergman, FISPE**, Drug Utilization – The Importance of Pharmacology in Pharmacoepidemiology Research
- **Syed Rizwanuddin (Rizwan) Ahmad, FISPE**, Challenges in including Patient's Perspective in Pharmacovigilance
- **Wei Zhou**, Career Paths Between Academic and Industry Pharmacoepidemiology in Developing Countries: Opportunities and Challenges

Noon -1:30pm

ISPE Committee/Council Meetings

Open to all participants.

- **Development Committee** (South Lounge, 3rd Floor)
- **Fellowship & Awards Committee** (South Lounge, 3rd Floor)
- **Finance Committee** (South Lounge, 3rd Floor)
- **Public Policy Committee** (South Lounge, 3rd Floor)
- **Student Council** (North Lounge, 3rd Floor)

12:15-1:15pm

Spotlight Poster Sessions (101)

- **Best of the Day**
- **Drug Utilization/Health Services Research**
- **Methods**
- **Pediatrics**
- **Vaccines**



More Than Data. **Answers.**

TRUVEN HEALTH ANALYTICS™

25 Years Using Big Data for Healthcare Research

The Truven Health MarketScan® Research Databases are considered the gold standard in U.S. research data. With longitudinal integrity that allows tracking of more than 200 million patients through the healthcare system, Big Data doesn't get much bigger.

To learn more about the MarketScan Research Databases and our unique strengths in oncology and rare disease research, stop by our booth or email us at lifesciences@truvenhealth.com.

Xue Song
Director of Statistical Services
Truven Health Analytics

©2014 Truven Health Analytics Inc. All rights reserved.

AGENDA Saturday, October 25

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Antibiotics and Other Exposures in Pregnancy (102)

Moderators: Sonia Hernandez-Diaz, FISPE & Andrea Margulis

1:30pm

- Antibiotic Use among Dutch Pregnant Woman and the Development of Toddler Asthma: The Influence of Confounding [37]
Bianca Mulder, Koen B Pouwels, Nynke CM Schuiling-Veninga, Jens Bos, Tjalling W de Vries, Susan S Jick, Eelko Hak. (Netherlands)

1:45pm

- Genital Herpes Infection and Its Treatment in Relation to Preterm Delivery Among 662,913 Births [38]
De-Kun Li, Marsha A Raebel, T Craig Cheetham, Craig Hansen, Lyndsay Avalos, Hong Chen, Robert Davis. (United States)

2:00pm

- Erythromycin in Early Pregnancy and Fetal Safety: A Register Based Nationwide Cohort Study [39]
Jon T Andersen, Nadia L Andersen, Arendse Torp-Pedersen, Vanja Cejvanovic, Henrik E Poulsen, Espen Jimenez-Solem. (Denmark)

2:15pm


- Antiepileptic Drug Use Before, During and After Pregnancy: A Study in 7 European Regions [40]
Rachel Charlton, Ester Garne, Hao Wang, Kari Klungsoyr, Sue Jordan, Amanda Neville, Anna Pierini, Anne Vinkle Hansen, Anders Engeland, Rosa Gini, Daniel Thayer, Karen Tingay, H Jens Bos, Aurora Puccini, Anne Marie Nybo Andersen, Helen Dolk, Lolkje de Jong-van den Berg. (Netherlands)

2:30pm

- Medications and Other Risk Factors for 2nd and 3rd Degree Hypospadias in the National Birth Defects Prevention Study, 1997-2009 [41]
Jennita Reefhuis, Sander Groen in't Woud, Iris van Rooij, Marleen van Gelder, Richard Olney, Suzan Carmichael, Nel Roeleveld. (United States)

2:45pm

- Statins during Pregnancy and the Risk of Congenital Malformations: A Cohort Study [42]
Brian T Bateman, Sonia Hernandez-Diaz, Helen Mogun, Michael A Fischer, Krista F Huybrechts. (United States)



RTI HEALTH SOLUTIONS®



Announcing the Expansion of Our Barcelona Office

With four recent senior hires (three epidemiologists with medical specialties and a statistician) to our Barcelona office, we've deepened our therapeutic expertise—including oncology, neurology, ophthalmology, respiratory, and cardiovascular—and added capacity and experience in pharmacoepidemiology and risk management consultation and research services.

Visit our exhibit booth to learn more about our new staff, what they bring to our growing 30+ person epidemiology team and how we can help you meet your epidemiological, risk management, and drug safety needs.

Research Triangle Park • Ann Arbor • Barcelona • Ljungskile • Waltham

www.rtihs.org

LEADING RESEARCH...
MEASURES THAT COUNT

AGENDA Saturday, October 25

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Cancer Care Continuum (201DE)

Moderators: Danica Marinac-Dabic & Geoffrey Liu

1:30pm

- Validation of Pancreatic Cancer Diagnosis Claims Within SEER-Medicare [43]
Mary E Ritchey, Jinghua He, Samuel S Engel, Mellissa Yong, Kimberly G Brodovicz. (United States)

1:45pm

- An Analysis of Biomarker Testing and Appropriate Treatment Among Women with Breast Cancer Using Oncology EMR Data [44]
Kathleen A Foley, Leigh G Hansen, Richard Bizier. (United States)

2:00pm

- Comparative Persistence to Oral Hormonal Agents in Women with Breast Cancer [45]
Edward Chia-Cheng Lai, Winson Y Cheung, Yinghong Zhang, Soko Setoguchi. (Taiwan)

2:15pm

- Elderly Breast Cancer Patient's Pill Burden and Adherence to Hormonal Therapy [46]
Kitaw Demissie, Joel N Swerdel, Kim M Hirshfield, Sheenu Chandwani, George G Rhoads. (United States)

2:30pm

- The Impacts of Competing Risks on Assessing the Association between Switch and Interruption of Adjuvant Hormone Therapy in Breast Cancer Women [47]
Kun-Pin Hsieh, Li-Chia Chen, Kwok-Leung Cheung, Yi-Hsin Yang. (Taiwan)

2:45pm

- Prognostic Impact of Tumor MET Expression among Patients with Stage IV Gastric Cancer: A Danish Cohort Study [48]
Rune Erichsen, Michael A Kelsh, Kelly S Oliner, Karsten B Nielsen, Trine Froslev, Anne-Vibeke Laenkolm, Morgan Vyberg, John F Acquavella, Henrik T Sorensen. (United States)

CER and Safety in CV TX/Care (201BC)

Moderators: Cynthia Girman & J Bradley Layton

1:30pm

- Comparative Effectiveness of Drug-Eluting Stents for Patients with Coronary Diseases: A Nationwide Population-Based Study in Taiwan [49]
Grace Hui-Min Wu, Yu-chiao Wang. (Taiwan)

1:45pm

- Real-World Effectiveness of Primary ICDs Implanted during Unplanned Medicare Hospitalizations [50]
Chih-Ying Chen, Garrick C Stewart, Lynne W Stevenson, Deepak L Bhatt, Manisha Desai, John D Seeger, Lauren Williams, Jessica J Jalbert, Soko Setoguchi. (United States)

2:00pm

- Concomitant Use of Clopidogrel with Calcium Channel Blockers and Cardiovascular Outcomes in Patients Received Percutaneous Coronary Intervention [51]
Chen-Yu Wang, Fei-Yuan Hsiao, Zhen-Fang Lin, Li-Jiuan Shen. (Taiwan)

2:15pm

- Integration of Healthcare Delivery System Characteristics into Pharmacoepidemiologic Research: An Analysis of Acute Stroke Care Effectiveness [52]
Mark O Loveless, Andrew Wilson, Stephen Agbor, Drew Levy, Aaron WC Kamau. (United States)

2:30pm

- Preadmission Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and 30-Day Stroke Mortality [53]
Jens Sundbøll, Morten Schmidt, Erzsébet Hovath-Puho, Christian F Christiansen, Lars Pedersen, Hans E Bøtker, Henrik T Sørensen. (Denmark)

2:45pm

- Severe Malabsorption Associated with Olmesartan: A French Nation-Wide Cohort Study [54]
Myriam Mezzarobba, Mickael Basson, Alain Weill, Philippe Ricordeau, Allemand Hubert, Alla François, Franck Carbonnel. (France)

Pseudorandom Exposures (4th Floor VIP)

Moderator: Mary E Ritchey

1:30pm

- Instrumental Variable Analysis Using Multiple Databases: An Example of Antidepressant Use and Risk of Hip/Femur Fracture [55]
Md Jamal Uddin, Rolf HH Groenwold, Anthonius de Boer, Helga Gardarsdottir, Elisa Martin, Gianmario Candore, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)
–Student Award Recipient –
Best Methods Abstract Submitted by a Student/Post-Doc

1:45pm

- Using Simulation to Explore the Properties of IV Bias Amplification and Unmeasured Confounding [56]
Jonathan V Todd, M Alan Brookhart. (United States)

2:00pm

- Instruments and Doubly Robust Estimation: Bias and Efficiency Compared to Conventional Estimators [57]
Michele Jonsson Funk, Virginia Pate, Til Stürmer. (United States)

2:15pm

- Evaluating Different Physician's Prescribing Preference Based Instrumental Variables in the Study of Beta2-Agonist Use and the Risk of Acute Myocardial Infarction [58]
Md Jamal Uddin, Rolf HH Groenwold, Anthonius de Boer, Ana Afonso, Paola Primatesta, Claudia Becker, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)

2:30pm

- The Performance of Different Disease Risk Score Methods for Estimating Unbiased Odds Ratio in the Presence of Multiple Confounders [59]
Chien-Chang Lee, Chen-Fang Chen. (Taiwan)

2:45pm

- Accounting for Cumulative Exposure Effects in Comparative Effectiveness and Safety Analyses [60]
Michal Abrahamowicz, Rolina D van Gaalen, Marie-Pierre Sylvestre, Marie-Eve Beauchamp. (Canada)

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Understanding Antidepressant Use and Safety (103)

Moderators: Ole Köehler & Tobias Gerhard, FISPE

1:30pm

- ▶ **Use of Antidepressants and Age: A Comparatively High Risk of Suicide Attempts but Not of Suicide among the Young [61]**
Fabian Termorshuizen, Marco P Boks, Hugo M Smeets, Eibert R Heerdink. (Netherlands)

1:45pm

- ▶ **Drug Use Patterns and Characteristics of Elderly Users of Antidepressants in Germany [62]**
Kathrin Jobski, Niklas Schmedt, Tania Schink, Edeltraut Garbe. (Germany)

2:00pm

- ▶ **Treatment Patterns among US Veterans Treated with Selegiline Transdermal System [63]**
Scott L DuVall, Kimberly B Portland, Terry Painter, Andrew Wilson, Stephen Agbor, Aaron WC Kamauu. (United States)

2:15 pm

- ▶ **Neighborhood Material and Social Deprivation and Adherence to Antidepressant Treatment in Depression [64]**
Sophie Lauzier, Hichem Kadachi, Jocelyne Moisan, Marie-Josée Fleury, Alain Lesage, Alain Vanasse, Josiane Courteau, Jean-Pierre Grégoire. (Canada)

2:30pm

- ▶ **Understanding Inconsistent Results from Observational Pharmacoepidemiological Studies: the Case of Antidepressant Use and Risk of Hip Fracture [65]**
V Abbing-Karahagopian, P Souverein, E Martin, C Huerta, F de Abajo, H Leufkens, G Candore, Y Alvarez, J Slattery, M Miret, G Requena, M Gil, R Groenwold, R Reynolds, R Schlienger, M de Groot, OH Klungel, T van Staa, T Egberts, ML De Bruin, H Gardarsdottir. (Netherlands)

2:45pm

- ▶ **(Non)availability of Dosage Instructions in Electronic Health Care Databases and Exposure (mis)classification: the Example of Antidepressants [66]**
Patrick C Souverein, Helga Gardarsdottir. (Netherlands)



Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical

Committed to bringing therapies to people that extend and significantly improve their lives

companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

> The Epidemiology group at Pfizer is proud to support the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Taipei, Taiwan.

AGENDA *Saturday, October 25*

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Watch Closely (201AF)

Moderators: Joshua Gagne & Hsueh-Yung Tai

1:30pm

- ▶ **A Paradigm Shift for Screening Individual Case Reports: Accounting for Quality and Content [67]**
Ola Caster, Kristina Juhlin, Sarah Watson, G Niklas Norén. (Sweden)

1:45pm

- ▶ **Sequential Analysis After a Signal in Safety Surveillance of Drugs or Vaccines [68]**
Bruce H Fireman, Edwin M Lewis. (United States)

2:00pm

- ▶ **Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries [69]**
Jude Nwokike, Elisabeth Ludeman, Melissa Thumm, Louis An. (United States)

2:15pm

- ▶ **SAFEGUARD Results: Analysis of Pharmacovigilance Databases [70]**
Lorna Hazell, Niklas Schmedt, Lorenza Scotti, Ingrid Leal, Gianluca Trifiro, Miriam Sturkenboom, Saad Shakir. (United Kingdom)

2:30pm

- ▶ **Beyond Traditional “Observed Versus Expected” Analyses: A Sensitivity Analysis Integrating Uncertainties Around Reporting Bias and Background Incidence Rate [71]**
Lionel Van Holle, Olivia Mahaux, Vincent Bauchau. (Belgium)

2:45pm

- ▶ **Validation of Signal Impact Assessment Tool in Order to Explore Pharmacovigilance Signals’ Follow-Up Actions [72]**
Leàn Rolfes, Judith Kolfshoten, Florence van Hunsel, Eugene van Puijenbroek, Kees van Grootheest. (Netherlands)

3:00-3:30pm

Break/Posters/Exhibits
(101/Main Entrance Lobby)

3:30-5:00pm

PLENARY SESSION (Plenary Hall, 3rd Floor)

Development in Pharmacoepidemiological Methods: Current Status and Future Direction

Speakers:

- ▶ **Ken Rothman**, FISPE, RTI Health Solutions
- ▶ **Alec Walker**, FISPE, World Health Information

Panelists:

- ▶ **Miguel Hernan**, Harvard School of Public Health
- ▶ **Robert Glynn**, Harvard Medical School/Brigham and Women’s Hospital
- ▶ **Olaf Klungel**, Utrecht University, Utrecht Institute for Pharmaceutical Sciences

Moderators:

- ▶ **Soko Setoguchi**, FISPE, *Duke Clinical Research Institute*
- ▶ **Til Stürmer**, FISPE, *Gillings School of Global Health, University of North Carolina at Chapel Hill*

Advancing epidemiologic methods has been a major focus of International Society for Pharmacoepidemiology (ISPE). ISPE researchers have made tremendous contributions to the methodological developments in the field of pharmacoepidemiology, device epidemiology, and health services, outcomes, and comparative effectiveness research. To celebrate 30 years of ISPE’s development since its first annual conference and to recalibrate us in ISPE for further development and contributions to the field of epidemiologic methods, this plenary session will address questions about where we are and where we are going with respect to methods. Prominent speakers/panelists from ISPE will review recent developments and current status of pharmacoepidemiology and discuss future directions in pharmacoepidemiological methods.

5:00-6:30pm **SYMPOSIA AND WORKSHOPS**

A Guide to Guidelines. A Symposium Sponsored by the ISPE Public Policy Committee [73] (201DE)

- Jesper Hallas, Kenneth J Rothman, Kiyoshi Kubota, Stella Blackburn, Alejandro A Navarro, Gerald Dal Pan. (Denmark)

Academic Detailing: Putting Pharmacoepidemiology into Practice [74] (103)

- Jerry Avorn, Stephen Chapman, Frank May, Loren Regier, Debra Rowett. (Australia)

Biospecimens From Asia in Pharmacoepidemiology Research: Opportunities and Challenges in a Global Environment [75] (4th Floor VIP)

- Arnold KW Chan, Bruce Carleton, Daniel FC Tsai, Mao Mao. (Taiwan)

Challenges in Risk Minimization Evaluation: CIOMS Working Group IX Consensus and Recent Field Experience [76] (102)

- Yola Moride, Elizabeth Andrews, Susana Perez-Gutthann, Montse Soriano-Gabarró, Stephen Heaton, Kiliana Suzart-Woischnik, Zdravko Vassilev, June M Raine. (Spain)

Gender Differences in Pharmacoepidemiology [77] (201BC)

- Björn Wettermark, Yea-Huei Kao Yang, Mikael Hoffmann, Vera Vlahovic-Palcevski, Mia von Euler, Soko Setoguchi-Iwata. (Sweden)

Impact of Methodological Choices on Findings from Pharmacoepidemiological Studies: Final Results of the IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) Project [78] (Plenary Hall, 3rd Floor)

- Olaf Klungel, Mark de Groot, Helga Gardarsdottir, Ruth Brauer, Lamiae Grimaldi-Bensouda, Xavier Kurz, Christiane Gasse, Robert Reynolds. (Netherlands)

The New ISPE Vaccine Special Interest Group (VAXSIG): Helping to Advance the Global Vaccine Agenda [79] (201AF)

- Huifeng Yun, Hak Eelko, Ajit Pal Singh, Jan Bonhoeffer, Daniel Weibel, Miriam Sturkenboom. (United States)

6:30-7:30pm

Special Interest Groups (SIGs)

Open to all interested participants

- **Adherence** (201DE)
- **AsPEN** (201BC)
- **Biologics** (Elegance Lounge, 4th Floor)
- **BRACE** (102)
- **Comparative Effectiveness Research** (North Lounge, 3rd Floor)
- **Databases** (103)
- **Drug Utilization/Health Services Research** (4th Floor VIP)
- **Medical Devices** (Elegance Lounge, 4th Floor)
- **Medications in Pregnancy** (201AF)
- **Molecular Epidemiology** (South Lounge, 3rd Floor)
- **Pediatrics** (Elegance Lounge, 4th Floor)
- **Vaccines** (Elegance Lounge, 4th Floor)

7:30pm

Students/Young Professionals Night Out SOLD OUT

7:30-9:00pm

PDS Editorial Board (202) - By Invitation



ANONYMOUS PATIENT-LEVEL INFORMATION

TECHNOLOGY-ENABLED ANALYTICS

SERVICES AND ENGAGEMENT

Prepare to unleash the power of RWE

IMS Real-World Evidence Solutions is your scientifically credible partner to pursue more impactful research and increase the reach of your insights.

IMS Health is committed to helping you succeed

- **Largest multi-disciplinary team** of RWE experts, including leading scientists in epidemiology, drug safety and risk management, based in 18 countries worldwide
- **Credible scientific voice** and deep therapy area knowledge, captured in over 2,500 publications
- **Most advanced capabilities in RWE** management and analysis, leveraging relevant IMS Health proprietary and other key external, third-party data assets
- **Proven expertise** in generating and communicating RWE to advance stakeholder engagement at all levels
- **Cutting-edge technology** to power scientific and commercial insights

Come and meet the IMS Health team in the exhibition area at ICPE in Taiwan.

We are excited to share our unique lens on the future of RWE.

Asia Pacific +65 6412 7365
USA +1 (703) 837 5150
Europe +44 (0) 20 3075 4800
Latin America +52 (55) 50 62 52 00
RWEinfo@imshealth.com
www.imshealth.com/rwe

IMS REAL-WORLD EVIDENCE SOLUTIONS
8 CROSS STREET #21-01/02/03, SINGAPORE 048424, SINGAPORE

©2014 IMS Health Incorporated and its affiliates. All rights reserved.
Trademarks are registered in the United States and in various other countries.

imshealth[™]
INTELLIGENCE APPLIED.

AGENDA *Sunday, October 26*

7:00am-6:00pm

Registration
(Main Entrance
Lobby)

7:00am-5:00pm

**Speakers' Ready
Room (105)**

7:00-8:00am

**Poster Session B
Set-up**
(101/Main
Entrance Lobby)

8:00am-6:00pm

Exhibits/Posters
(101/Main
Entrance Lobby)

8:00-9:30am **CONCURRENT ORAL PRESENTATION SESSIONS**

Antidepressants During Pregnancy and Diverse Outcomes (103)

Moderators: Li Ling Liu & Darren Toh

8:00am

- ▶ **Impact of Right Truncation in Studies of Drug Safety during Pregnancy [313]**
Sonia Hernández-Díaz, Brian Bateman, Krista Huybrechts. (United States)

8:15am

- ▶ **Comparative Safety of Depression Treatments in Late Pregnancy for the Neonate [314]**
Krista Huybrechts, Brian Bateman, Raisa Levin, Helen Mogun, Sonia Hernández-Díaz. (United States)

8:30am

- ▶ **Teratogenicity of Selective Serotonin-Reuptake Inhibitors and Venlafaxine – A Population-Based Study of 2.3 Million Births in Five Nordic Countries [315]**
Kari Furu, Helle Kieler, Bengt Haglund, Helga Zoega, Mika Gissler, Mette Nørgaard. (Norway)

8:45am

- ▶ **Use of Antidepressants during Pregnancy and the Risk of Pregnancy-Induced Hypertension [316]**
Fianne MAM van Loveren, Monique Boekema, Eelko Hak, Jens HJ Bos, Jan G Aarnoudse, Catharina CM Schuiling-Veninga. (Netherlands)

9:00am

- ▶ **Use of Antidepressants and Induced Abortions: Population Based Case-Control Study from Three Nordic Countries [317]**
Helle Kieler, Kari Furu, Mika Gissler, Mette Noergaard, Unnur Valdimarsdottir, Bengt Haglund. (Sweden)

9:15am

- ▶ **Selective Serotonin Reuptake Inhibitors and Congenital Heart Anomalies: Comparative Cohort Studies [584]**
Irene Petersen, Stephen Evans, Louise Marston, Ruth Gilbert, Irwin Nazareth. (United Kingdom)



Better Health, Brighter Future



Takeda Pharmaceuticals International, Inc.

AGENDA Sunday, October 26

8:00-9:30am CONCURRENT ORAL PRESENTATION SESSIONS

Diabetes and Cancers: The Double Whammy (201BC)

Moderators: Marie De Bruin & Brian Strom, FISPE

8:00am

- ▶ **Electronic Health Data Capture of Clinical Evaluation and Pancreatic Cancer (PC) Diagnosis (DX) in Patients with Type 2 Diabetes (T2DM) [319]**
Mary E Ritchey, Yong Chen, Jinghua He, Samuel S Engel, Weifeng Xu, Mellissa Yong, Kimberly G Brodovicz. (United States)

8:15am

- ▶ **Proteinuria Testing Among Patients with Diabetes Mellitus Is Associated with Bladder Cancer Diagnosis: Potential for Unmeasured Confounding in Studies of Pioglitazone and Bladder Cancer [320]**
James D Lewis, Laurel Habel, Charles Quesenberry, Ronac Mamtani, Tiffany Peng, Warren B Bilker, Monique Hedderson, Lisa Nessel, David J Vaughn, Brian L Strom, Assiamira Ferrara. (United States)

8:30am

- ▶ **The Risk of Colorectal Cancer in Patients with Type 2 Diabetes: Associations with Treatment Stage and Obesity [321]**
Paulus JHL Peeters, Marloes T Bazelier, Hubert GM Leufkens, Frank de Vries, Marie L De Bruin. (Netherlands)

8:45am

- ▶ **Colorectal Cancer Risk in Metformin Initiators – A Matched Cohort Study [322]**
Anne S Geier, Ina Wellmann, Jürgen Wellmann, Jessica M Franklin, Hiltraud Kajüter, Oliver Heidinger, Georg Hempel, Hans-Werner Hense. (Germany)

9:00am

- ▶ **Duration of Metformin Use and Risk of Prostate Cancer in Men with Diabetes [323]**
Laurel A Habel, Stephen K Van Den Eeden, Lori C Sakoda, Ninah S Achacoso, Charles P Quesenberry, Tiffany Peng, Samantha F Ehrlich, Assiamira Ferrara. (United States)

9:15am

- ▶ **Exposure to Pioglitazone and Risk of the 10 Most Common Cancers [324]**
Assiamira Ferrara, Charles P Quesenberry, James D Lewis, Samantha F Erlich, Stephen K Van Den Eeden, Tiffany Peng, Brian L Strom, Laurel A Habel. (United States)



**Billions of Records. Millions of Patient Lives.
Think of the possibilities.**

Visit us at booth #17

Posters and Oral Presentations:

"Treatment Patterns among US Veterans Treated with Selegiline Transdermal System"

*"Integration of Healthcare Delivery System Characteristics into Pharmacoepidemiologic Research:
An Analysis of Acute Stroke Care Effectiveness"*

"Clinical Burden of ANCA Associated Vasculitis"

"Methods and Guidelines for Integrity of Multivariable Analysis of Real World (observational) Data"

"Interactive Web-based Tool for Cohort Creation and Disease Outcome Feasibility"

anolinx.com

ANOLINX™

AGENDA *Sunday, October 26*

8:00-9:30am CONCURRENT ORAL PRESENTATION SESSIONS

Equity, Elderly & Ecclecticism (201AF)

Moderators: Meng-Ting Wang & Anna Almarsdottir

8:00am

- Disparities in the Use of Prescription Medications: A Population-Based Approach [325]
Dima Qato. (United States)

8:15am

- Racial/Ethnic Disparities in US Prescribing Patterns of Sleep Medications from 1996-2010 [326]
Christopher N Kaufmann, Adam P Spira, Sarah L Canham, Lian-Yu Chen, G Caleb Alexander, Pia Mauro, Ramin Mojtabai. (United States)

8:30am

- Sex Differences in Utilization of Cardiovascular Drugs in Sweden and Taiwan [327]
Desirée Loikas, Marlin Isteifo, Ching-Lan Cheng, Yea-Huei Kao Yang, Karin Schenck-Gustafsson, Björn Wettermark, Mia von Euler. (Sweden)

8:45am

- Cross-National Comparison of Prescribing Patterns in Australian and Dutch Nursing Homes [328]
Katja Taxis, Sjoerd Kochen, Sanne Geerens, Hans Wouters, Froukje Boersma, Jan G Maring, Hans Mulder, Jugoslav Pavlovic, Gerard Stevens, Andrew J McLachlan, Lisa Pont. (Netherlands)

9:00am

- Bladder Antimuscarinics and Cognitive Decline in Elderly Patients Enrolled in the National Alzheimer's Coordinating Center Cohort [329]
Daniela C Moga, Erin Abner, Gregory Jicha. (United States)

9:15am

- Utilization and Predictors of Active Surveillance among Elderly Men with Low-Risk Localized Prostate Cancer [330]
Huei-Ting Tsai, Arnold Potosky, George Philips, Katherine Taylor. (United States)

How Thin Is Your Blood? (201DE)

Moderators: Kiliana Suzart-Weischnik & Tzu-Chieh Lin

8:00am

- Avoiding "Crystal Ball" Epidemiology: The Case of Low-Dose Aspirin and Major Bleeding [331]
Jennifer L Lund, Til Sturmer, Erzsebet Horvath-Puho, Szimonetta Szépligeti, Lars Pedersen, Vera Ehrenstein, Henrik T Sorensen, John A Baron. (United States)

8:15am

- AUDIT-C Alcohol Misuse Screening Score and Major Bleeding in Warfarin Therapy: An Evaluation of Main Effects and Interaction with VKORC1 Genetic Status [332]
Joshua A Roth, Katharine Bradley, Kenneth Thummel, David L Veenstra, Denise Boudreau. (United States)

8:30am

- An International Comparison of Spontaneous Adverse Event Reports and Potentially Inappropriate Medicine Use Associated with Dabigatran [333]
Lisa M Kalisch Ellet, Cameron J McDonald, John D Barratt, Gillian E Caughey. (Australia)

8:45am

- Intravenous Thrombolytic Therapy Is Beneficial for Acute Stroke Patients with Renal Dysfunction [334]
Cheng-Yang Hsieh, Chih-Hung Chen, Huey-Juan Lin, Sheng-Feng Sung, Yea-Huei Kao Yang. (Taiwan)

9:00am

- Adherence and Persistence to New-Users of Dabigatran Among Patients with Non-Valvular Atrial Fibrillation in an Administrative Claims Database [335]
Meijia Zhou, Hsien-Yen Chang, G Caleb Alexander, Sonal Singh. (United States)

9:15am

- Utilization of Anticoagulants in Atrial Fibrillation: Influences of Clinical Risk Scores in Real-World Practice [336]
Julie C Lauffenburger, Joel F Farley, Denise H Rhoney, Anil K Gehi, M. Alan Brookhart, Gang Fang. (United States)

Student Award Recipient – Third Best Abstract Submitted by a Student/Post-Doc

AGENDA *Sunday, October 26*

8:00-9:30am CONCURRENT ORAL PRESENTATION SESSIONS

Sticks and Stones May Break My Bones (102)

Moderators: Patrick Souverein & Mitsuyo Kinjo

8:00am

► **Use of Pharmacologic Agents for the Secondary Prevention of Osteoporotic Fracture: A Cross-National Study [337]**

Seoyoung C Kim, Mi-Sook Kim, Gabriel Sanf elix-Gimeno, Hong Ji Song, Liu Jun, Isabel Hurtado, Salvador Peir o, Joongyub Lee, Nam-Kyong Choi, Byung-Joo Park, Jerry Avorn. (United States)

8:15am

► **Patterns of Pharmacological Treatment for Osteoporosis among Patients Qualified for Pharmacotherapy According to the National Osteoporosis Foundation Guidelines [338]**

Chi-Chuan (Emma) Wang, Chung-Hsuen (Alvin) Wu, Joel F Farley. (Taiwan)

8:30am

► **Distributed Analysis of Total Hip Arthroplasties Using Six International Registries: Comparing the Effects of Implant Bearing Surface and Size [339]**

Art Sedrakyan, Elizabeth W Paxton, Steven E Graves, Guy Cafri, Samprit Banerjee, Alejandro Allepuz, Leif I Havelin, Susan Mehle, Susanna Stea, Denica Marinac-Dabic. (United States)

8:45am

► **Shiny and New: Examining Patient and Physician Utilization of Non-Oral Osteoporosis Medications in Ontario, Canada [340]**

Andrea M Burden, Mina Tadrous, Lindsay Wong, Andrew Calzavara, Yan Yun Liu, Suzanne M Cadarette. (Canada)

9:00am

► **Mortality in British Hip Fracture Patients, 2000 – 2010: A Population-Based Retrospective Cohort Study [341]**

Corinne Klop, Paco MJ Welsing, Cyrus Cooper, Nicholas C Harvey, Johannes WJ Bijlsma, Petra JM Elders, Hubert GM Leufkens, Frank de Vries. (Netherlands)

9:15am

► **Medicine Use and the Risk of Hip Fracture in the Elderly: A Case-Crossover Study [342]**

Michael J Leach, Nicole L Pratt, Elizabeth E Roughead. (Australia)

Well Adjusted by Design (4th Floor VIP)

Moderators: David Dore & Almut Winterstein, FISPE

8:00am

► **The Dual-Time-Adjusted Case-Crossover Design [343]**

Joshua J Gagne, Sebastian Schneeweiss, Shirley V Wang. (United States)

8:15am

► **Adapting and Evaluating Self-Controlled Case Series Method (SCCS) for Signal Screening of a Recently Marketed Drug Using a US Claims Database [344]**

Xiaofeng Zhou, Rongjun Shen, Jamie Geier, Andrew Bate. (United States)

8:30am

► **The Use of Prior Event Rate Ratio Adjustment Method for Controlling Unmeasured Confounding in Pharmacoepidemiologic Studies: A Cautionary Note [345]**

Md Jamal Uddin, Rolf HH Groenwold, Tjeerd P van Staa, Anthonius de Boer, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)

8:45am

► **Controlling Time-Dependent Confounding by Frailty: Restriction Versus Statistical Adjustment [346]**

Leah J McGrath, Alan R Ellis, M Alan Brookhart. (United States)

9:00am

► **Comparator Choice in Diabetes Drug Studies: Single Class or Non-User Comparator Group? [347]**

Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Cynthia J Girman, Ravi Shankar, Zhiwen Liu, Samuel S Engel. (United States)

9:15am

► **Comparing Estimation Strategies for Disease Risk Scores: A Simulation Study [348]**

Richard Wyss, M Alan Brookhart, Virginia Pate, Til St urmer. (United States)

9:30-10:00am

Break/Posters/Exhibits
(101/Main Entrance Lobby)

AGENDA *Sunday, October 26*

10:00-11:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Diverse Topics in Pediatric Populations (103)

Moderators: Timothy Beukelman & Wanning Xu

10:00am

- ▶ **Increasing Trend of Type 1 Diabetes in Dutch Children and Adolescents (1998-2010) [349]**
Soulmaz Fazeli Farsani, Patrick C Souverein, Marja MJ van der Vorst, Catherijne AJ Knibbe, Ron MC Herings, Anthonius de Boer, Aukje K Mantel-Teeuwisse. (Netherlands)

10:15am

- ▶ **Cancer Incidence among Infants in the United States, 2000-2010 [350]**
Logan Tyler, Jinghua He. (United States)

10:30am

- ▶ **Chronic Comorbidities in Children and Adolescents with Type 1 Diabetes [351]**
Soulmaz Fazeli Farsani, Patrick C Souverein, Marja MJ van der Vorst, Catherijne AJ Knibbe, Anthonius de Boer, Aukje K Mantel-Teeuwisse. (Netherlands)

10:45am

- ▶ **Antimuscarinic Utilization in the Pediatric Population in the United States, 2000-2011 [352]**
Alan Kinlaw, Jennifer Wu, Mitchell Conover, Virginia Pate, Michele Jonsson Funk. (United States)

11:00am

- ▶ **Prevalence of Pediatric Chronic Hepatitis C Patients in the European Union (EU) in 2012 [353]**
Shih-Chen Chang, Katie M Miller, Gregory Hooper. (United States)

11:15am

- ▶ **Association between Use of Asthma Drugs in Children and Hepatotoxicity [354]**
Carmen Ferrajolo, Marjolein Engelkes, Katia MC Verhamme, Gianluca Trifirò, Annalisa Capuano, Miriam CJM Sturkenboom. (Netherlands)

Don't Go Breaking My Heart (201BC)

Moderators: Emily Brouwer & K Arnold Chan, FISPE

10:00am

- ▶ **Use of Oral Contraceptives and Risk of Hemorrhagic Stroke in Denmark (2003 - 2012) [355]**
Klaus K Andersen, Christian Dehlendorff, Charlotte Skriver, Søren Friis, Tom S Olsen. (Denmark)

10:15am

- ▶ **Comparative Cardiovascular Safety of Testosterone Formulations in the United States and United Kingdom [356]**
J Bradley Layton, Julie L Sharpless, Christoph R Meier, Til Stürmer, Susan S Jick, M Alan Brookhart. (United States)

10:30am

- ▶ **Dipeptidyl Peptidase-4 Inhibitors Do Not Increase the Risk of Cardiovascular Events in Type 2 Diabetes [357]**
Seoyoung C Kim, Robert Glynn, Jun Liu, Brendan Everett, Allison Goldfine. (United States)

10:45am

- ▶ **Risk of Out-of-Hospital Sudden Cardiac Death with Use of Domperidone, Proton Pump Inhibitors, and Metoclopramide [358]**
Alejandro Arana, Catherine Johannes, Cristina Varas, Kenneth J Rothman, Lisa J McQuay, Qing Yang, Daniel Fife. (Spain)

11:00am

- ▶ **Association of Azithromycin and Ventricular Arrhythmia: the ARITMO Project [359]**
Gianluca Trifiro, Alessandro Oteri, Maria de Ridder, Peter Rijnbeek, Serena Pecchioli, Giampiero Mazzaglia, Irene Bezemer, Edeltraut Garbe, Tania Schink, Elisabetta Poluzzi, Trine Frøslev, Miriam Sturkenboom. (Netherlands)

11:15am

- ▶ **Risk of Hemorrhagic Stroke Associated with Combined Use of Antidepressants and Non-Steroidal Anti-Inflammatory Drugs [360]**
Ju-Young Shin, Mi-Ju Park, Mi-Hee Kim, Nam-Kyong Choi, Joong-Yeup Lee, Byung-Joo Park. (Korea)

10:00-11:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS

How Sick We Are (102)

Moderators: Ulf Bergman, FISPE & Sumitra Shantakumar

10:00am

- ▶ **Comparison of Chronic Disease Burden of Chinese in US and in China: Findings from Two Large Nationally Representative Surveys in US and China [361]**
Chenghui Li. (United States)

10:15am

- ▶ **Safety of Anticholinergic Medications in the Elderly: Anticholinergic Burden and Lower Urinary Tract Symptoms (LUTS) [362]**
Lisa G Pont, JTH (Yannick) Nielen, Andrew McLachlan, Danijela Gnjdic, Lewis Chan, Robert Cumming, Katja Taxis. (Australia)

10:30am

- ▶ **Oral Corticosteroids and the Risk of Serious Infections in Patients with Elderly-Onset Inflammatory Bowel Diseases [363]**
Paul Brassard, Alain Bitton, Alain Suissa, Liliya Sinyavskaya, Valerie Patenaude, Samy Suissa. (Canada)

10:45am

- ▶ **Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients Compared to Non-Psoriatic Arthritis Patients [835]**
Lin Li, Katrina W Hagberg, Michael M Peng, Susan Jick. (United States)

11:00am

- ▶ **Incidence of Barrett's Esophagus and Esophageal Adenocarcinoma in the United Kingdom and the Netherlands: Did We Reach a Plateau? [365]**
Gwen MC Masclee, Preci M Coloma, Marcel de Wilde, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)

11:15am

- ▶ **Incidence of Drug-Induced Acute Liver Failure: A Population-Based Study [366]**
David Goldberg, Kimberly Forde, Kevin Haynes, James D Lewis, Dena Carbonari, Kimberly Leidl, Rajender Reddy, Melissa Nezamzadeh, Jason Roy, Daohang Sha, Amy Marks, Jolanda De Boer, Jennifer Schneider, Brian Strom, Douglas Corley, Vincent Lo Re III. (United States)

Not All Diabetes Are Alike: Issues of Diagnosis (201DE)

Moderators: Deborah Layton & Kiyoshi Kubota, FISPE

10:00am

- ▶ **Identification of Type 2 Diabetes Mellitus in Different Electronic Databases Within the SAFEGUARD Project [367]**
Ingrid Leal, Gwen MC Masclee, Lorenza Scotti, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martin, Cormac Sammon, Niklas Schmedt, John D Seeger, Gianluca Trifiro, Serena Pecchioli, Cristina Varas-Lorenzo, Mark M Smits, Peter Rijnbeek, Miriam CJM Sturkenboom, Silvana Romio. (Netherlands)

10:15am

- ▶ **Identification of Prediabetes, Healthcare Utilization and Progression to Diabetes in CPRD [368]**
Jin-Liern Hong, Ann Marie McNeill, Jinghua He, Kimberly Brodovicz. (United States)

10:30am

- ▶ **Characteristics of Patients with Type 2 Diabetes (T2DM) Captured in Administrative Claims and Electronic Medical Records (EMR) [369]**
Mary E Ritchey, Samuel S Engel, Zhiwen Liu, Catherine Ntabadde, Michael Senderak, Ravi Shankar, Ying Qiu, Larry Radican, Swapnil Rajpathak, Kimberly G Brodovicz. (United States)

10:45am

- ▶ **Monitoring for Proteinuria in Patients with Type 2 Diabetes Mellitus in the UK Clinical Practice Research Datalink [370]**
Paul Dolin, Huifang Liang, Carlos Vallarino, Sudhakar Manne. (United Kingdom)

11:00am

- ▶ **Characteristics of Patients with Type 2 Diabetes Starting Sitagliptin vs. Other Oral Diabetes Medications and Propensity Score Balance [371]**
Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Samuel S Engel, Ravi Shankar, Zhiwen Liu, Cynthia J Girman. (United States)

11:15am

- ▶ **Baseline Characteristics of Patients with Type 2 Diabetes Initiating Sitagliptin or GLP-1 Receptor Agonists [372]**
Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Cynthia J Girman, Ravi Shankar, Zhiwen Liu, Samuel S Engel. (United States)

AGENDA Sunday, October 26

10:00-11:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS

PS or What?? (4th Floor VIP)

Moderators: Til Stürmer, FISPE & John D Seeger, FISPE

10:00am

- ▶ **Comparison of Matching on Key Confounders, High-Dimensional Propensity Score (HDPS) and a Combination of Both to Adjust for Confounding** [373]

Fei Xue, Patrick Ventura, Trevor McMullan, Paul Petraro, Violeta Hennessey. (United States)

10:15am

- ▶ **Head to Head Comparison of the Propensity Score and High-Dimensional Propensity Score Matching Methods in Reducing Potential Indication Bias** [374]

Jason R Guertin, Elham Rahme, Colin R Dormuth, Jacques LeLorier. (Canada)

10:30am

- ▶ **High-Dimensional Propensity Score Versus Lasso Outcome Regression for Confounding Adjustment** [375]

Jessica M Franklin, Wesley Eddings, Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

10:45am

- ▶ **Trimming on Propensity or Disease Risk Scores to Enhance Validity in the Design of Comparative Effectiveness Studies** [376]

Robert J Glynn, Mark Lunt, Til Stürmer. (United States)

11:00am

- ▶ **Antidepressant Use and Risk of Hip Fracture: A Comparison of Marginal Structural Models, Conventional Regression and Propensity Score Methods** [377]

M Sanni Ali, Rolf HH Groenwold, Svetlana V Belitser, Patrick C Souverein, Helga Gardarsdottir, Arno W Hoes, A de Boer, Olaf H Klungel. (Netherlands)

11:15am

- ▶ **Preference and Propensity: Evaluating Oral Treatment of Type 2 Diabetes (T2DM)** [378]

Mary E Ritchey, Yong Chen, Cynthia J Girman, Kimberly G Brodovicz. (United States)

To Use or Not to Use Psychotropic Medications (201AF)

Moderators: Paul Stang, FISPE & Karolina Anderson-Sundell

10:00am

- ▶ **Do Patients Initiate Therapy? Primary Non-Adherence to Statins and Antidepressant in Iceland** [379]

Gudrun Thengilsdottir, Anton Pottegård, Anna B Almarsdottir, Helga Gardarsdottir. (Netherlands)

10:15am

- ▶ **Patterns of Statin Prescribing for the Primary Prevention of Cardiovascular Disease in People with Severe Mental Illness** [380]

Ruth Blackburn, David Osborn, Irene Petersen, Kate Walters, Irwin Nazareth. (United Kingdom)

10:30am

- ▶ **Drug Utilization Pattern in Children with Autism Spectrum Disorder (ASD) in Asian Countries: A Population Based Study** [381]

Ching-Lan Cheng, Kenneth KC Man, Yingfen Hsia, Yea-Huei Kao Yang, Ian CK Wong. (Taiwan)

10:45am

- ▶ **Sex Differences in Utilization of Nervous System Drugs in Sweden and Taiwan** [250]

Mia von Euler, Maria Sperling, Ching-Lan Cheng, Yea-Huei Kao Yang, Björn Wettermark. (Sweden)

11:00am

- ▶ **The Impacts of Non-Adherence on Hospitalizations in Patients with Schizophrenia in Thailand** [383]

Piyameth Dilokthornsakul, Oraluck Patanaprteep, Ronnachai Kongsakon, Nathorn Chaiyakunapruk. (Thailand)

11:15am

- ▶ **Discontinuation of Somatic Medication during Psychiatric Hospitalisation** [384]

Heshu Abdullah-Koomees, Helga Gardarsdottir, Lennart J Stoker, Judith Vuyk, Toine CG Egberts, Eibert R Heerdink. (Netherlands)

11:30am-1:00pm

Lunch/Poster Session B/Roundtable Discussions (Banquet Hall, 3rd Floor)

Roundtable Discussions: To foster the ability of the more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Saturday and Sunday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange and networking. Seating is limited; first-come, first-served.

- **Til Stürmer, FISPE**, *Challenges and Approaches to Controlling for Confounding in Pharmacoepidemiology*
- **Susana Perez-Gutthann, FISPE**, *The Conduct of Well-Designed Multi-Country Observational Studies in Databases*
- **Yea-Huei Kao Yang, FISPE**, *Publishing in Pharmacoepidemiology*

ISPE Committee/Council Meetings

–Open to all participants, unless otherwise specified.

- **Bylaws and Policies - By Invitation** (Banquet Hall, 3rd Floor)
- **Education** (South Lounge, 3rd Floor)
- **Global Development** (North Lounge, 3rd Floor)
- **Membership** (South Lounge, 3rd Floor)
- **Publications** (South Lounge, 3rd Floor)

AGENDA Sunday, October 26

11:45am-12:45pm

Spotlight Poster Sessions (101)

- Best of the Day
- Adherence
- Benefit Risk Assessment, Communication and Evaluation (BRACE)
- Comparative Effectiveness Research
- Pregnancy

1:00-2:30pm **PLENARY SESSION** (Plenary Hall, 3rd Floor)

Using Patient-Centered Information in Pharmacoepidemiology: A Global Perspective

Faculty:

- Priya Bahri, *Pharmacovigilance, EMA*
- Nancy Dreyer, *FISPE, Quintiles*
- Francois Houyez, *Director of Treatment Information & Access, Eurordis; Co-Chair of ISPOR Patient Centered Advocacy Group*
- Lynn Weekes, *CEO NPS Medicinewise*

Moderators:

- Kate Lapane, *FISPE, University of Massachusetts Medical School*

Patient-centered information (PCI) has gained increasing recognition in recent years, particularly in the realm of comparative effectiveness and safety research. While clinicians have routinely utilized social, behavioral, functional, and symptom-related PCI from their patients to make informed clinical decisions, there is an increasing emphasis from regulatory and payer organizations to supplement traditional outcomes measures with patient reported ones. The idea behind this emphasis is that events need to be interpreted in the context of the impact that they have on patients. A good example for this concept is palliative cancer treatment, where extensions of lifespan need to be weighed against the side effects of the treatment itself on quality of life. The majority of databases used in pharmacoepidemiologic studies today, however, do not capture PCI. This plenary session will help to clarify what part of pharmacoepidemiologic research would benefit most from inclusion of PCI and provide examples from various settings where PCI has been successfully included in the evaluation of medicines.

Through personal reflections and experiences, regional and global examples will be presented that describe how and why PCI has been used in the evaluation of medicines, the impact PCI made, the challenges and opportunities to consider when collecting and assessing PCI, and a vision for the role of PCI in future pharmacoepidemiology studies.



Visit **Booth #19** to learn more about **Degge's** services:

- Pharmacoepidemiology
- Pharmacovigilance
- Oversight Group Management
- Risk Management
- Regulatory/Legal
- Safety Analysis

Tel: +1 571.490.8020 E-mail: info@deggegroupp.com Web: www.deggegroupp.com

Consulting in Drug Safety Research and Pharmacoepidemiology since 1988

Identify databases by subscribing to our online compendium of ~250 population database profiles from 33 countries

- Search, compare, organize, and export database profiles
- Access specialized glossary and interactive map of database lists

Profiles are reviewed by database managers and frequently updated

www.BRIDGETODATA.org +1 571.490.8400

Your connection to healthcare databases worldwide®

B.R.I.D.G.E. TO DATA® is an online service provided by DGI, LLC, a non-profit organization



AGENDA Sunday, October 26

2:30-4:00pm (Open to all participants) (Plenary Hall, 3rd Floor)

ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY



ANNUAL MEETING

Call to Order and Presidential Address

- ▶ Til Stürmer, FISPE, ISPE President

Financial Report

- ▶ Kate Lapane, FISPE, Vice President Finance

AWARDS CEREMONY

The Ronald D. Mann Best Paper Awards for Manuscripts Published in Volume 22 (2013), PDS

First Prize

Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control.

Adriana M Hung, Christianne L Roumie, Robert A Greevy, Xulei Liu, Carlos G Grijalva, Harvey J Murff and Marie R Griffin

Honorable Mentions

Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years.

Shahed Iqbal, John P Barile, William W Thompson and Frank DeStefano

Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study.

Carlos Iribarren, Alfred D Round, Jonathan A Peng, Meng Lu, Jonathan G Zaroff, Taylor J Holve, Amit Prasad and Paul Stang

Use of case–time–control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly.

Sylvie D Price, C D'Arcy, J Holman, Frank M Sanfilippo and Jon D Emery.

Presenters

- ▶ Brian L Strom, FISPE, Editor-in-Chief
- ▶ Sean Hennessy, FISPE, Regional Editor for the Americas
- ▶ BJ Park, FISPE, Regional Editor for Asia-Pacific and ROW

30th ICPE

- ▶ Yea-Huei Kao Yang, FISPE, Chair, Local Host Committee
- ▶ Soko Setoguchi, FISPE, Chair, Scientific Program Committee

The Andrew McAfee Award

(Best abstract submitted from a developing country)

- ▶ Hisham Aljadhey

Student Awards

—Best Methods Abstract: Md Jamal Uddin

—Third Best Abstract: Julie Lauffenburger

—Second Best Abstract: Kirstine Søgaard

The Stanley A. Edlavitch Award & Oral Presentation

(Best abstract submitted by a student/post-doc):

- ▶ Jin-Liern Hong
Assessment of Prediabetes in the United Kingdom CPRD and Its Association with Incident Cancers [385]
Jin-Liern Hong, Ann Marie McNeill, Jinghua He, Kimberly Brodovicz. (United States)

Induction of ISPE Fellows (FISPE)

- ▶ Alison Bourke, FIPSE
- ▶ Jennifer B Christian, FISPE
- ▶ Kevin Haynes, FISPE
- ▶ Andrew Leigh Gilbert, FISPE
- ▶ John D Seeger, FISPE

BOARD TRANSITION

Retiring Board Members & Officers

- ▶ Ariel E Arias
- ▶ Edeltraut Garbe
- ▶ Kate Lapane, FISPE, Vice President Finance
- ▶ Stella Blackburn, FISPE, Immediate Past President

Induction of New Board Members

- ▶ Andrew Bate
Industry/Service Provider; Europe/Africa
- ▶ Helga Gardarsdóttir
Academic/Europe/Africa
- ▶ Marie Linquist
Government/Regulatory/Americas
- ▶ Almut Winterstein, FISPE
Academic/Americas
- ▶ Wei Zhou
Industry/Service Provider/Asia/Pacific

Installation of 2014-2015 Officers

- ▶ Allison Bourke, FISPE, Vice President Finance
- ▶ Til Stürmer, FISPE, Immediate Past President
- ▶ Sonia Hernandez-Diaz, FISPE, President-Elect
- ▶ John D Seeger, FISPE, President

ADJOURNMENT

AGENDA *Sunday, October 26*

4:00-4:30pm

Break/Posters/Exhibits (101/Main Entrance Lobby)

4:30-6:00pm

SYMPOSIA AND WORKSHOPS

Adherence to Drug Treatment: A Practical Look at Complex Measurement Issues [386] (201DE)

- Jean-Pierre Grégoire, Petra Denig, Colin Dormuth, Gillian Caughey. (Canada)

Databases in China: Are We Ready Yet? [387] (201AF)

- Xiaofei Ye, Siyan Zhan, Wei Zhou, Xin Sun. (China)

Evaluating the Drug Regulatory System: Lessons from the Escher Project Challenges in Implementing Findings of Regulatory Science to Evaluate and Improve the Drug Regulatory System [388](103)

- Xavier Kurz, David Martin, Jarno Hoekman, Jacqueline C Bouvy, Andrew Roddam, Hans Ebbers, Hubert GM Leufkens, K Arnold Chan, Gerald Dal Pan, Robert Reynolds, Marie L De Bruin. (United States)

Guidelines and Recommendations for Comparative Effectiveness Research (CER) Methods: International Assessment and Exchange [389] (Plenary Hall, 3rd Floor)

- Eunsun Noh, Nancy A Dreyer, Jeonghoon Ahn, Thamer M Alshammari, Mary E Ritchey, J Bradley Layton, Aisling R Caffrey. (United States)

Leveraging Electronic Health Data for Medical Device Epidemiology: Approaches To Post-Market Surveillance of Joint Replacement Surgery [390] (102)

- Stephen Graves, Nicole Pratt, Liz Paxton, Tzu-Chieh Lin, Maria Inacio. (Australia)

Primary Data Collection in Pharmacoepidemiology: Design, Practical, and Methodologic Considerations [391] (201BC)

- Jessica J Jalbert, Kiyoshi Kubota, Gurumurthy Parthasarathi, Soko Setoguchi, Lamiae Grimaldi-Bensouda. (United States)

Tracking of Adverse Drug Reactions in Social Media: Current Status of Requirements, Best Practices, Methods and Tools [392] (4th Floor VIP)

- Massoud Toussi, Carl de Moor, Siva Nadarajah, Alasdair Breckenridge. (France)

6:00-7:00pm

Council Meetings

Open to all members and new members.

- **Academic** (201DE)
- **Government/Regulatory** (201AF)
- **Industry/Service Provider** (201BC)

7:30-10:30pm

Gala Dinner at the Grand Hotel*

(*Registration required)

- Buses will shuttle between the Taipei International Convention Center (TICC) and the Grand Hotel. The first bus will leave the TICC at 6:30pm, and the last one from the TICC is 7:10pm. The last bus from the Grand Hotel to TICC is 10:30pm.
- Shuttle pick up from TICC is South Entrance at 1F
- Shuttle pick up from Grand hotel is Main Entrance or Lobby



The Grand Hotel retains the elements of classical Chinese architecture in its building. It is a splendid landmark of Taipei, and representative of contemporary palatial architecture.



Join your colleagues for a superb Chinese banquet and traditional entertainment in a unique venue. Performance Group: Ming Hwa Yuan, a Ge Zai Xi performance group - 80 years of establishment, documenting the legend musical of the Orient.

- Performance sponsored by Ming Hwa Yuan

7:00am-4:00pm

Registration
(Main Entrance Lobby)

7:00am-3:30pm

Speakers' Ready Room (105)

7:00-8:00am

Poster Session C Set-up (101/Main Entrance Lobby)

7:30-8:25am

2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm

Exhibits/Posters (101/Main Entrance Lobby)

8:30-10:00am **CONCURRENT ORAL PRESENTATION SESSIONS**

Kids Up and Down and All Around (103)

Moderators: Miriam Sturkenboom, FISPE & Ian Wong

8:30am

- ▶ **Second Generation Antipsychotics and Risk of Type 2 Diabetes in Publicly Insured Children and Adolescents [596]**
Tobias Gerhard, William V Bobo, Mark Olsson, Christoph U Correll, Cecilia Huang, Stephen Crystal. (United States)

8:45am

- ▶ **Attention-Deficit/Hyperactivity Disorder (ADHD) Pharmacological Treatment and Its Effect on Accident and Emergency Admission Due to Injury: A Self-Controlled Case-Series Study [597]**
Kenneth KC Man, Esther W Chan, Ian Douglas, Patrick Ip, Wilfred HS Wong, David Coghill, Ian CK Wong. (Hong Kong)

9:00am

- ▶ **Antidepressants and Risk of Suicide or Self-Harm in Canadian Youth: A Study Involving a Common Data Model in Quebec and British Columbia [598]**
Larry L Lynd, Thierry Ducruet, Kathy Li, Marie Tournier, Brian Greenfield, Yola Moride. (Canada)

9:15am

- ▶ **Trend in the Prescribing of Antipsychotics for Children and Adolescents in Japan: A Descriptive Epidemiological Study from the Large-Scale Pharmacy Database [599]**
Sayuri Nakane, Chika Nishiyama, Kenji Kochi, Yusuke Ogawa, Toshiaki A Furukawa, Koji Kawakami. (Japan)

9:30am

- ▶ **Does Physicians' Treatment of Pediatric Depression Reflect Evidence-Based Practice? Findings from a National Sample of Privately Insured Children and Adolescents [600]**
Rene Soria-Saucedo, Heather J Walter, Howard Cabral, Mary Jane England, Lewis Kazis. (United States)

9:45am

- ▶ **Development of a Novel Approach to Assess Psychotropic Polypharmacy in Administrative Databases [601]**
Xinyue Liu, Paul Kubilis, Regina Bussing, Almut G Winterstein. (United States)



Transforming the language of life into vital medicines

转化生物科技为有效治疗药物

AMGEN
Pioneering science delivers vital medicines™

Amgen is a proud sponsor of the 30th annual International Conference on Pharmacoepidemiology

8:30-10:00am CONCURRENT ORAL PRESENTATION SESSIONS

On or Off Course (201BC)

Moderators: Felin Lin & Jean-Pierre Gregoire, FISPE

8:30am

- Does a Cardiovascular Event Change Adherence to Statin Treatment in Patients with Type 2 Diabetes? A Matched Cohort Design [602]
Dianna de Vries, Petra Denig, Stefan Vegter, HJ Bos, Maarten J Postma, Eelko Hak. (Netherlands)

8:45am

- Factors Associated with Patients' Adherence to Antihypertensive Drug Classes in the UK [603]
Amanj Baker, Li-Chia Chen, Rachel Elliott. (United Kingdom)

9:00am

- Factors Associated with β -Blocker Initiation and Discontinuation among Seniors with Heart Failure (HF) [604]
Catherine Girouard, Jean-Pierre Grégoire, Paul Poirier, Jocelyne Moisan. (Canada)

9:15am

- A Cross Country Comparison of the Impact of Cost-Sharing Policies on Adherence to Prescription Medicines [605]
Sarah-Jo Sinnott, Helen Whelton, Jessica M Franklin, Jennifer M Polinski. (Ireland)

9:30am

- Primary Care Prescriptions and Subsequent Pharmacy Dispensing: A Population-Based Study [606]
Daniel Prieto-Alhambra, Josep M Elorza-Ricart, Eduardo Herмосilla, Jordi Rodriguez-Ruiz, Leonardo Mendez-Boo, Manuel Medina-Peralta. (Spain)

9:45am

- Statin Adherence and Treatment LDL-Cholesterol Response in Type 2 Diabetes Patients [607]
Dianna de Vries, Jaco Voorham, Eelko Hak, Petra Denig. (Netherlands)

Steroids With a Twist! (201DE)

Moderators: Gianluca Trifirò & Jesper Hallas, FISPE

8:30am

- Effect of Long-Term Aspirin Use on the Risk for Neovascular Age-Related Macular Degeneration [608]
Ruben G Duijnhoven, Redmer van Leeuwen, Sabine M Straus, Saskia M Imhof, Arno W Hoes, Anthonius de Boer, Marie L De Bruin. (Netherlands)

8:45am

- Preadmission Non-Steroidal Anti-Inflammatory Drug Use and 30-Day Stroke Mortality [609]
Morten Schmidt, Erzsébet Hovath-Puho, Christian F Christiansen, Karin L Petersen, Hans E Bøtker, Henrik T Sørensen. (Denmark)

9:00am

- Chemoprevention of Esophageal Adenocarcinoma among Patients with Barrett's Esophagus [610]
Gwen MC Masclee, Preci M Coloma, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)

9:15am

- Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study [611]
Gianluca Trifirò, Ylenia Ingrassiotta, Francesco Giorgianni, Janet Sultana, Daniele Ugo Tari, Margherita Perrotta, Claudio Linguiti, Andrea Fontana, Fabio Pellegrini, Achille P Caputi. (Italy)

9:30am

- Impact of Dose and Duration of Oral Glucocorticoid Therapy on the Risk of Incident Type II Diabetes in Patients with Rheumatoid Arthritis [612]
Mohammad Movahedi, Marie-Eve Beauchamp, Kaleb Michaud, Sofia Pedro, Michal Abrahamowicz, Will G Dixon. (United Kingdom)

9:45am

- Use of Glucocorticoids and Postoperative Bleeding after Gastric Bypass Surgery [613]
Sigrid B Gribsholt, Elisabeth Svensson, Stine Skovbo, Reimar W Thomsen, Bjørn Richelsen, Henrik T Sørensen. (Denmark)

Strings Making Sense (SMS) Harvesting Data (201AF)

Moderators: Martijn Schuemie & Brian Sauer

8:30am

- Statistical Natural Language Processing Can Accurately Identify Venous Thromboembolism (VTE) Events from Narrative Electronic Health Record Data [614]
Christian M Rochefort, Aman D Verma, David L Bucheridge. (Canada)

8:45am

- Validity of Current Procedural Terminology (CPT) Codes and Natural Language Processing of Infusion Notes to Identify Outpatient Infliximab Infusion [615]
Chao-Chin Lu, Chia-Chen Teng, Jianwei Leng, Grant Cannon, Tao He, David Harrison, Derek Tang, Neel Shah, Brian Sauer. (United States)

9:00am

- Linguistic Variability and Clinical Terminology in a Large Dutch General Practitioners Database [616]
Zubair Afzal, Martijn J Schuemie, Miriam CJM Sturkenboom, Jan A Kors. (Netherlands)

9:15am

- Generating and Evaluating a Propensity Score Model Using Textual Features from Electronic Medical Records [617]
Zubair Afzal, Gwen MC Masclee, Miriam CJM Sturkenboom, Jan A Kors, Martijn J Schuemie. (Netherlands)

9:30am

- Handling Missing Exposure: A Simulation Study [618]
Andrea V Margulis, Alejandro Arana. (Spain)

9:45am

- Assessment of Daily Dose of Domperidone in the Clinical Practice Research Datalink (CPRD) Using Multiple Information Sources [619]
Alejandro Arana, Catherine Johannes, Cristina Varas, Kenneth J Rothman, Lisa J McQuay, Qing Yang, Daniel Fife. (Spain)

AGENDA *Monday, October 27*

8:30-10:00am CONCURRENT ORAL PRESENTATION SESSIONS

Translating Policy into Practice (102)

Moderators: Susana Perez-Gutthann, FISPE & Peter Mol

8:30am

- ▶ **Impact of Direct-To-Consumer Advertising on Asthma Prescriptions [620]**
Susan Hutfless, Matthew Daubresse, Yoonsang Kim, Rachel Kornfield, Dima Qato, Jidong Huang, Kay Miller, Sherry Emery, Caleb G Alexander. (United States)

8:45am

- ▶ **Lessons Learned on the Design of European Post Authorisation Safety Studies (PASS): Review of 18 Months of PRAC Oversight [621]**
Pierre Engel, Michelle Bulliard, Louise Parmenter, Kathryn Starzyk, Nancy Dreyer. (France)

9:00am

- ▶ **Hospital Based Electronic Medical Record Databases in China [622]**
Wei Zhou, Ting Wu, Zhiwen Liu, Ronghua Chen. (China)

9:15am

- ▶ **Development of Thailand Rational Drug Use Indicators [623]**
Penkarn Kanjanarat, Sirikwan Boriharn. (Thailand)

9:30am

- ▶ **Prevalence of Suboptimal Processes of Care Prior to Hospitalisation [624]**
Gillian E Caughey, Lisa M Kalisch Ellett. (Australia)

9:45am

- ▶ **Understanding Patterns of Drug Utilization Studies (DUS) Requested By the European Medicines Agency (EMA) [625]**
Claudia Schroeder, Jacco Keja, Ben Hughes, Birgit Ehlken, Massoud Toussi. (France)



Bayer HealthCare



Bayer HealthCare is a globally operating company with sites on all five continents. Approximately 55,700 people work for the Bayer subgroup in more than 100 countries at all stages of the value-added chain. Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG.

We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products.

We concentrate on five big therapeutic groups in which we make essential contributions to medical progress:

- Cardiovascular and blood diseases
- Oncological diseases
- Ophthalmology
- Women's healthcare
- Imaging techniques

Our Global Epidemiology organization is currently establishing its operations around the world. Opportunities for Epidemiologists with pharmaceutical experience exist at the Associate Director/Senior Epidemiologist and Director level in the US and Europe. To learn more, contact: Montse Soriano-Gabarró at + 49 30 468 194270

For Information about Bayer Healthcare go to
<http://www.bayerhealthcare.com/scripts/pages/en/index.php>

Bayer is an equal opportunity employer, embracing diversity throughout our global workforce.

Treatment of Diabetes: Is It Safe Enough? (4th Floor VIP)

Moderators: Syed Ahmed, FISPE &
Chih-Ying (Natasha) Chen

8:30am

▶ **Comparison of Clinical Measures between Those with and Without a Diagnosis of Diabetes among Patients Prescribed Antidiabetic Drugs Within the Humedica EHR Database [626]**

Donnie P Funch, Anthony P Nunes, Yan Ding, Robin C Clifford, Nicholas J Everage, David D Dore. (United States)

8:45am

▶ **Patterns and Determinants of New First-Line Antihyperglycaemic Drug Use in Patients with Type 2 Diabetes Mellitus [627]**

Anne S Geier, Ina Wellmann, Jürgen Wellmann, Hiltraud Kajüter, Oliver Heidinger, Georg Hempel, Hans-Werner Hense. (Germany)

9:00am

▶ **Incretin Therapy and Risk of Pancreatitis in Type 2 Diabetes Mellitus: Systematic Review of Randomized and Non-Randomized Studies [628]**

Ling Li, Jiantong Shen, Malgorzata M Bala, Shanil Ebrahim, Per Olav Vandvik, Jason W Busse, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani, Gordon H Guyatt, Xin Sun. (China)

9:15am

▶ **Incidence of New Onset Type 2 Diabetes (T2DM) with Seroquel XL™ in Primary Care in England: Results from an Observational Post-Marketing Cohort Study [629]**

Miranda Davies, Deborah Layton, Vicki Osborne, Saad AW Shakir. (United Kingdom)

9:30am

▶ **Glitazone Antidiabetics and the Risk of Parkinson's Disease [630]**

Ruth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, David Dexter, Liam Smeeth, Ian Douglas. (United Kingdom)

9:45am

▶ **Postmarketing Evaluation of the Safety of Saxagliptin: An Interim Analysis [631]**

Kevin Haynes, Melissa S Nezamzadeh, Craig W Newcomb, Jason Roy, Whitney Kite, Dena M Carbonari, Sean Hennessy, Serena Cardillo, Cristin P Freeman, Crystal N Holick, Daina B Esposito, Tjeerd Van Staa, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re. (United States)

10:00-10:30am

Break/Posters/Exhibits
(101/Main Entrance Lobby)

10:30am-Noon

SYMPOSIA AND WORKSHOPS

Comparative and Clinical Effectiveness Studies Based on Taiwan National Health Insurance Research Database [632] (201BC)

- I-Shou Chang, Mei-Shu Lai, Chung-Yi Li, Jung-Der Wang, Li-Kwang Chen, Tzeng-Ji Chen. (Taiwan)

Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharmacoepidemiology (PE) Studies [633] (402)

- Gerald Dal Pan, Vera Ehrenstein, Seeger John, Veena Thyagarajan, Nicole C Wright, Hairong Xu, Fei Xue. (United States)

Drugs and Devices: Challenges and Opportunities for the Evaluation of Combination Medical Products [634] (201DE)

- Michael E Matheny, Irene B Murimi, Mary E Ritchey, Ted Lystig, Myoung Kim, Danica Marinac-Dabic, Michael Steinbuch. (United States)

HOT, HOT, HOT and Getting HOTTER? - Climate Change and Pharmacoepidemiology [635] (102)

- Debra S Rowett, Richard Hill, Genevieve Gabb, Peng Bi, Soko Setoguchi. (Australia)

How Do We Overcome Challenges of Diverse Views in Multi-Disiplinary Collaboration on CER? [636] (4th Floor VIP)

- Cynthia J Girman, Sebastian Schneeweiss, Leona E Markson, Til Stürmer, Stella Blackburn. (United States)

Improving the Science of Regulatory Decision-Making – Advances in 2013/2014 [637] (201AF)

- Stanley A Edlavitch, Gerald J Dal Pan, June M Raine, Hubert G Leufkens, Byung-Joo Park, Jerry Avorn. (United States)

International Collaboration on Pharmacogenomics in Epidemiology Research [638] (103)

- Wei Zhou, Issam Zineh, Bruce Carleton, Fredrik Nyberg, Wen-Hung Chung. (China)

Noon-1:30pm

Lunch/Poster Session C/Exhibits (Banquet Hall, 3rd Floor)

ISPE Board of Directors Luncheon (401)

(Meeting open to all members; check with staff if you wish to attend)

12:15-1:15pm

Spotlight Poster Sessions (101)

- Best of the Day
- Database
- Asian Pharmacoepidemiology Network (AsPEN)
- Biologics
- Device

AGENDA *Monday, October 27*

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

From Epilepsy to Dementia (201BC)

Moderators: Rob Heerdink & Churn-Shiouh Gau

1:30pm

- ▶ **Lithium Treatment and Risk for Dementia Among Patients with Bipolar Disorder [639]**
Tobias Gerhard, Davangere P Devanand, Cecilia Huang, Stephen Crystal, Mark Olfson. (United States)

1:45pm

- ▶ **Incidence of Antipsychotic Use in Relation to Diagnosis of Alzheimer's Disease among Community-Dwelling Persons: Nationwide Population Based Study [640]**
Sirpa Hartikainen, Marjaana Koponen, Heidi Taipale, Anna-Maija Tolppanen, Jari Tiihonen, Antti Tanskanen, Kristuna Johnell, Johan Fastbom. (France)

2:00pm

- ▶ **Psychotropic Use among Patients with Dementia Receiving Donepezil in Japan [641]**
Kasumi Daidoji, Yukinori Sakata, Kenta Sumitomo, Toshihisa Arai, Mika Ishii. (Japan)

2:15pm

- ▶ **Comparative Risk of Pneumonia among Different Cholinesterase Inhibitors [642]**
Edward Chia-Cheng Lai, Monera Wong, Isao Iwata, Yinghong Zhang, Cheng Yang Hsieh, Yea-Huei Kao Yang, Soko Setoguchi. (Taiwan)

2:30pm

- ▶ **Comparative Effectiveness of Antiepileptic Drugs in Adult Patients with Epilepsy [643]**
Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Soko Setoguchi, Swu-Jane Lin, Yea-Huei Kao Yang. (Taiwan)

2:45pm

- ▶ **Recent Trends in Antiepileptic Drug Prescribing in UK Primary Care [644]**
Jesca Brouwer, Irene Petersen, Irwin Nazareth, Linda Wijlaars. (United Kingdom)



Proven epidemiology expertise to meet your comprehensive drug safety research needs

Rooted in scientific rigor, Optum™ methodologically innovative pharmacoepidemiology experts can assist you with customized services tailored to any scope or speciality, including:

- Retrospective and prospective studies
- Medical record confirmation of exposures/outcomes
- Validation of algorithms
- Safety signal detection and refinement
- Risk management — study design, execution of risk management programs and safety assessments
- Regulatory/safety consulting
- Natural history of disease
- Provider/patient surveys
- Publication and presentation

Visit Optum at our stand during the 30th ICPE, October 24-27, 2014, to learn more about how we can support your epidemiology and drug safety research.

For additional information, contact David Dore, VP Epidemiology, today at +1 781-472-8458 or david.dore@optum.com.
optum.com/life-sciences

©2014 Optum, Inc. All rights reserved. OPTUM090 03/14

1:30-3:00pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Gain on Pain (201AF)

Moderators: Gunnar Brobert & Abraham Hartzema, FISPE

1:30pm

- ▶ **Trends of Substance Misuse and Pharmaceutical Treatment Recorded in England and Wales Primary Care (1994-2012) [645]**
Hilary R Davies, Irene Petersen, Irwin Nazareth. (United Kingdom)

1:45pm

- ▶ **Impact of Abuse-Deterrent OxyContin on Prescription Opioid Utilization in the United States [685]**
Catherine S Hwang, Hsien-Yen Chang, G Caleb Alexander. (United States)

2:00pm

- ▶ **Effect of Facility Opioid Treatment Availability on Opioid Analgesic Overdose Deaths [647]**
Ting-Ying J Huang, Linda Simoni-Wastila. (United States)

2:15pm

- ▶ **The Impact of Opioid Substitution Therapy on Mortality Post-Release from Prison: A Retrospective Data Linkage Study [648]**
Louisa Degenhardt, Sarah Larney, Jo Kimber, Natasa Gisev, Michael Farrell, Timothy Dobbins, Don J Weatherburn, Amy Gibson, Richard Mattick, Tony Butler, Lucy Burns. (Australia)

2:30pm

- ▶ **Treatment Utilisation and Retention with Opioid Substitution Therapy between 2001 and 2010: A Comparison of Buprenorphine and Methadone Users [649]**
Natasa Gisev, Louisa Degenhardt, Sarah Larney, Timothy Dobbins, Briony Larence, Amy Gibson, Jo Kimber, Tony Butler, Richard Mattick, Lucy Burns. (Australia)

2:45pm

- ▶ **The Misuse, Abuse and Diversion of Opioid Replacement Therapies (ORT): A Study of Street Abusers [650]**
Scott P Novak, Lynn Wenger, Lorvick Jennifer, Kral H Alex. (United States)

Probably a Good Link (201DE)

Moderators: Arlene Gallagher & Soko Setoguchi, FISPE

1:30pm

- ▶ **When To Conduct Probabilistic Linkage vs. Deterministic Linkage? A Simulation Study [651]**
Ying Zhu, Yutaka Matsuyama, Yasuo Ohashi, Soko Setoguchi. (Japan)

1:45pm

- ▶ **Performance of Methods for Linking Registry Data to Insurance Claims When Unique Identifiers Are Unavailable [652]**
Stacie B Dusetzina, Seth Tyree, Anne-Marie Meyer, William Carpenter. (United States)

2:00pm

- ▶ **Comparing Validity of Methods to Select Appropriate Cutoff Weight for Probabilistic Linkage Without Unique Identifiers [653]**
Ying Zhu, Chih-Ying Chen, Yutaka Matsuyama, Yasuo Ohashi, Jessica M Franklin, Soko Setoguchi. (Japan)

2:15pm

- ▶ **Incorporating Linked Outpatient Data to Improve Confounding Control in a Study of In-Hospital Medication Use [654]**
Jessica M Franklin, Wesley Eddings, Sebastian Schneeweiss, Jeremy A Rassen. (United States)

2:30pm

- ▶ **Predicting Linkage Within a Validated Algorithm That Identifies Mother-Infant Pairs Within the Medicaid Analytic EXtract (MAX) Database [655]**
Caitlin A Knox, Kristin Palmsten, Soko Setoguchi, Richard Segal, Almut G Winterstein. (United States)

2:45pm

- ▶ **Accounting for Outcome Misclassification in Pharmacoepidemiologic Studies [656]**
Xiaojuan Li, Nihan Potas, Anne M Butler, Jess Edwards, Jason Fin, M Alan Brookhart. (United States)

The Answer Is Not Clear (4th Floor VIP)

Moderators: James Lewis, FISPE & Wei Zhou

1:30pm

- ▶ **Five-Year Safety Results from the ENCORE Registry: Malignancies in Patients with Crohn's Disease Treated with Infliximab, Standard Therapy, or Switched from Standard Therapy to Infliximab [657]**
G D'Haens, W Reinisch, J-F Colombel, J Panes, S Ghosh, C Prantera, S Lindgren, DW Hommes, Z Huang, S Huyck, DK Chitkara. (United States)

1:45pm

- ▶ **Evaluation of Cancer Risk Following Use of Becaplermin, a Topical Platelet-Derived Growth Factor [658]**
Donald R Miller, Cindy L Christiansen, Daniel Fife, Berlin A Jessie, Patricia Tremblay, Qing Shao, Madhuri Palnati, Graeme Fincke. (United States)

2:00pm

- ▶ **Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Risk of Non-Hodgkin's Lymphoma (NHL): A Systematic Review and Meta-Analysis [659]**
Xibiao Ye, Natalie Casaclang, Salaheddin Mahmud. (Canada)

2:15pm

- ▶ **Calcium Channel Blockers and Cancer Risk Using the UK CPRD [660]**
Lamia Grimaldi-Bensouda, Mark de Groot, Robert Reynolds, Olaf Klungel, Michel Rossignol. (France)

2:30pm

- ▶ **Spirolactone and Incidence of Cancers: A Propensity Score Matched Cohort Study in the Clinical Practice Research Datalink (CPRD) [661]**
Isla S Mackenzie, Alastair M Thompson, Li Wei, Steve Morant, Thomas M MacDonald. (United Kingdom)

2:45 pm

- ▶ **Use of Statins and Prostate Cancer Mortality [662]**
Christian Dehendorff, Charlotte Skriver, Christina G Jespersen, Michael Borre, Mette Nørgård, Henrik T Sørensen, Klaus Brasso, Jesper Hallas, Klaus K Andersen, Søren Friis. (Denmark)

AGENDA *Monday, October 27*

1:30-3:00pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS

World War V: Vaccines and Viruses (102)

Moderators: Lawrence Baril & Vincent Lo Re, III, FISPE

1:30pm

- Effectiveness of Herpes Zoster Vaccination for Prevention of Post-Herpetic Neuralgia among Individuals with Herpes Zoster [663]
Hung Fu Tseng, Sara Tartof, Bruno Lewin, Craig Hales, Lina Sy, Rafael Harpaz, Stephanie Bialek, Kavya Reddy, Po-ying Huang, Jeff Zhang, Sean Anand, Erin Mary Bauer, Jennifer Chang, Steven Jacobsen. (United States)

1:45 pm

- Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination [664]
Hui Feng Yun, Shuo Yang, Lang Chen, Kevin Winthrop, Fenglong Xie, John W Baddley, Kenneth G Saag, Singh Jasvinder, Jeffrey R Curtis. (United States)

2:00pm

- Utilization of Nordic Countries National Registries to Monitor the Impact of HPV Vaccination [665]
Kai-Li Liaw, Susanne Kruger Kjaer, Mari Nygard, Joakim Dillner. (United States)

2:15pm

- Accuracy of Administrative Claims Data to Identify Dose Specific Rotavirus Vaccination Information: Implications for Studies of Vaccine Safety [666]
T Christopher Mast, Scott Quinlan, Nancy Santanello, Steve Lanes. (United States)

2:30pm

- Narcolepsy and Pandemic H1N1 Vaccine: A Simulation Study to Explore the Effect of Bias [667]




Caitlin N Dodd, Leonoor Wijnans, Maria AJ de Ridder, Silvana A Romio, Daniel Weibel, Jan Bonhoeffer, Miriam CJM Sturkenboom. (Netherlands)

2:45pm

- Safety of Seasonal Influenza Vaccination in Solid Organ Transplant Recipients [668]

Gaël Dos Santos, François Haguinet, Germano LC Ferreira, Dave Webb, John Logie, Dominique Rosillon, Vivek Shinde, Catherine Cohet. (Belgium)

Japanese Claim Database



Characteristics of Our Database

- Vast Data Volume**
Staggering over **8.0 million** patient data
- Descriptive Data**
Obtainable data are based on day by day data...
 - ▶ Disease name
 - ▶ Medication (Drug Name, Prescript Days/Amount)
 - ▶ All medical diagnosis (surgery etc.)
 - ▶ **Blood test results** (Partly obtainable)

Data Set Analysis ▶
55 Year Old Male with Rectal Cancer
※ This is a sample

Medical Data Vision Co., Ltd.
7 Kanda Mitoshirocho, Chiyoda-ku
Tokyo, Japan 101-0053

<https://www.mdv.co.jp> (Available only in Japanese)
Email ebm_sales@mdv.co.jp

For Better or for Worse (103)

Moderator: Jessica Jalbert

1:30pm

Modelling the Predicted Net Impact of Contraindication: the Example of Glaucoma Treatment [669]

Andrew Maguire, Francisco J de Abajo. (United Kingdom)

1:45pm

Patients' Preferences for Benefits and Risks of Anticoagulant Therapy: A Discrete Choice Experiment (DCE) [670]

Mehdi Najafzadeh, Joshua J Gagne, Niteesh K Choudhry, Jennifer M Polinski, Jerry L Avorn, Sebastian Schneeweiss. (United States)

2:00pm

Comparing Incremental Net Benefit (INB) of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Patients with Atrial Fibrillation (AF) [671]

Mehdi Najafzadeh, Sebastian S Schneeweiss, Niteesh K Choudhry, Amanda R Patrick, Jennifer M Polinski, Jerry L Avorn, Joshua J Gagne. (United States)

2:15pm

Comparison of ATRIA and CHA₂DS₂-VASc Risk Stratification Schemes for the Prediction of Stroke in the Individual Patient with Atrial Fibrillation and the Impact on Treatment Decisions [672]

Hendrika A van den Ham, Olaf H Klungel, Daniel E Singer, Hubert GM Leufkens, Tjeerd P van Staa. (Netherlands)

2:30pm

Testosterone Laboratory Testing and Testosterone Supplementation Use among Adult Males in Denmark [673]

Thomas Bøjer Rasmussen, Helene Nørrelund, Sinna Pilgaard Ulrichsen, J Bradley Layton, M Alan Brookhart, Henrik Toft Sørensen, Christian Fynbo Christiansen. (Denmark)

2:45pm

Time-Dependent Impact of Pre-Infarction Angina Pectoris and Intermittent Claudication on Mortality Following Myocardial Infarction as Measures of Inherent Local and Remote Ischemic Preconditioning: A Danish Nationwide Cohort Study [674]

Morten Schmidt, Erzsébet Hovath-Puho, Lars Pedersen, Hans E Bøtker, Henrik T Sørensen. (Denmark)

3:00-3:15pm

Break

3:15-4:45pm SYMPOSIA & WORKSHOPS

The Common Data Model: Lessons from Past Projects and Ongoing Initiatives [675] (201DE)

- Patrick Ryan, Morten Anderson, Martijn Schuemie, Alison Burke, Kevin Haynes, Kenneth Man, Helga Gardarsdottir, Marie L De Bruin.

Comparisons in Pharmacoepidemiology: New Challenges and Limitations of Current Approaches [676] (4th Floor VIP)

- Saad AW Shakir and Deborah Layton (United Kingdom), Joshua Gagne, Bob Glynn (United States)

How to Bridge the Gap between Requirements of Regulatory and Health Technology Assessment Authorities for Post Authorization Studies? Examples from Europe and Asia [677] (103)

- Massoud Toussi, Nicholas Moor, K Arnold Chan, Ian CK Wong. (France)

Multi-National Pharmacoepidemiological Studies in Asia - Methodological Challenges and Potential Cross-Continental Collaboration [678] (201BC)

- Edward Chia-Cheng Lai, Ian Douglas, Kiyoshi Kubota, Byung Joo Park, Nicole Pratt, Ian Wong, Yea-Huei Kao Yang, Soko Setoguchi. (Taiwan)

Special Issues in Pharmacovigilance in Emerging Countries [679] (Elegance Lounge, 4th Floor)

- Syed Rizwanuddin Ahmad, David Lee, Gloria Shalviri, Marie Lindquist. (United States)

The Patient's Voice in the Heart of BRACE (Benefit-Risk Assessment, Communication and Evaluation) [680] (201AF)

- Meredith Smith, Priya Bahri, Gerald Dal Pan, Swapu Banerjee, Peter Mol, Debashish Dey. (United States)

Using Pharmaceutical Data for Evaluating Medicines Policy and Informing Quality Use of Medicines [681] (102)

- Libby Roughead, Flora Haaijer-Ruskamp, Veronika Wirtz, Parthasarathi Gurumurthy, Lisa G Pont. (Australia)

4:45-5:30pm

THE FINAL WORD (4th Floor VIP)

Poster Walk Awards

- Mary E Ritchey, 2014 Poster Walk Chair

2015 Meetings

Mid-Year Meeting - Bordeaux

- Annie Fourier-Réglat, Co-Chair, Program Committee

ICPE 2015 - Boston

- John D Seeger, Chair, 2015 Scientific Program Committee

5:30pm

Adjournment of 2014 ICPE

SEE YOU NEXT YEAR IN BOSTON!

Poster Session Guidelines

OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

NOTE:
Neither ISPE nor the TICC will be responsible for any poster that is left up overnight or is lost or damaged.

POSTER SESSION

Posters will be displayed in Room 101 of the Taipei International Convention Center (TICC) August 25-27. Each day will have a separate poster session. All posters for a specific day's session must be removed that day.

- ▶ **Saturday, October 25** Poster Session A
- ▶ **Sunday, October 26** Poster Session B
- ▶ **Monday, October 27** Poster Session C

1. Set Up:

- ▶ 7:00am-8:00am; all posters must be in place by 8:00am. Poster sessions will be held in room Room 101 of the TICC.

2. Hours:

- ▶ Posters will be displayed from 8:00am-6:00pm on Saturday and Sunday, and 8:00am-1:45pm on Monday.

3. Discussion Time:

- ▶ Presenters should be at their posters between 12:15-1:15pm on Saturday (A) and Monday (C); and between 11:45am-12:45pm on Sunday (B)
- ▶ **Spotlight Sessions** – Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters at the following times: Saturday (A) & Monday (C) 12:15-1:15pm; Sunday (B) 11:45am-12:45pm.

Saturday	<ul style="list-style-type: none">▶ Best of the Day▶ Drug Utilization/Health Services Research	<ul style="list-style-type: none">▶ Methods▶ Pediatrics▶ Vaccines
Sunday	<ul style="list-style-type: none">▶ Best of the Day▶ Adherence▶ Benefit Risk Assessment, Communications & Evaluation (BRACE)	<ul style="list-style-type: none">▶ Comparative Effectiveness Research▶ Pregnancy
Monday	<ul style="list-style-type: none">▶ Best of the Day▶ Database▶ Asian Pharmacoepidemiology Network (AsPEN)	<ul style="list-style-type: none">▶ Biologics▶ Device

The spotlight sessions offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

A group of judges will select the best posters of each Spotlight Session. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The winners will be announced during The Final Word session at 4:30pm, Monday, October 27.

4. Take Down:

- ▶ All posters must be taken down by 6:30pm on Saturday and Sunday, and by 5:00pm on Monday.

NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster on that day in the Final Program. The poster number is the first number listed. The abstract number, for use in locating abstracts in the Final Program, is listed after the abstract title in brackets []. The Abstracts2View site, accessible on a mobile device, also indicates the poster number and abstract number.

POSTER CONDITIONS

1. Poster Specifications

Posters must be designed to fit a freestanding poster board approximately **3 feet WIDE x 7 feet HIGH (1 meter WIDE x 2.4 meters HIGH)**. Only **VERTICAL/PORTRAIT** posters will be allowed.

2. Disclosure Statement

A disclosure statement must accompany each abstract submission and each presentation. This statement should follow the title page of your presentation and should be a positive disclosure statement. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.

3. Call4Posters

Posters ordered through Call4Posters/ Learner's Digest can be picked up in Room 101.

Spotlight Session- Top 8 Abstracts (A)

- 1 **Risk of Hip Fractures Associated with Benzodiazepines: Applying Common Protocol To a Multi-Database Nested Case-Control Study. The PROTECT Project [80]**
Gema Requena, John Logie, Rocío González-González, Helga Gardarsdóttir, Ana Afonso, Patrick C Souverein, Elisa Martin Merino, Nada Boudiaf, Consuelo Huerta, Andrew Bate, Yolanda Alvarez, Luis A García-Rodríguez, Robert Reynolds, Raymond G Schlienger, Mark CH de Groot, Olaf H Klungel, Francisco J de Abajo. (Spain)
- 2 **Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study [81]**
Kasper S Larsen, Anton Pottegård, Hanne M Lindegaard, Jesper Hallas. (Denmark)
- 3 **Opioids and Breast Cancer Recurrence: A Danish Population-Based Cohort Study [82]**
Deirdre P Cronin-Fenton, Mette Nørgaard, Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Ejlersen, Per Sjøgren, Henrik Kehlet, Henrik T Sørensen. (Denmark)
- 4 **Intrauterine Devices and the Risk of Uterine Perforations: Final Results from the EURAS-IUD Study [83]**
Klaas Heinemann, Sabine Moehner, Thai Do Minh. (Germany)
- 5 **Prevalence of Potentially Inappropriate Medication Prescribing Among Older US Adults Using STOPP Criteria [84]**
Marcela Jirón, Virginia Pate, Michele Jonsson Funk, Til Stürmer. (Chile)
- 6 **Use of Antipsychotics and Risk of Acute Respiratory Failure in COPD: A Case-Crossover Study [85]**
Meng-Ting Wang, Che-Li Chu, Bi-Juiuan Wu. (Taiwan)
- 7 **A Prospective Multicenter Study of the Incidence of Adverse Drug Events in Saudi Arabia: The (ADESA) Study [86]**
Hisham Aljadhey, Mansour A Mahmoud, Michael D Murray, David W Bates. (Saudi Arabia)
Andrew McAfee Award Recipient – Best Abstract Submitted by a Researcher or Student Residing in a Developing Country
- 8 **Understanding Pharmacy Compounding in the Retail Setting: Practice and Role of Pharmacists in Singapore [87]**
Yuen-Teng Choo, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

Burden of Disease/ Epidemiology of Illness

- 9 **Is There Geographic Variation of the Frequency and the Profile of Adverse Drug Reactions? [88]**
Krunal Pawar, Tanja Tran, Joerg Hasford. (Germany)
- 10 **Rates of Opportunistic Infections in Psoriatic Arthritis Patients Compared to Non-Psoriatic Arthritis Patients [89]**
Katrina W Hagberg, Lin Li, Michael M Peng, Susan Jick. (United States)
- 11 **Increased Benzodiazepine Abuse Among HIV-Infected Individuals in the United States [90]**
Sarah E Wixson, Emily S Brouwer. (United States)
- 12 **Disease Burden of Hospitalized Influenza Patients: A Database Analysis in 2007 – 2012 [91]**
Shih-Chen Chang, Jeffrey M Harris, Andrew McKee, Roman Barbalat, Tracy Burgess, Jose M Trevejo. (United States)
- 13 **Etiologic Features of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) with Ocular Involvement [92]**
Kotone Matsuyama, Chie Sotozono, Mayumi Ueta, Satomi Sakabayashi, Shigeru Kinoshita. (Japan)
- 14 **Childhood Atopic Dermatitis and Antidepressant Drug Use in Young Adults: A Nationwide Population-Based Cohort Study [93]**
Jette L Riis, Mette Deleuran, Christian Vestergaard, Morten Olsen. (Denmark)
- 15 **Epidemiology of Hepatic Impairment among Diabetes Patients in Japan [94]**
Chia-Hsien Chang, Motonobu Sakaguchi. (Japan)
- 16 **Prevalence and Demographic Characteristics of Acromegaly in the United States [95]**
R A Cantrell, R Walls, N Singh, P Napalkov, A Surinach, Y Mu, E Fischeleva. (United States)
- 17 **Health Outcomes for Older Australians After Transient Ischaemic Attack (TIA) or Ischaemic Stroke (IS) [96]**
Janet K Sluggett, Gillian E Caughey, Michael B Ward, Andrew L Gilbert. (Australia)
- 18 **Cataract in Cystic Fibrosis Patients [97]**
Nicholas J Everage, Yan Bai, Brett Loop, Nataliya Volkova, Nan Liu, Cheryl Enger. (United States)
- 19 **Longitudinal Analysis of Dengue Fever Infections Reported in the UK between 2002 – 2013 Using the Health Improvement Network (THIN) Primary Care Database [98]**
David Ansell, Caroline O'Leary, Ahmed Nasser. (United Kingdom)
- 20 **Regional Variation in Serum Urate amongst Patients Recruited for the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [99]**
Robert W Flynn, Claudine G Jennings, Isla S Mackenzie, George Nuki, Ian Ford, Thomas M MacDonald. (United Kingdom)
- 21 **Prevalent Conditions among Elderly and Non-Elderly Patients with Type 2 Diabetes (T2DM) [100]**
Catherine Ntabadde, Mary E Ritchey, Zhiwen Liu, Michael Senderak, Samuel Engel, Ravi Shankar, Kimberly G Brodovicz. (United States)
- 22 **Incremental Direct and Indirect Cost of Untreated Vasomotor Symptoms (VMS) [101]**
Philip Sarrel, Patrick Lefebvre, Marie-Hélène Lafeuille, Jonathan Gravel, Mei Sheng Duh, Peter Aupperle, David Portman. (Canada)
- 23 **Clinical Characteristics of Patients with Lupus Nephritis [102]**
Huifang Liang, Jennifer H Lin, Sudhakar Manne, Ryou Nakaya, Motonobu Sakaguchi, Ali Hariri. (United States)
- 24 **Epidemiology of Parkinson's Disease in China [103]**
Wilson HH Low, Siau Lin Yee, Soraya Azmi, Lan Ge, Dominique Milea. (Malaysia)
- 25 **Adverse Drug Events in Medical and Surgical Patients of an Academic Hospital [104]**
Hisham Aljadhey, Mansour A Mahmoud, Thamer Alshammari. (Saudi Arabia)
- 26 **Severity and Patient Reported Outcomes of Dry Eye Disease in Taiwan [105]**
Hsu-Chih Chien, Po-Ting Yeh, Sun-Huei Tseng, Wei-Li Chen, Yu-Chih Hou, I-Jong Wang, Hsiao-Sung Chu, Kwong Ng, Yea-Huei Kao Yang, Fung-Rong Hu. (Taiwan)
- 27 **Global Incidence of Acute Lymphoblastic Leukemia, 2003-2007 [106]**
Aaron J Katz, Victoria M Chia, Michael A Kelsh. (United States)
- 28 **Prescriptions, Nonmedical Use and Emergency Department Visits of ADHD Stimulants [107]**
Lian-Yu Chen, Rosa Crum, Eric C Strain, G Caleb Alexander, Christopher N Kaufmann, Ramin Mojtabai. (United States)

- 29 **Medical Comorbidities and Drug Utilization of Sickle Cell Disease Patients in a Large US Health-Claims Database [108]**
Lauren Oliva, Made Wenten, Jin Wang, Anne Dilley. (United States)

Spotlight Session- Drug Utilization/Health Services Research SIG

- 30 **Risk Modification of Dementia in Patients Aged ≥ 75 Years - Influence of PPIs [109]**
Britta Haenisch, Klaus von Holt, Birgitt Wiese, Karl Broich, Frank Jessen, Gabriele Doblhammer, Wolfgang Maier. (Germany)
- 31 **The Inappropriate Prescribing of Antibacterial Medicines in Sudan; a National Study at National Health Insurance Fund Setting [110]**
Isam Eldin Mohammed Ali Mustafa. (Sudan)
- 32 **Predictors of G-CSF Prophylaxis in the First Cycle of Chemotherapy in Non-Hodgkin's Lymphoma Patients [111]**
Julius Asubonteng, Sally Wetten, Pieterella J Lugtenburg, Lucy DeCosta, Zsolt Szabo, John H Page. (United States)
- 33 **Do Case-Only Designs Yield Consistent Results Between Them and Across Different Databases (DB)? Hip Fractures Associated with Benzodiazepines (BZD) as a Case Study [112]**
Gema Requena, John Logie, Elisa Martin, Consuelo Huerta, Rocio González-González, Nada Boudiaf, Arturo Álvarez, Andrew Bate, Luis A García-Rodríguez, Robert Reynolds, Raymond G Schlienger, Mark CH de Groot, Olaf H Klungel, Francisco J de Abajo, Ian Douglas. (Spain)
- 34 **Use of Antidepressant Medications in Depressed Older Adults and Predictors of Discontinuation of Antidepressant Use [113]**
Eunsun Noh, Brian J Quilliam. (United States)
- 35 **Therapeutic Inertia and Intensified Treatment in Diabetes Prescription Patterns: A Nationwide Population-Based Study [114]**
Huang Li-Ying, Shau Wen-Yi, Su Syi, Lai Mei-Shu. (Taiwan)
- 36 **AHRQ/HCUPNet-Derived Pharmacoepidemiologic Evidence on Ventilation-Associated Iatrogenic Pneumothorax [115]**
Yelizaveta Torosyan, Qianlai Luo, Sarah Hoffman, Danica Marinac-Dabic. (United States)

- 37 **Disparities in Oral Antidiabetic Agents for Newly Diagnosed Type 2 Diabetes in Taiwan [116]**
Chia-Hung Liu, Chia-Hsuei Chang, Shu-Ting Chen, Mei-Shu Lai. (Taiwan)

Drug Utilization/Health Services Research

- 38 **Differential Healthcare Utilization in Metformin Versus Sulfonylureas Users Pre- and Post-Initiation [117]**
Jin-Liern Hong, Michele Jonsson Funk, Jennifer L Lund, Virginia Pate, Til Stürmer. (United States)
- 39 **The Pattern and Prescription Cost of Diabetes in a Municipal Hospital in Ghana [118]**
Archibald Nii Boye Okotah. (Ghana)
- 40 **Treatment Patterns and Comorbidities in Adult Patients Treated for Gaucher Disease in the US [119]**
Stephanie Tcherny-Lessenot, Lili Wang, Taylor Wang, Cristina Chang, Juhaeri Juhaeri. (France)
- 41 **Anti-Diabetic Medication Pattern during Inpatient Care for Patients with Diabetes in West China Hospital [120]**
Sheyu Li, Chuan Yu, Yun Li, Rui Zhang, Qingtao Hou, Tao Zheng, Yi Ma, Miye Wang, Na Su, Ting Wu, Xia Sheng, Nan Li, Guanjian Liu, Yong Huang, Xin Sun, Haoming Tian. (China)
- 42 **Three Years Antibacterial Consumption in the Indonesian Public Primary Health Care Center: The Application of ATC/DDD and DU90% Method To Monitor Antibiotic Use [121]**
Ivan Surya Pradipta, Elis Ronasih, Arrum Dyah Kartikawati, Hartanto Hartanto, Rizki Amelia, Eli Halimah, Ajeng Diantini, Keri Lestari, Rizky Abdulah. (Indonesia)
- 43 **Using Drug Case Studies for Individual Case Management to Enhance Appropriateness of Vancomycin and Amikacin [122]**
Ming-Shen Lin, Jen-Wei Liu, Chun-Yu Wang. (Taiwan)
- 44 **Inappropriate Initial Dosing of Fluconazole in Patients with Candidemia [123]**
Wen-Liang Lin, Pheng-Ying Yeh-Liu, Hui-Jen Chang. (Taiwan)
- 45 **Different Use of Antibiotics in Rural and Urban Regions in the Netherlands, an Observational Drug Utilization Study [124]**
Josta de Jong, Jens HJ Bos, Tjalling W de Vries, Lolkje TW de Jong-van den Berg. (Netherlands)
- 46 **Perspectives and Experiences of Community Pharmacists about Antibiotic Dispensing in Riyadh, Saudi Arabia [125]**
Hisham Aljadhey, Mohammed Al-Dhaefi, Mansour A Mahmoud, Aziz Sheikh. (Saudi Arabia)
- 47 **Systemic Antimicrobials Consumption and Expenditures in Russian Multi-Profile Hospitals: the Results of Multicenter Trial [126]**
Maksim V Polyakov, Yuliya A Belkova, Svetlana A Rachina, Roman S Kozlov, Vladimir M Mischenko, Ivan A Zakharenkov, Alfiya I Abubakirova, Boris V Berezhanskiy, Ekaterina V Eliseeva, Irina A Kopylova, Shamil Kh Palyutin, Uliana S Portnyagina, Olga V Pribytkova, Evgeniy K Samuylo, Nadezhda A Zubareva. (Russian Federation)
- 48 **Comparison of Outpatient Antibiotic Use Between Portugal and 5 European Countries in 2012 - There Is (Much) Room for Improvement! [127]**
Carla Torre, José Guerreiro, Marta Gomes, Suzete Costa. (Portugal)
- 49 **Empirical Antimicrobial Therapy or Directed To Hemoculture and Mortality in Patients with Sepsis in ICU: A Retrospective Cohort [128]**
Camila Schultz Cordeiro, Celso Nakagawa, Luciane Cruz Lopes. (Brazil)
- 50 **Analysis of Prescriptions Before and After Intervention of Evidence-Based Drug Formulary in Private Hospital in South Sumatra, Indonesia: A Quasi-Experimental Study [129]**
Erna Kristin, Iwan Dwiprahasto, Dwi Indria Anggraini, Jarir At Thobari, Alf Yasmina. (Indonesia)
- 51 **Endocrine Therapy for Breast Cancer Patients in South Africa [130]**
Yaser T Bazargani, Anthonius de Boer, Hubertus GM Leufkens, Aukje K Mantel-Teeuwisse. (Netherlands)
- 52 **Utilization Trends of Anti-Tumor Necrosis Factor Therapy in Taiwan [131]**
Meng-Ju Chan, Chien-Ning Hsu, Yen-Hsia Wen, Yu-Chin Lily Wang. (Taiwan)
- 53 **Trends in the Use of Maintenance Immunosuppressive Drugs among Liver Transplant Recipients in Taiwan: A Nationwide Population-Based Study [132]**
Chia-Chen Hsu, Ying-Yu Huang, Yuh-Lih Chang, Che-Chuan Loong, Yeuh-Ching Chou. (Taiwan)

- 54 **Utilization Evaluation of Anticancer Drugs as Adjuvant and Neo-Adjuvant Therapy in the Management of Breast Cancer: A Study from a Developing Country** [133]
Himanshu Patel, Richard Samuel, Parthasarathi Gurumurthy. (India)
- 55 **Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients** [134]
Yi-Han Liu, Tzu-Chieh Lin, Yea-Huei Kao Yang, Hui-Jen Chang. (Taiwan)
- 56 **Outpatient Use of Oral Anticancer Drugs in the Permanent Sample of the French Healthcare Insurance Database (2006-2011)** [135]
Julien Bezin, Régis Lassalle, Sophie Broussy, Pernelle Noize, Nicholas Moore, Annie Fourrier-Réglat. (France)
- 57 **Safety and Efficacy Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Adavagraf) in Stable Liver Transplant Recipients** [136]
Chiu-Yen Li, Chih-I Wu, Yao-Li Chen, Sock-Ping Ng, Su-Yu Chien. (Taiwan)
- 58 **Blood Cell, Renal and Liver Function Monitoring among Psoriasis Patients Who Initiated Methotrexate Use in Taiwan** [137]
Hsin-Chun Chou, Wen-Wen Chen, Wei-Ming Ke, Pi-Hui Chao, Fei-Yuan Hsiao. (Taiwan)
- 59 **Treatment Patterns for Anemia among Breast Cancer Patients Treated with Chemotherapy in 2000-2013** [138]
Hairong Xu, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Chun Chao. (United States)
- 60 **Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013** [139]
Chun Chao, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Hairong Xu. (United States)
- 61 **Utilisation and Baseline Risk of Bleeding in Patients Prescribed Rivaroxaban: Interim Results from a Post-Marketing Observational Cohort Study** [140]
Vicki Osborne, Miranda Davies, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 62 **Trends in Cardiovascular Risk Factors and Change over Time across Education Levels, and the Influence from Medicine Use and Gender. The Tromsø Study 1994-2008** [141]
Anne Elise Eggen, Ellisiv B Mathiesen, Inger Njølstad, Bjarne K Jacobsen, Tom Wilsgaard. (Norway)
- 63 **Drug Utilization Studies of Antihypertensive Drugs for Hospitalized Patients with Hypertension in Shenyang** [142]
Jian Gong, Wen Pan, Feng Guo, Kaishun Bi. (China)
- 64 **Utilization of Oral Anticoagulants in Patients with Non Valvular Atrial Fibrillation** [143]
Layla Saliba, Pierre Mondoly, Alexandre Duparc, Marc Delay, Philippe Maury, Anne Rollin, Violaine Calmels, Atul Pathak, Alessandra Bura-Riviere, Jean-Louis Montastruc, Haleh Bagheri. (France)
- 65 **Withdrawn By Author**
- 66 **Pharmacoeconomic Aspects of Angiotensin II Receptor Blockers in Patients with Essential Hypertension** [145]
Viet Thanh Truong, Cornelis Boersma. (Canada)
- 67 **Preadmission Use of Calcium Channel Blockers or Beta-Blockers and 30-Day Stroke Mortality** [146]
Jens Sundbøll, Morten Schmidt, Erzsébet Hovath-Puho, Christian F Christiansen, Lars Pedersen, Hans E Bøtker, Henrik T Sørensen. (Denmark)
- 68 **Effects of Pitavastatin on Glucose and Lipid Metabolism in Nondiabetic Patients in a Taiwan Medical Center** [147]
Yu-Chuan Tsai, Chien-Hui Chen, Su-Yu Chien. (Taiwan)
- 69 **Calcium Channel Blockers and Gingival Overgrowth: An Intensive Pharmacosurveillance Monitoring in Chiang Mai, Thailand** [148]
Kannika Thiankhanithikun, Surapon Nochaiwong, Thitima Makaew, Pison Sribundit. (Thailand)
- 70 **Adverse Drug Reaction Reports for Cardiometabolic Drugs from Sub Sahara Africa: A Study in VigiBase** [149]
Derbew F Berhe, Kristina Juhlin, Kristina Star, Flora M Haaijer-Ruskamp, Kidane Michael, Katja Taxis, Peter GM Mol. (Netherlands)
- 71 **The Use of Pillbox and Time in Therapeutic Range Among New Users of Warfarin: A Propective Cohort Study** [150]
Stéphanie Dumas, Étienne Rouleau-Mailloux, Nawal Bouchama, Halima Lahcene, Jean-Claude Tardif, Mario Talajic, Marie-Pierre Dubé, Sylvie Perreault. (Canada)
- 72 **Excellent Outcome of Intensive Medical Care for Type B Aortic Dissection – A Single-Center Retrospective Study** [151]
Shih-Han Wang, Chaw-Chi Chiu, Jiann-Woei Huang, Chung-Yu Chen, Yaw-Bin Huang. (Taiwan)
- 73 **A Population-Based Study of the Drug Interaction between Clarithromycin and Statins** [152]
Bitá Mesgarpour, Ghazaleh Gouya, Harald Herkner, Berthold Reichardt, Michael Wolzt. (Islamic Republic of Iran)
- 74 **Regional Variations in Physician Case Volume and Outcomes for Carotid Artery Stenting (CAS) vs. Carotid Endarterectomy (CEA)** [153]
Hiraku Kumamaru, Jessica J Jalbert, Louis L Nguyen, Soko Setoguchi. (United States)
- 75 **Treatment with Statins and Fibrates in Chinese Type 2 Diabetes Mellitus Patients Initiating Hospitalization at the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in Qingdao, China** [154]
Lei Zhang, Xiaoli Wu, Weiguo Gao, Qing Qiao, Niklas Hammar, Claudia Cabrera, Yanhu Dong, Jia Wei. (China)
- 76 **Evaluation for Statin Usage in Taiwan by Using National Health Insurance Claim Database** [155]
Grace Hui-Min Wu, Yu-chiao Wang, Yongchen Chen. (Taiwan)
- 77 **Patterns of Chronic Use of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker in Pre-Dialysis Chronic Kidney Disease Patients with Anemia** [156]
Chi-Tai Yen, Ming-Cheng Wang, Tzu-Chieh Lin, Yea-Huei Kao Yang. (Taiwan)
- 78 **The Incidence of Actinic Keratosis and Risk of Non-Melanoma Skin Cancer in Taiwan** [157]
Chi-Feng Hsieh, Weng-Foung Huang, Yi-Ting Chiang. (Taiwan)
- 79 **Compliance with Pregnancy Prevention Recommendations in 7,663 French Women of Childbearing Age Exposed to Acitretin** [158]
Fanny Raguideau, Myriam Mezzarobba, Mahmoud Zureik, Alain Weill, Philippe Ricordeau, François Alla. (France)
- 80 **Utilization Pattern of Phosphodiesterase Type 5 (PDE5) Inhibitors for Erectile Dysfunction among Commercially Insured Adults in the United States** [159]
Wei Liu, Philipp Dahm, Tobias Gerhard, Patrick Antonelli, Joseph Chris Delaney, Almut G Winterstein. (United States)

- 81 **A Survey on the Utilization Pattern and Adverse Events of Oral Contraceptives in Korean Women Aged 20 to 49 Years** [160]
Hye-Yeon Um, Hyun-Jung Kim, Hyun-Joo Jung, Sun-Young Jung, Byung-Joo Park. (Republic of Korea)
- 82 **The Risk of Major and Any (non-Hip) Fracture after Hip Fracture in the United Kingdom: 2000 – 2010** [161]
Corinne Klop, Deborah Gibson-Smith, Petra JM Elders, Natasja van Schoor, Paco MJ Welsing, Hubert GM Leufkens, Nicholas C Harvey, Tjeerd P van Staa, Frank de Vries. (Netherlands)
- 83 **Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects with Type 2 Diabetes Mellitus** [162]
Ya Wen Huang, Hui Ju Tsai, Yueh Han Hsu, Yu Kang Chang, Jia Sin Liu, Chih Cheng Hsu. (Taiwan)
- 84 **Comparing Prescribing Pattern between Bisphosphonate and Raloxifene in Osteoporosis Patients** [163]
Jungmee Kim, Joongyub Lee, Ju-Young Shin, Hong-Ji Song, Nam-Kyong Choi, Byung-Joo Park. (Republic of Korea)
- 85 **Research on Asian Psychotropic Prescription Patterns for Antidepressants II: REAP-AD 2013** [164]
Shu-Yu Yang, Mian-Yoon Chong, Yi-Hsin Yang, Shih-Ku Lin, Kuan-Pin Su, Tsung-Ming Hu. (Taiwan)
- 86 **The Insomnia Treatment, Drug Usage and Their Side Effects in Taiwan: Analysis of 2009-2011 Nationwide Health Insurance Database** [165]
Ching-Hu Chung. (Taiwan)
- 87 **Resource Utilisation of Patients with Alzheimer's Disease in Taiwan** [166]
Yong-Chen Chen, Raoh-Fang Pwu, Yu-Chiao Wang, Yi-Ju Chen, Robert Chao-Jen Huang, Jung-Chun Wang, Grace Hui-Min Wu. (Taiwan)
- 88 **Use of Psychotropic Medication for People with Learning Disability or Autism in England: A Descriptive Study Using the Clinical Practice Research Datalink** [167]
Rachael Boggon, Gyles Glover, Keith Ridge, Ray Avery. (United Kingdom)
- 89 **Disease Progression, Treatment Patterns, and Outcomes in Schizophrenia Over a 3-Year Period: Results from the Cohort for the General Study of Schizophrenia (CGS)** [168]
Jessica J Jalbert, Michel Rossignol, Frederic Rouillon, Bernard Astruc, Benoit David, Jacques Benichou, Lucien Abenham, Lamiae Grimaldi-Bensouda. (United States)
- 90 **Factors Associated with the Use of Pain Management-Related Medications among the Non-Cancer Elderly Patients Ever Utilized Traditional Chinese Medicine Services: A Retrospective Population-Based Cohort Study** [169]
Hsiang-Wen Lin, Li-Ping Chen, Chih-Hsueh Lin, Che-Yi Chou, Hsin-Hui Tsai. (Taiwan)
- 91 **Association between Antipsychotic Treatment and Risk of Hip Fracture in Subjects with Schizophrenia** [170]
Yu-Ting Tsai, Chi-Shin Wu, Chia-Ming Chang, Ya-Wen Huang, Hui-Ju Tsai. (Taiwan)
- 92 **Healthcare Utilization Prior to Self-Poisoning: Variation by Age and Gender** [171]
Fei-Yuan Hsiao, Shu-I Wu, Chia-Yi Wu. (Taiwan)
- 93 **Differences in ADHD Medication Usage Patterns in Children and Adolescents from Different Ethnic Backgrounds in the Netherlands** [172]
Els F van den Ban, Patrick C Souverein, Herman van Engeland, Hanna Swaab, Toine CG Egberts, Eibert R Heerdink. (Netherlands)
- 94 **Evaluating the Safety of Atypical Antipsychotic Drugs among Patients in Jos University Teaching Hospital** [173]
Rachel U Odesanya, Moses D Audu, Silas Fwangshak. (Nigeria)
- 95 **Trends in Volume and Mortality in Carotid Endarterectomy (CEA) After Introduction of Carotid Artery Stenting (CAS) in Medicare Population** [174]
Hiraku Kumamaru, Jessica J Jalbert, Louis L Nguyen, Jun Liu, Marie D Gerhard-Herman, Chih-Ying Chen, Lauren A Williams, John D Seeger, Jessica M Franklin, Soko Setoguchi. (United States)
- 96 **Drug Use Patterns of Elderly Neuroleptic Users in Germany** [175]
Niklas Schmedt, Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Denmark)
- 97 **Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy** [176]
Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)
- 98 **Follow-Up of Psychoactive Drug Use in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada)** [177]
Caroline Croteau, Laurent Mottron, Marc Dorais, Jean-Éric Tarride, Sylvie Perreault. (Canada)
- 99 **Characterization of Potential Pharmacodependence of Zolpidem, Zopiclone and Zaleplone Users** [178]
Pei-Hua Hsieh, Chia-Yi Wu, Fei-Yuan Hsiao. (Taiwan)
- 100 **Testing the Robustness of Background Knowledge Confounder Selection in a Case-Control Study** [179]
Johnny Kahlert, Reimar W Thomsen, Lars Pedersen, Morten Madsen, Niels Møller, Henning Beck-Nielsen, Henrik T Sørensen. (Denmark)
- 101 **The Effect of a Comprehensive Approach to Blood Product Management: Automated Decision Support, Education, and Feedback** [180]
Keri J Donaldson, Thomas A Abendroth. (United States)
- 102 **Medication and Patient Safety in a Community Teaching Hospital** [181]
Luis-Meave Gutiérrez-Mendoza, Abraham Torres-Montes, Elizabeth Ramírez-Hernández, Aldanely Padrón-Salas, Ricardo Villanueva-Alvarez, Viviana Juárez-Cruz. (Mexico)
- 103 **The Association between Long-Term Bisphosphonate Use and the Risk of Fracture among Females with Osteoporosis in Taiwan** [182]
Chung-Hsuen Wu, Chi-Chuan Wang, Hsien-Tsung Lu. (Taiwan)
- 104 **Evaluate the Effectiveness of Preventive Medicine Curriculum among Medical Students of Public Universities in Malaysia** [183]
Kavitha Devi, Shukry Zawahir, Mohd Fadli Mohd Asmani, R Rekarani, Dashnilatha Permal, Redhwan Ahmed Al-Naggar. (Malaysia)
- 105 **Evaluate the Effectiveness of Preventive Medicine Curriculum among Pharmacy Students of Private Universities in Malaysia** [184]
Dashnilatha Permal, Shukry Zawahir, Redhwan Ahmed Al-Naggar, Eddy Yusuf. (Malaysia)
- 106 **Are Prescription Drugs Substitutes for Inpatient Services? Evidence from Medicare Part D** [185]
Robert Kaestner, Cuiping Long, G Caleb Alexander. (United States)
- 107 **Misuse, Abuse, and Diversion of Instanyl® (Fentanyl Nasal Spray) in France** [186]
Patrick Blin, Caroline Dureau, Stéphanie Lamarque, Marie-Agnès Bernard, Philip Robinson, Régis Lassalle, Adeline Grolleau, Cécile Droz, Nicholas Moore. (France)

- 108 Is Preventive Medicine Curriculum among Medical Students of Private Universities in Malaysia Effective? [187]**
Rekarani Rajantharan, Shukry Zawahir, Redhwan Ahmed Al-Naggar, Eddy Yusuf. (Malaysia)
- 109 The Utilization Pattern of Glucocorticoids in Taiwan Established Systemic Lupus Erythematosus Patients [188]**
Chun-Ming Chen, Yea-Huei Kao Yang, Tzu-Chieh Lin, Shu-Hua Tai, Hui-Jen Chang. (Taiwan)
- 110 Evaluating the Impact of the Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain in Utah [189]**
Brian C Sauer, Chai-Chen Teng, Christy Porusnik, Erin Johnson, Robert Rolfs, Jonathan Nebeker. (United States)
- 111 Examining the Impact of the Utah Opioid Guideline Based Intensive Educational Intervention on Opioid Prescribing in Utah [190]**
Brian C Sauer, Chai-Chen Teng, Christy Porusnik, Erin Johnson, Robert Rolfs, Jonathan Nebeker. (United States)
- 112 Use of Bipolar Disorder Medications Prior to Diagnosis [191]**
Zhiwen Liu, Melissa Whipple, Jane Liao, Edward A Bortnichak, Mellissa Yong, Herve Besson. (United States)
- 113 Assessment of Appropriateness and Safety of Dihydroergotamine Use [192]**
Ching Yu Chang. (Taiwan)
- 114 The Utilization and Safety of Abraxane® for the Treatment of Metastatic Breast Cancer in the USA: Results from Health Insurance Claims Data [193]**
Caihua Liang, Ling Li, Cindy Duval, Amy Ko, Debra Patt, Deyanira Corzo, Cheryl Enger. (United States)
- 115 Patterns of Analgesic Initiation among Hemodialysis Patients [194]**
Magdalene M Assimon, Anne M Butler, Lily Wang, Abhijit V Kshirsagar, M Alan Brookhart. (United States)
- 116 Prevalence of Inappropriate Prescribing of Inhaled Corticosteroids for Respiratory Tract Infections in the Netherlands [195]**
Martina Teichert, Andre Wissenburg, Peter de Smet, Michel Wensing, Tjard Schermer. (Netherlands)
- 117 Impact of Tuberculosis Treatment on Health-Related Quality of Life of Pulmonary Tuberculosis Patients: A Follow-Up Study [196]**
Muhammad Atif, Syed Azhar Syed Sulaiman, Asrul Akmal Shafie, Muhammad Asif, Zaheer Ud-Din Babar. (Malaysia)
- 118 Characteristics Associated with Use of Oral or Inhaled Respiratory Medications at Initiation for Patients with Chronic Obstructive Pulmonary Diseases [197]**
Yaa-Hui Dong, Chia-Hsuei Chang, Shu-Ting Chen, Mei-Shu Lai. (Taiwan)
- 119 Changes in Drug Prescriptions After the SMART Trial – Secondary Data Analysis of Bavarian Asthma Patients [198]**
Marietta Rottenkolber, Rainald Fischer, Luisa Ibáñez, Joan Fortuny, Robert Reynolds, Roman Gerlach, Martin Tauscher, Petra Thuermann, Joerg Hasford, Sven Schmiedl. (Germany)
- 120 Changes in Thiazolidinedione Utilization and Outcomes Following Safety Warning and Risk Evaluation & Mitigation Strategies (REMS) in Taiwan [199]**
Jason C Hsu, Dennis Ross-Degnan, Ching-Lan Cheng, Anita K Wagner, Fang Zhang, Yea-Huei Kao Yang, Li-Ling Liu, Hsueh-Yung Tai, Ke-Hsin Chen, Po-Wen Yang, Yi-Chen Juan, Christine Y Lu. (Taiwan)
- 121 The Prescribing Pattern of Postnatal Steroids on Preterm Infants in Taiwan [200]**
Tzu-Ling Kuo, Ching-Lan Cheng, Yea-Huei Kao Yang, Yung-Chieh Lin. (Taiwan)
- 122 Prescribing of Drugs in the Therapy of Acute and Chronic Pain in Family Medicine Practice in Croatia [201]**
Danijela Stimac, Meri Margreitner, Zvonimir Sostar. (Croatia)
- 123 Utilization and Government Cost of Antisecretory Drugs among Elderly in Australia and New Zealand [202]**
Suvimol Niyomnaitam, Alesha Smith. (Australia)
- 124 Hospital Length of Stay for Patients with Acute Myocardial Infarction in China [203]**
Qian Li, Zhenqiu Lin, Frederick A Masoudi, Xi Li, Sonia Hernández-Díaz, Sudhakar V Nuti, Lingling Li, Qing Wang, John A Spertus, Harlan M Krumholz, Lixin Jiang. (United States)
- 125 Hospital Registry of Stroke or Transient Ischemic Attack (LIS-2). Design and Prehospital Medical Treatment Analyses [204]**
Sergey Yu Martsevich, Liubov Yu Drozdova, Natalia P Kutishenko, Moisey L Ginzburg, Alexander Yu Suvorov, Anna V Akinova, Natalia Yu Zhuravskaya. (Russian Federation)
- 126 The Efficacy and Safety of Liraglutide for Patients with Type 2 Diabetes Mellitus in Changhua County, Taiwan [205]**
Lih-Jen Shyu, Ya-Mei Hsu, Sock-Ping Ng, Su-Yu Chien. (Taiwan)
- 127 Adherence to Treatment Guidelines in Type 2 Diabetes (T2DM) Patients Treated with Metformin (MET) Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care [206]**
Inbal Goldshtein, Kaan Tunceli, Larry Radican, Harvey Katzeff, Shengsheng Yu, Bernd Voss, Ofer Sharon, Noga Gadir, Kimberly Brodovitz, Varda Shalev, Gabriel Chodik, Avraham Karasik. (Israel)
- 128 Geriatric Homecare Patients' Awareness on the Side-Effects of NSAID Abuse [207]**
Andjelija Arandjelovic, Valentina Stankovic-Cekic. (Serbia)
- 129 The Impact of Diabetes on Mortality in Non-ICU Inpatients from a Chinese Tertiary Hospital [208]**
Chuan Yu, Sheyu Li, Yun Li, Miye Wang, Rui Zhang, Qingtao Hou, Yi Ma, Tao Zheng, Nan Li, Ting Wu, Na Su, Xia Sheng, Qianrui Li, Yong Huang, Xin Sun, Haoming Tian. (China)
- 130 Drug Safety Education among Outpatient Using Teriparatide: Improving Patients Care [209]**
Meichi Chang, Tzuyun Huang, Hsinlin Liang, KuoSheng Fan. (Taiwan)
- 131 A Pilot Analysis of a Pharmacist Initiated Home Medication Review Programme with Type 2 Diabetes Patients in Penang, Malaysia [210]**
Ee Pin Chow, Mohamed Azmi Hassali. (Malaysia)
- 132 Predictors of Prescription Drug Importation by United States Adults [211]**
Andrew R Zullo, David D Dore, Omar Galarraga, Tim Rocafort, Vincent Mor. (United States)
- 133 Prevalence and Treatment of Pain in Emergency Departments in the United States, 2000-2010 [212]**
Hsien-Yen Chang, Matthew Daubresse, Stefan P Kruszewski, G Caleb Alexander. (United States)
- 134 Continuous Use of Medicines: Pattern and Characteristics Associated among Participants of the ELSA-Brasil Study [213]**
Roberta Carvalho de Figueiredo, Francisco de Assis Acurcio, Sandhi Maria Barreto, Sotero Mengue, Maria de Jesus Mendes da Fonseca. (Brazil)
- 135 Regional Variation in Strong Opioid Prescribing in UK Primary Care Settings [214]**
Muna Adan, Li-Chia Chen, Roger Knaggs. (United Kingdom)

- 136 Attitudes in Antidepressants Use in Greece [215]**
Paraskevi Papaioannidou, Achilleas Ntaralas. (Greece)
- 137 Asthma Prevalence and Utilization of Antiasthmatic Drugs among All Children in Stockholm, Sweden [216]**
Elin Dahlén, Ramin Zarrinkoub, Björn Wettermark. (Sweden)
- 138 Bone Density Screening and Reduced Risk of Hip Fracture: Effectiveness or Confounding? [217]**
Jie Zhang, Jeffrey R Curtis, Hong Zhao, Kenneth G Saag, Meredith L Kilgore, Nicole C Wright, Huifeng Yun, Luqin Deng, Elizabeth Delzell. (United States)
- 139 Long Term Usage of Opioids by Chronic Intractable Non Cancer Pain Patients in TAIWAN from 2003 to 2012 [218]**
Wen-Ing Tsay, I-Chen Cheng, Chih-Shiuh Chang, Ping-Chang Hsu. (Taiwan)
- 140 Over-the-Counter Aspirin Use, Comorbidities, and Timing of Aspirin Therapy Initiation in Multiple Myeloma Patients [219]**
Syd Phillips, Nancy A Brandenburg, Kimberley J Woodcroft, Karen E Wells, Susan A Oliveria. (United States)
- 141 Ophthalmologists Practice Patterns on Performing Intraocular Injections in Europe [220]**
Kui Huang, Marla B Sultan, Duo Zhou, Charles S Tressler, Jingping Mo. (United States)
- 142 Temporal Changes in Polypharmacy, Hyperpolypharmacy and Exposure to Anticholinergic and Sedative Drugs: A Five-Year Study of Community-Dwelling Older Men [221]**
Clara Leung, Sarah Hilmer, Sallie-Anne Pearson, Danijela Gnjjidic. (Australia)
- 143 The Validity of a Patient-Reported Adverse Drug Event Questionnaire Using Different Recall Periods [222]**
Sieta T de Vries, Flora M Haaijer-Ruskamp, Dick de Zeeuw, Petra Denig. (Netherlands)
- 144 Analyzing the Short-Term Social Media Impact of a Drug Safety Publication-A Case Study Approach [223]**
Ingrid S Sketris, Anatoliy Gruzd, Philip Mai, John M Gamble, Colin Dormuth. (Canada)
- 145 A Qualitative Study Exploring Perspectives towards Generic Medicines among Medical Specialists and Consultants at a District Hospital in Malaysia [224]**
Zhi Yen Wong, Mohamed Azmi Hassali, Abdulk Haniff Yahaya, Fahad Saleem, Hisham Aljadhey, Tahir Mehmood Khan. (Malaysia)
- 146 Practices and Self Confidence towards Antibiotic Prescribing: An Exploratory Study Focusing Prescribers in the District of Kota Setar, Kedah, Malaysia [225]**
Rabiatul Salmi Rezal, Mohamed Azmi Hassali, Fahad Saleem. (Malaysia)
- 147 A Qualitative Study Exploring Perspectives towards Generic Medicines among Medical Specialists at a District Hospital in Malaysia [226]**
Zhi Yen Wong, Mohamed Azmi Hassali, Fahad Saleem, Abdul Haniff Mohd Yahaya, Hisham Hisham, Tahir Mehmood Khan. (Malaysia)
- 148 Prescribing Drug Use and Costs among Adult Outpatients with Type 2 Diabetes in Taiwan: A Nationwide Population-Based Study [227]**
Chi Wen Chiang, Chun Chi Chiu, Zon Min Lee, Yuh Min Cheng. (Taiwan)
- 149 Drug Discrepancy and Medication Error of Admitted Patients by Medication Reconciliation Process [228]**
Jaruwan Unin, Pramote Tragulpiankit, Thida Ningsananda, Rattana Nilpetchploy. (Thailand)
- 150 Drug-Related Hospital Readmission in Community Hospital, Thailand [229]**
Jaruwan Unin, Pramote Tragulpiankit, Chaweevan Mounngnoi, Porntip Channalao. (Thailand)
- 151 Post Authorization Safety Studies (PASS): Application of Prospective Observational Study Methodology [230]**
Irene Pan, Amy Walton, Gretchen Dieck. (Canada)
- 152 European Drug Lists for Integration in a Decision Support Tool for Optimization of Drug Therapy in Older Persons [231]**
Anna Birna Almarsdottir, Shane Cullinan, Birna Björg Masdottir, Stephen Byrne. (Denmark)
- 153 Registry: Its Use in Real-World Data Collection [232]**
Irene Pan, Gretchen Dieck, Annette Stemhagen. (Canada)
- 154 Post Authorization Safety Studies (PASS): Application of Retrospective Chart Review Methodology [233]**
Dara Stein, Irene Pan, Krista A Payne. (Canada)
- 155 Utilization Trend and Management of Oral Anticancer Medicines Using Nationwide Pharmacy Database and Questionnaire Survey at Pharmacies in Japan [234]**
Osamu Takizawa, Hisashi Urushihara, Shiro Tanaka, Koji Kawakami. (Japan)
- 156 Novel Methods of Adverse Event Detection Using Electronic Health Record Data: A Critical Review of the Literature [235]**
Christian M Rochefort. (Canada)
- 157 Associations of Drug Burden Index with Falls, General Practitioner Visits, and Mortality in Older People [236]**
Prasad S Nishtala, Sujita W Narayan, Ting Wang, Sarah N Hilmer. (New Zealand)
- 158 Drug Utilization Pattern for the Treatment of Septic Shock in the ICU: A Comparison between Survivors and Non-Survivors in a Tertiary Care Teaching Institute [237]**
Anirban Hom Choudhuri, Rajeev Uppal. (India)
- 159 Development of Pharmacy-Based Patient Registry for Long-Term Medication Use Monitoring [238]**
Manabu Akazawa, Shinichi Yamamura, Hiroyasu Ogata. (Japan)
- 160 The Incidence of Adverse Drug Events among the Critically Ill Patients: A Prospective Multicenter Study [239]**
Hisham Aljadhey, Mansour A Mahmoud. (Saudi Arabia)
- 161 Drug Use Study of Heparin Using Japanese Claim Data of Inpatients [240]**
Maki Noguchi, Ayumi Endo, Kaori Yamada, Kazuhiro Matsui, Shinichi Watanabe. (Japan)
- 162 Utilization and Predictors of Ophthalmic Steroids in Patients with Dry Eye Disease: A Nationwide Population-Based Study in Taiwan [241]**
Mei-Chieh Chen, Chia-Hsien Chang, Yea-Huei Kao Yang, Yi-Sheng Chang. (Taiwan)
- 163 Longitudinal Changes of Polypharmacy in the Elderly: A Population-Based Study over a 10-Year Period in Taiwan [242]**
Wan-Hsuan Lu, Liang-Kung Chen, Fei-Yuan Hsiao. (Taiwan)

- 164 Find the Risk of Drug Usage from the Surveillance Results of the Electronic Media Advertisements [243]**
Chao-Yi Wang, Chia-Ping Liu, Ping-Chang Hsu, Shwu-Huey Her, I-Hsuan Wu, Ming-Kung Yeh. (Taiwan)
- 165 Use of Ezetimibe in Australia [244]**
Samantha A Hollingworth, Remo Ostini, David Michael, Jennifer Martin, Tett Susan. (Australia)
- 166 Appropriate Prescribing of Medications among Diabetic Medicare Patients Treated by Nurse Practitioners or Physicians [245]**
Yong-Fang Kuo, Nai-Wei Chen, Mukaila A Raji. (United States)
- 167 Using Routinely Collected Administrative Health Claims Data to Improve the Uptake of Primary Healthcare Services [246]**
Vanessa T Le Blanc, Andrew L Gilbert, Lisa M Kalisch Ellett, Nicole L Pratt, John D Barratt, Emmae N Ramsay, Mhairi M Kerr, Robert Peck, Graeme Killer, Elizabeth E Roughead. (Australia)
- 168 Assessment of Clinical Features and Medical Treatment of Patients with Atrial Fibrillation in Outpatient Registry in Moscow [247]**
Sergey Yu Martsevich, Natalia P Kutushenko, Liubov Yu Drozdova, Arthur R Navasardyan, Alla V Zakharova. (Russian Federation)
- 169 Do Rational Use Meet Reality in a Country Under Financial Assistance Program for Cost-Saving Expenditures? The Two Sides of the Portuguese Coin [248]**
Carla Torre, José Guerreiro, Marta Gomes, Suzete Costa. (Portugal)
- 170 Surveillance of New Drug Adoption in Australia Using Primary Care EHR Data [249]**
Malcolm B Gillies, Margaret Williamson, Alistair Merrifield, Stephen Morrell, Nancy Huang. (Australia)
- 172 Evaluation of Control Activities of Antibiotic Prescribing Practices and Multidrug-Resistant Bacteria in Healthcare Organizations of Paris City and Inner Suburbs [251]**
J-Frederic Westphal. (France)
- 173 Analysis of Essentiality of the Medicines from the "Popular Pharmacy Program in Brazil" [252]**
Sueli Miyuki Yamauti, Silvio Barberato-Filho, Luciane Cruz Lopes. (Brazil)
- 174 Influenza Vaccination According to Dementia Diagnosis in French Nursing Homes [253]**
Adeline Gallini, Virginie Gardette, Maryse Lapeyre-Mestre, Philippe De Souto Barreto, Bruno Vellas, Sandrine Andrieu, Yves Rolland. (France)
- 175 Sex, Gender and Drugs – A Tool for Gender-Conscious Prescribing [254]**
Desirée Loikas, Emma Hultén, Linnéa Karlsson, Seher Korkmaz, Fadiea Al-Aieshy, Mia von Euler, Björn Wettermark, Eva Andersén Karlsson, Karin Schenck-Gustafsson. (Sweden)
- 176 Comparison of Medication Use in Taipei with Non-Taipei City by Beers Criteria in Elderly Based on the National Health Insurance Research Database in Taiwan [255]**
Mei-Hsiouh Guan, Su-Yu Yang, Li-Chi Chen. (Taiwan)
- 177 Erythropoietin Stimulating Agent Prescribed Pattern for the Incident Uremia Patients in Taiwan [256]**
An-Bang Wu, Tzu-Chieh Lin, Ming-Cheng Wang, Yea-Huei Kao Yang. (Taiwan)
- 178 Using Administrative Healthcare Data to Study the Treatment of Inflammatory Bowel Disease in the Region of Stockholm, Sweden [257]**
Thomas Cars, Mikael Lördal, Björn Wettermark. (Sweden)
- 179 An Audit of Prescriptions from the Dental Outpatients Department of a Tertiary Hospital in Ado-Ekiti, South-West Nigeria [258]**
Joseph O Fadare, Obiade Obimakinde. (Nigeria)
- 180 Medication Utilization in the Palestine Refugee Population in the Middle East: A Cross-Country Comparative Analysis [259]**
Dima Qato. (United States)
- 181 Psychotropic Utilization in Ribeirao Preto, Brazil [260]**
Iahel Manon Lima Ferreira, Manuela Roque Siani Morello, Leonardo Régis Leira Pereira, Marcela Jirón. (Brazil)
- 182 Rational Usage of Medicines at the Public Health Facilities in Rajasthan, India [261]**
Ravi Kumar Balu, Preeti Kumar, Maulik Chokshi, Sakthivel Selvaraj. (India)
- 183 Interactions between Pharmaceutical Company Representatives and Physicians in Jos, Nigeria [262]**
Maxwell LP Dapar, Comfort N Sariem, Isaac O Abah, Meshak SA Dayol, Noel N Wannang. (Nigeria)
- 184 What Makes Prescribers Switch to Fixed-Dose Combination Therapy for Japanese Hypertensive Patients? [263]**
Makiko Kusama, Shigeki Zeniya, Katsushi Fukuoka, Manabu Akazawa. (Japan)
- 185 Investigation of Drug Safety Information of Ethnic Medicine from 622 Drug Instructions in Guizhou [264]**
Chen Ao, Lei Xiaoqing. (China)
- 186 Persistence Rate and Adherence Level To Oral Antidiabetics and Their Associated Determinants [265]**
Patrice Simard, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Râkel, Sylvie Perreault. (Canada)

Spotlight Session- Methods

- 187 Investigating Time-Varying Factors Associated with Lipid Lowering Medications for Primary CVD Prevention Using Multistate Markov Modeling [266]**
Suzanne L West, Barry S Eggleston, Marianne Kluckman, Amanda Hansen, Eric Solano, Kenneth LaBresh, Vincent Bufalino, Michael F O'Toole. (United States)
- 188 Dimension Reduction and Shrinkage Methods for Improving High Dimensional Disease Risk Score Estimation in a Historical Cohort [267]**
Hiraku Kumamaru, Joshua J Gagne, Robert J Glynn, Soko Setoguchi, Sebastian Schneeweiss. (United States)
- 189 Diabetogenic Effects of Atypical Antipsychotics – Exploration of Measurement Bias [268]**
Almut G Winterstein, Rhonda Cooper-DeHoff, Paul Kubilis, Gregory A Nichols, Joseph A Delaney. (United States)
- 190 Construction of Treatment Episodes in Elderly Neuroleptic and Antidepressant Users [269]**
Niklas Schmedt, Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Germany)
- 191 Manual Versus Automated Coding of Free-Text Self-Reported Drug Use in the 45 and Up Study: A Validation Study [270]**
Danijela Gnjidic, Sallie-Anne Pearson, Sarah Hilmer, Jim Basilakis, Fiona Blyth, Emily Banks. (Australia)
- 192 Composite Testing in Pharmacovigilance: The Benefit of Window Shopping [271]**
Rolina D van Gaalen, Michal Abrahamowicz, David L Buckeridge. (Canada)

Analytic Methods

- 193 Evaluation of Analytical Method Performance Using Self-Controlled Case Series [272]**
Jasmanda Wu, Ling Zhang, Patrick Caubel, Wanju Dai, Cristina Chang, Dennis Shao, Juhaeri Juhaeri. (United States)
- 194 Application of Multivariate Statistical Methods to the Assessment of Drug Abuse Potential Based on Spontaneously Reported Adverse Events [273]**
Manfred Hauben, Cynthia Arons, Eric Hung, Sian Ratcliffe. (United States)
- 195 Health Outcomes and Medical Effectiveness Research (HOMER): A Systematic Approach to Exploring Hill's Causal Viewpoints in Observational Data [274]**
Patrick Ryan, Martijn Schuemie, David Madigan, Marc Suchard, Paul Stang, J Marc Overhage, Christian Reich, Mark Khayter, Abraham Hartzema, Bill DuMouchel, Jesse Berlin. (United States)
- 196 Determination of Shrinkage Parameters in Spontaneous Reporting System in China [275]**
Jia He, Xiaofei Ye, Jing Wang, Xiaojing Guo. (China)
- 197 Treating Analysis of Dose Flexibly Within a Post-Authorisation Safety Study of an Atypical Antipsychotic [276]**
Deborah Layton, Ian Ratcliffe, Sarah Clarke, Saad AW Shakir. (United Kingdom)
- 198 Performance of the High-Dimensional Propensity Score Algorithm When In-Hospital Medico-Administrative Data Are Unavailable [277]**
Jason R Guertin, Elham Rahme, Colin R Dormuth, Alexis Matteau, Louis-Mathieu Stevens, Jacques LeLorier. (Canada)
- 199 Performance of Disease Risk Score Matching in Nested Case-Control Studies [278]**
Rishi J Desai, Robert J Glynn, Joshua J Gagne. (United States)
- 200 Strategies for Modeling the Relationship between a Biomarker and a Binary Outcome [279]**
Yanli Li, John H Page. (United States)
- 201 Covariate Balance When Matching on Disease Risk Scores in Cohort Studies [280]**
Joshua J Gagne, Rishi Desai, Robert J Glynn, Katsiaryna Bykov, Hiraku Kumamaru, Sebastian Schneeweiss. (United States)

- 202 Measurement Bias in Billing Data – A Simulation Study [281]**
Almut G Winterstein, Paul Kubilis. (United States)

Spotlight Session-Pediatrics SIG

- 203 The Use of Complementary Medicines for HIV-Infected Children in Lagos, Nigeria [282]**
Kazeem A Oshikoya, Mubarak Hassan, Ibrahim A Oreagba, Olayinka O Ogunleye, Idowu O Senbanjo. (Nigeria)
- 204 Predictors of Broad Spectrum Antibiotics Use in Children in a Nigerian Hospital [283]**
Chukwuemeka M Ubaka, Chinwe J Eneaji, Chinwe V Ukwue. (Nigeria)
- 205 Determination of a Possible Association between Human Papillomavirus (HPV) Vaccination and Migraine [284]**
Tessa M Schurink-van 't Klooster, Maria AJ de Ridder, Jeanet M Kemmeren, Johan van der Lei, Frans Dekker, Miriam Sturkenboom, Hester E de Melker. (Netherlands)
- 206 Stimulant Effectiveness on Driving Citations and Crashes of Children with ADHD [285]**
Almut G Winterstein, Tobias Gerhard, Paul Kubilis, Jon Shuster. (United States)
- 207 Antipsychotic Initiation and Stability of Foster Placement Among Youth with Disruptive Behaviors [286]**
Ming-Hui Tai, Susan dosReis. (United States)
- 208 Long-Acting 2 Agonist Without Concomitant Inhaled Corticosteroids in Children with Asthma in Primary Care [287]**
Marjolein Engelkes, Hettie M Janssens, Johan C de Jongste, Miriam CJM Sturkenboom, Katia MC Verhamme. (Netherlands)
- 209 Healthcare Databases for Paediatric Studies: A Report from the GRiP Network Global Survey [288]**
Carmen Ferrajolo, Osemeke Osokogu, Cassandra Nan, Yolanda Brauchli Pernus, Daniel Weibel, Katia Verhamme, Madlen Gazarian, Ian CK Wong, Hidefumi Nakamura, Jan Bonhoeffer, Carlo Giaquinto, Miriam JCM Sturkenboom. (Netherlands)
- 210 Off-Label Prescription in Pediatric Patients in Bandung City, Indonesia [289]**
Rizky Abdulah, Miski A Khairinisa, Ami A Pratiwi, Ivan S Pradipta, Eli Halimah, Ajeng Diantini, Keri Lestari. (Indonesia)

Pediatrics

- 211 Epidemiology of Rotavirus Gastroenteritis (RGE) in Young Children in Rural Guangxi, China [290]**
Yi Nong, Xu Yang, Yimei Wu, Qinglin Yang, Yan Liang, Minmei Chen, Zhaojun Mo, Shusen Liu, Christopher Mast, Rongcheng Li. (China)
- 212 Adverse Effect of Reactions in Time of Hospital Stay and Delay in Pediatric Patients with Chemotherapy Leukemia [291]**
Fabiola Patricia Medina Barajas, Fernando Antonio Sanchez Zubieta, Sergio Sanchez Enriquez, Carmen Zavala Sanchez, Ana Rosa Rincon Sanchez. (Mexico)
- 213 PMSI Database Consultation: Evaluation of Hospital Stay Length for Infantile Haemangioma in France Previous To and Subsequent To Propranolol Use [292]**
Charles Taieb. (France)
- 214 Medical and Economic Impact of Infantile Haemangioma in France Previous To Propranolol Use [293]**
Charles Taieb. (France)
- 215 Infantile Haemangioma: A Burden for Families [294]**
Charles Taieb. (France)
- 216 Adolescent Asthmatics' Needs and Preferences Regarding Medication Counseling: Results from Online Focus Groups [295]**
Ellen S Koster, Daphne Philbert, Liset L van Dijk, Tjalling W de Vries, Marcel L Bouvy. (Netherlands)
- 217 Pediatric Drug Safety Surveillance in Italian Pharmacovigilance Network: An Overview over the Years 2001-2012 [296]**
Carmen Ferrajolo, Annalisa Capuano, Francesco Rossi, Ugo Moretti, Gianluca Trifirò, Carmela Santuccio. (Italy)
- 218 Adverse Drug Reactions of Spontaneous Reports in Shanghai Pediatric Population [297]**
Jia He, Hui Li, Xiaojing Guo, Xiaofei Ye, Hong Jiang. (China)
- 219 Adverse Reactions in Children: French Data [298]**
François Krabansky, Malak Abou Taam, Baptiste Demailly, Emmanuelle Herlem, Marie-Paule Roux, Thierry Trenque. (France)
- 220 Inhaled Corticosteroids for Preschool Children – A Norwegian Register Study [299]**
Øystein Karlstad, Knut Øymar, Kari Furu, Wenche Nystad. (Norway)

Vaccines

221 Serious Adverse Drug Reactions Associated with Pneumococcal Vaccine: Experience in Thailand [300]
Pakawadee Sriphiromya. (Thailand)

222 Design of Randomized, Double-Blind, Controlled, Multi-Centre Phase IIb Trials as Part of the EU-Funded UNISEC Project to Assess the Safety, Immunogenicity and Clinical Efficacy of Cross-Seasonal Universal Influenza Vaccines with or Without Pandemic Influe [301]

Heng Liu, Stuart Robinson, Tamar Ben-Yedidia, Wilson Caparros-Wanderley, Tanya Gottlieb, Ron Babecoff, Ed Schmidt, Anke Huckriede, Eelko Hak. (Netherlands)

223 Tolerability Survey of a Two-Dose Pandemic Vaccine [Focetria®], Administered after the Seasonal 2009-2010 Influenza Vaccination in the Netherlands [302]

Sarah Godefrooij, Nicoline AT van der Maas, Hester E de Melker, Jeanet M Kemmeren. (Netherlands)

224 Assessment of Vaccination Rates among Children Within the Humedica EHR Database, 2007-2013 [303]

Anthony P Nunes, Florence T Wang, Yan Ding, Robin C Clifford, Nancy D Lin. (United States)

225 Impact of Vaccine Effectiveness on Signal Detection Based on Disproportionality [304]

Lionel Van Holle, Iris De Ryck. (Belgium)

Spotlight Session-Vaccine SIG

226 Detection and Validation Strategy of Herpes Zoster (HZ) Cases for a Vaccine Effectiveness Study in a Managed Care Organization Database [305]

Patricia Saddier, John Hansen, Joan Bartlett, Edwin Lewis, Bruce Fireman, Laurie Aukes, Morgan Marks, Roger Baxter. (United States)

227 Effectiveness of the 2009 Pandemic H1N1 Influenza Vaccines in Preventing H1N1 Infection: A Meta-Analysis [306]

Songul Bozat-Emre, Xibiao Ye, Adrienne Morrow, Natalie Casacang, Salaheddin M Mahmud. (Canada)

228 Linkage of the Vaccination Registration Praeventis with the IPCI Medical Record Database in the Netherlands - A Pilot Study [307]

Jeanet M Kemmeren, Johan van der Lei, Petra Oomen, Hester E de Melker, Miriam Sturkenboom. (Netherlands)

229 Safety of Rotavirus Vaccines: Analysis of Adverse Events Reported Under Reexamination System and Spontaneous Reporting System in Korea [308]

Je-Yon Kim, Jong-Mi Seong, Byung-Joo Park. (Republic of Korea)

230 Adverse Events Following Rabies Pre- and Post-Exposure Prophylaxis in Taiwan, July-December 2013 [309]

Wan-Ting Huang, Chi-Hsi Chang, Wei-I Huang, Ding-Ping Liu. (Taiwan)

231 The Association Between Pneumococcal Vaccine and Thrombocytopenia in Elderly Patients with Chronic Obstructive Pulmonary Disease: A Case-Crossover Study [310]

Piyameth Dilokthornsakul, Todd A Lee. (Thailand)

232 Uptake of Influenza Vaccination in Elderly People: Impact of Dementia Diagnosis [311]

Adeline Gallini, Virginie Gardette, Sandrine Andrieu, Maryse Lapeyre-Mestre. (France)

233 Design and Feasibility of a Study Using the Clinical Practice Research Datalink General Practice OnLine Database (CPRD GOLD) To Assess the Risk of New Onset of Auto-Immune Diseases (NOAD) Following Administration of the Human Papillomavirus (HPV)-16/18 AS [312]

Dominique Rosillon, Corinne Willame, Manel Pladevall, Julia Zima, Judith H van den Bosch, Eveline Bunge, Tjeerd van Staa, Rachael Boggon, Laurence Baril. (Belgium)

▶ END SESSION A

Spotlight Session- Top 8 Abstracts (B)

- 1 **Quantitative Benefit-Risk Assessment of the Quadrivalent HPV Vaccine for the Prevention of Anal Cancer in Males – Results [393]**
Lydie Marcelon, Thomas Verstraeten, Geraldine Dominiak-Felden, François Simondon. (France)
- 2 **Application of Targeted Maximum Likelihood Estimation in Pharmacoepidemiology [394]**
Menglan Pang, Tibor Schuster, Kristian B Filion, Maria Eberg, Robert W Platt. (Canada)
- 3 **Incidence of Gastrointestinal Perforation among Patients with Crohn's Disease and Those Patients Dispensed with Anti-TNF Therapy [395]**
Xiaofeng Zhou, Yun Gu, Sundaresan Murugesan, Andrew Bate. (United States)
- 4 **Idiopathic Thrombocytopenic Purpura After Seasonal Influenza Vaccination [396]**
Chunfu Liu, Laura Polakowski, Hozefa A Divan, Yun Lu, Hector Izurieta, Nandini Selvam. (United States)
- 5 **30-Year Mortality Following Venous Thromboembolism: A Population-Based Cohort Study [397]**
Kirstine K Sogaard, Morten Schmidt, Lars Pedersen, Erzsébet Horváth-Puhó, Henrik T Sørensen. (Denmark)
Second Best Abstract Submitted by a Student/Post-Doc
- 6 **Malignant Diseases in Swedish Person with Hemophilia-A Longitudinal Registry Study [398]**
Susanna Lövdahl, Karin M Henriksson, Fariba Baghaei, Margareta Holmström, Erik Berntorp, Jan Astermark. (Sweden)
- 7 **The Risk of Malignant Melanoma among Patients with Multiple Sclerosis [399]**
Made Wenten, Sarah Gheuens, Sandra Richman, Susan Eaton, Li Li, Anne Dilley. (United States)
- 8 **Combining Information from an Electronic Healthcare Database and Spontaneous Reporting Database for Enhancing Signal Detection [400]**
Alexandra C Pacurariu, Preciosa M Coloma, Gianluca Trifiro, Sabine M Straus, Martijn Schuemie, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom. (Netherlands)

Adherence

- 9 **Preventable Drug Related Problems and Factors That Affect Heart Failure Treatment at Maharaj Nakorn Chiangmai Hospital [401]**
Poukwan Arunmanakul, Thanisa Kritsathath, Thanyaluk Poonnirrat, Rungrit Kanjanavanit. (Thailand)
- 10 **Association between Generic Substitution and Refill Adherence to ACE-Inhibitors - Analysing the Impact of Using Multiple Medications [402]**
Pernilla Jonsson, Anna K Jönsson, Eva Lesén, Ann-Charlotte Mårdby, Karolina Andersson Sundell. (Sweden)
- 11 **Effect of a Medication Adherence Program for Long-Acting Injectable Atypical Antipsychotics on Adherence and Psychiatric Hospitalizations [403]**
Frederic Rouillon, Jessica J Jalbert, Bernard Astruc, Michel Rossignol, Franck Bayle, Benoit David, Ryma Bennoune, Bernard Avouac, Lucien Abenhaim, Lamiae Grimaldi-Bensouda. (United States)
- 12 **Associations between Generic Switch and Adherence - Do Patients' Discomfort, Need of Information and Concerns about Medicine Influence Adherence: A Combined Cross-Sectional Questionnaire and Register Study [404]**
Jette Rathe, Dorte E Jarbøl, René dePont Christensen, Morten Andersen, Jens Søndergaard. (Denmark)
- 13 **Physician Adherence to Antihypertensive Drug Treatment Guidelines and Cost of Antihypertensive Drugs in Indian Setting [405]**
Kapil Gudala, Dipika Bansal, Anil Bhansali. (India)
- 14 **Predictive Validity of Four Self-Reported Measures of Medication Adherence in Patients with Type 2 Diabetes [406]**
Arsène Zongo, Line Guénette, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)
- 15 **Evaluation of Adherence To Therapy in Patients with Chronic Kidney Disease [407]**
Smita Sontakke, Ritu Budania, Chaitali Bajait, Kavita Jaiswal, Sonali Pimpalkhute. (India)
- 16 **Factors Affecting the Regular Admission of Statins (according to the Register PROFILE) [408]**
Sergey Yu Martsevish, Oleg V Gaisenok, Alexandr V Zagrebniy. (Russian Federation)
- 17 **Barriers to Medication Adherence among Outpatients in Jos University Teaching Hospital [409]**
Rachel U Odesanya, Ngozi Oragwu. (Nigeria)
- 18 **A Medicines List Is a Simple Tool to Improve Adherence [410]**
Yeqin Zuo, Leanne Atkins, Stephen Morrell, James Reeve. (Australia)
- 19 **Association between Adherence to Secondary Prevention Therapies and Mortality in Acute Myocardial Infarction (AMI) [411]**
Tzu-Chi Liu, Yea-Huei Kao Yang, Ching-Lan Cheng, Cheng-Han Lee. (Taiwan)
- 20 **The Investigation of Potential Prescription Medications Waste in a Medical Center: A Pilot Study [412]**
Yi-Jung Chiang, Yen-Yu Hsieh, Wen-Hsin Chan, Yi-Syuan Lai, Su-Yu Chien. (Taiwan)
- 21 **HIV/AIDS Clinical Care Program Certification International: Pharmaceutical Care Model Established and Efficacy Analysis [413]**
Shiue-Shiang Lin, Chun-Eng Liu, Yuan-Meng Liu, Su-Yu Chien. (Taiwan)
- 22 **Pharmacist-Led Educational Interventions to Improve Inhalation Technique in Pediatric Asthma Patients [414]**
Hsin-Lien Lin, Sock-Ping Ng, Chien-Hui Chen, Su-Yu Chien. (Taiwan)
- 23 **Self-Reported Adherence To Antiretroviral Therapy in Sub-Saharan Africa: A Meta-Analysis [415]**
Obinna Ikechukwu Ekwunife, Charles Ebuka Okafor. (Nigeria)

Spotlight Session Adherence SIG

- 24 **Enriching Persistence Prediction Models Using Prior Adherence and Empirically Selected Claims Data Components [416]**
Hiraku Kumamaru, Joshua J Gagne, Robert J Glynn, Soko Setoguchi, Sebastian Schneeweiss. (United States)
- 25 **Persistence to Osteoporosis Drugs Following an Incident Osteoporotic Fracture: the PREFRAC Study [417]**
Corinne Klop, Paco MJ Welsing, Jetty A Overbeek, Patrick C Souverein, Hubert GM Leufkens, Johannes WJ Bijlsma, Frank de Vries. (Netherlands)
- 26 **Efficacy and Content Analysis of Adherence Interventions to Enhance Oral Antidiabetic Adherence (OAD) in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis [418]**
Hervé Tchala Vignon Zomahoun, Marjin deBruin, Laurence Guillaumie, Jocelyne Moisan, Jean-Pierre Grégoire, Norma Perez, Lydi-Anne Vézina-Im, Line Guénette. (Canada)

- 27 **The Impact of Two Consecutive Prescription Charges on Adherence to Chronic Medications in the Irish General Medical Services Population [419]**
Sarah-Jo Sinnott, Stephen Byrne, Noel Woods, Helen Whelton. (Ireland)
- 28 **The Influence of Anxiety and Depression on Barriers to Antiretroviral Treatment Adherence Reported by People Living with HIV in Brazil [420]**
Celline C Almeida, Maria das Graças B Ceccato, Maria Inês B Nemes, Mark DC Guimaraes, Francisco A Acurcio. (Brazil)
- 29 **Association between the Medicare Part D Coverage Gap and Non-Adherence to Hormonal Treatment for Breast Cancer [421]**
Joel Swerdel, Kitaw Demissie, Kim Hirshfield, Sheenu Chandwani. (United States)
- 30 **Erratic or Poor Psychiatric Medications Adherence and Prescribed Antipsychotics: Prime Components in a Clinical Prediction Rule for Suicide Attempt in Major Depressive Disorder Individuals [422]**
Chidchanok Ruengorn, Wilaiwan Chongruksut. (Thailand)
- 31 **The Discrepancy of Perceived Medication Use Patterns among the Elderly from Patient-Related and Health Professionals' Perspectives [423]**
Hsiang-Wen Lin. (Taiwan)
- Benefit Risk Assessment, Communication and Evaluation**
- 32 **Consumption of Rosiglitazone and Pioglitazone Following Safety Warnings – A Time Series Intervention Analysis in Portugal [424]**
Carla Torre, Marta Gomes, José Guerreiro. (Portugal)
- 33 **Safety of Azithromycin Therapy in Patients with High Cardiovascular Risk. A Meta-Analysis of Randomized Controlled Trials [425]**
Ziyad S Almalki, Jeff J Guo. (United States)
- 34 **Prevalence and Antimicrobial Resistance Pattern of Community Acquired Pathogens Against Beta Lactam Antibiotics Isolated from Residents of Holy Makkah, Saudi Arabia [426]**
Abdul Haseeb, Hani Saleh Faidah, Abdul Rehman Bakhsh, Abrar Al Anazi, Weam Clinton, Nada Bogus, Mahmood Essam Uddin Raggal. (Saudi Arabia)
- 35 **Prevalence and Antimicrobial Resistance Pattern of Community Acquired Pathogens Against Aminoglycoside and Quinolones, Isolated from 2 Emergency Settings from Multinational Patients, Holy Makkah, Saudi Arabia [427]**
Abdul Haseeb, Hani Saleh Faidah, Abdul Rehman Bakhsh, Maab Khalid Sultan, Maram Al Anazi, Fatima Al Juhani, Mahmood Essam Uddin Raggal. (Saudi Arabia)
- 36 **A Meta-Analysis of the Harms Associated with the Novel Oral Anticoagulants (NOACs) for Stroke Prevention in Atrial Fibrillation (AF) and the Treatment of Venous Thromboembolism (VTE) in the Elderly [428]**
Manuj Sharma, Victoria R Cornelius, Jignesh P Patel, J Graham Davies, Mariam Molokhia. (United Kingdom)
- 37 **The Bleeding Risk with Warfarin-Based Antithrombotic Regimen among Acute Coronary Syndrome Patients with Atrial Fibrillation [429]**
Lai Yi-Shan, Cheng Ching-Lan, Yea-Huei Kao Yang, Ping-Yen Liu. (Taiwan)
- 38 **Increased Bleeding Risk of Dabigatran Usage in Patient with Renal Impairment [430]**
Tzu -Yu Lin, Chi-Hua Chen, Yu-Jr Lin, Cheng-Hung Lee. (Taiwan)
- 39 **Low Body Mass Index Predictor for Dabigatran Related-Bleeding [431]**
Tzu-Yu Lin, Chi-Hua Chen, Kuo-Chun Hung, Ming-Shien Wen, Cheng-Hung Lee. (Taiwan)
- 40 **Improving the Use of Lipid Lowering Treatment in Primary Prevention: A Randomized Clinical Trial [432]**
Yolima Cossio, Eduardo Hermosilla, Francesc Fina, Daniel Prieto-Alhambra, Bonaventura Bolibar. (Spain)
- 41 **Estimate of Venous Thromboembolism and Related-Deaths Attributable to the Use of Combined Oral Contraceptives in France [433]**
Aurore Tricotel, Fanny Raguideau, Cedric Collin, Mahmoud Zureik. (France)
- 42 **Are ECG Monitoring Recommendations before Prescription of QT Prolonging Drugs Applied in Daily Practice? The Example of Haloperidol [434]**
Miriam Warnier, Frans Rutten, Patrick Souverein, Arno Hoes, Anthonius de Boer, Marie De Bruin. (Netherlands)
- 43 **Interferon β and Rate of Hospitalization Due to Infections among Multiple Sclerosis Patients [435]**
Cynthia Jones, Jawad Hasan, Jin Wang, Gary Bloomgren. (United States)
- 44 **Proportionality between Adverse Events Identified in Spontaneous Reporting Databases and Population-Based Estimates of Drug Exposure [436]**
Joseph Kim, Marion Gaskin, David Prieto-Merino, Wilhelmine Meeraus, Andrew Thomson, Adam Collier, Stephen JW Evans. (United Kingdom)
- 45 **Health Care Professionals' Knowledge and Attitudes of Drug Benefits and Risks in Africa [437]**
Derbew F Berhe, Katja Taxis, Flora M Haaajer-Ruskamp, Peter GM Mol. (Netherlands)
- 46 **Used of Potentially Inappropriate Medications among Older Outpatient with Long-Term Prescription at a Medical Center in Taiwan [438]**
Huei-Chao Lee, Min-Ling Tsai, Kuo-Jen Lee, Mao-Chung Weng, Shiuian-Chih Chen. (Taiwan)
- 47 **Validation of a Refined Health Related Quality of Life Comorbidity Index in Populations through Cross-Sectional Surveys [439]**
Huang-tz Ou, Steven R Erickson. (Taiwan)
- 48 **Risk Factors of Colistin Nephrotoxicity and Severe Nephrotoxicity in the Clinical Setting [440]**
Shin-Woo Kim, Hyun-Ha Chang, Su-Jung Kim, Jong-Myung Lee. (Republic of Korea)
- 49 **Anti-Tuberculosis Drug Induced Liver Injury in a Regional Hospital [441]**
Shu-Tzu Chen, Sheng-Kang Huang. (Taiwan)
- 50 **Safety Information, Boxed Warning, and Contraindications in Drug Labeling: A Comparison of the USA, the UK, and Canada [442]**
Joud K Alfraih, Lama S Alfehaid, Hisham S Aljadhey, Thamir M Allshammari. (Saudi Arabia)
- 51 **Deployment and Evaluation of the Doctor-Consulting System for Home-Care Cases (DSHC) in a Medical Center [443]**
Yun-Chia Chang, Mei-Jr Huang, Shih-Jung Huang, Jung-Chuan Ko, Chun-Yu Wan. (Taiwan)
- 52 **Inappropriate Prescribing Defined by Start and STOPP Criteria and Association with Adverse Drug Events in Elderly Hospitalized Patients [444]**
Mohd Taufiq Azmy, Mathumalar Loganathan, Yahaya Hassan, Noorul Afidza Muhammad, Christopher Lee, Azmillah Rosman. (Malaysia)

- 53 **How the Transparency Data Regulations Are Changing the Communication Regarding Benefit-Risk of Medications [445]**
Sylvie Tomczyk. (United States)
- 54 **Useability of Harm Profile Data in Product Descriptions: A Comparison between the US and Europe [446]**
Victoria R Cornelius, Kun Liu, Janet Peacock, Manuj Sharma, Odile Sauzet. (United Kingdom)
- 55 **Evaluation of the Value of Web Data for Detecting Drug Adverse Events [447]**
Mei S Duh, Pierre Cremieux, Marc Van Audenrode, Francis Vekeman, Paul Karner, Philippe Giguere-Duval, Yongling Xiao, Joe Damron, Paul Greenberg. (United States)
- 56 **A Regulators' Challenge: the Transfer of New Scientific Knowledge into Regulatory Practice. The Example of PROTECT [448]**
Xavier Kurz, Peter Arlett. (United Kingdom)
- 57 **Study of Medication Errors Which May Occur in the Process of Electronic Prescription and Dispensing Using Failure Mode and Effects Analysis (FMEA) [449]**
Massoud Toussi, Hélène Berthelot, Gérard Simon. (France)

Spotlight Session- Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG

- 58 **Quantitative Benefit-Risk Assessment of the Quadrivalent HPV Vaccine for the Prevention of Anal Cancer in Males – Method [450]**
Thomas Verstraeten, François Simondon, Geraldine Dominiak-Felden, Lydie Marcelon. (Belgium)
- 59 **The Application of the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Algorithm to Evaluate Suicidal Ideation and Behaviour Within a Post-Authorisation Safety Study [451]**
Deborah Layton, Nasser Qayum, Vicki Osborne, Miranda Davies, Saad AW Shakir. (United Kingdom)
- 60 **Comparative Quantitative Benefit-Risk Assessment of High- and Low-Dose Methylprednisolone in Multiple Sclerosis Relapse Management [452]**
Ola Caster, I Ralph Edwards. (Sweden)
- 61 **Simulation Modelling for Quantitative Benefit Risk: An Example of Comparative Harm for Glaucoma Treatment [453]**
Andrew Maguire, Francisco J de Abajo. (United Kingdom)

- 62 **Effectiveness of Risk Minimisation Measures for Vandetanib in Canada: A Process and Outcome Evaluation [454]**
Yola Moride, Michael Kozmenko, Francesco Salvo, Alia Yousif, Sarah Frise. (Canada)
- 63 **The Timing of Safety Regulatory Decisions Compared with Cumulative Meta-Analysis' Risk Estimates [455]**
Carlos Alves, Ana F Macedo, Francisco Batel Marques. (Portugal)
- 64 **A Unified Framework for Classification of Methods for Benefit-Risk Assessment [456]**
Mehdi Najafzadeh, Sebastian Schneeweiss, Nitesh K Choudhry, Kate Bykov, Kristijan Kahler, Diane P Martin, Stephen Arcona, Joshua J Gagne. (United States)
- 65 **Drug-Drug Interaction Alerts in Hospital Setting: Distribution, the Prevalence of Overrides, and Prescriber Determinants [457]**
Tewodros Eguale, Diane L Seger, Sarah P Slight, Mary G Amato, Karen C Nanji, Nivethietha Maniam, Patricia C Dykes, Julie M Fiskio, David W Bates. (United States)

Comparative Effectiveness Research

- 66 **Comparative Effectiveness Research of Metformin-Based Oral Hypoglycemic Therapy in Taiwan's Population-Based Database [458]**
Huang-Tz Ou, Yen-Ting Chen. (Taiwan)
- 67 **Effect of Body Mass Index on Choice of Initiating Diabetes Therapies [459]**
Mugdha N Gokhale, John B Buse, Til Sturmer. (United States)
- 68 **Clinical Evaluation of Tigecycline in the Treatment of Nosocomial Infection in a Hospital in Taiwan [460]**
Man-Tzu M Wu, Hsiang-Yin Chen, Li-Na Kuo, Kuei-Ju Cheng. (Taiwan)
- 69 **Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Nevirapine-Containing Antiretroviral Therapy [461]**
Jin-Han Yang, Chien-Ching Hung, Ching-Hua Kuo, Bing-Ru Wu, Sue-Yo Tang, Wen-Chun Liu, Sui-Yuan Chang, Shu-Wen Lin. (Taiwan)
- 70 **Use of Granulocyte Colony-Stimulating Factor and Neutropenic Events among Breast Cancer and Non-Hodgkin's Lymphoma Patients [462]**
Wan-Ting Lin, Tsun-Jen Wen, Shao-Chin Chiang, Li-Juan Shen, Fei-Yuan Hsiao. (Taiwan)

- 71 **A Retrospective Study of the Liver Transplantation Recipients for Finding Risk Factors of Post-Transplant Metabolic Syndrome (PTMS) [463]**
Kazuyuki Niki, Mayumi Hamada, Taizo Murata, Yasushi Matsumura, Hiroaki Nagano, Toshinori Ito, Etsuko Uejima. (Japan)
- 72 **Inverse-Probability-of-Selection Weighting of Rich Subsample Data Provides Informed Estimates of Treatment Effects for a Larger Sample [464]**
Alan R Ellis, M Alan Brookhart. (United States)
- 73 **Drug Safety Monitoring with a Self-Controlled Design and Time-Trend Adjustments Using Dabigatran and Warfarin as an Example [465]**
Shirley V Wang, Joshua J Gagne, Sebastian Schneeweiss. (United States)
- 74 **Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes Mellitus – A Retrospective Cohort Study in Taiwan [466]**
Ching-Ying Huang, Shun-Jin Lin, Wei-Hua Chen. (Taiwan)
- 75 **Association between Statin Use and Cardiovascular Mortality Decline at the Population Level in the Netherlands 1994-2010 [467]**
Maarten J Bijlsma, Fanny Janssen, Jens HJ Bos, Pieter Willem Kamphuisen, Stijn Vansteelandt, Eelko Hak. (Netherlands)
- 76 **Association between eGFR Decline and JNC7 Concordant Antihypertensive Treatment [468]**
Christopher G Rowan, Jeffrey A Spaeder. (United States)
- 77 **Comparative Efficacy and Safety of New Oral Anticoagulants Versus Vitamin K Antagonists: Rationale, Design and Baseline Characteristics of the NACORA-BR Observational Study [469]**
Géric Maura, Pierre-Olivier Blotiere, Kim Bouillon, Cécile Billionnet, Philippe Ricordeau, François Alla, Mahmoud Zureik. (France)
- 78 **Systematic Review of of Kudiezi Injection for Acute Cerebral Infarction [470]**
Zhuo Lin, Wang Weiwei, Hu Jing, Wang Jing, Zhang Yuelun. (China)
- 79 **Comparative Effectiveness of Different Oral Antibiotics Regimens for Treatment of Urinary Tract Infection in Outpatient Settings-A Cohort Study on National Healthcare Administrative Database [471]**
Chien-Chang Lee, Meng-tse Gabriel Lee, Shih-Hao Lee, Tse-Chih Chou. (Taiwan)

- 80 Looking Both Ways Before Using the Disease Risk Score (DRS): Performance of the DRS in a Cohort with Known Selection Bias [472]**
Mina Tadrous, Muhammad M Mamdani, David N Juurlink, Murray D Krahn, Linda E Lévesque, Suzanne M Cadarette. (Canada)
- 81 Effect of Conventional Enzyme-Inducing Antiepileptic Drugs on Cancer Mortality and Survival: An Exposed-Unexposed Study of Carcinoma Breast and Glioblastoma Multiforme [473]**
Gagandeep Singh, Ley Sander, Gail Bell. (India)
- 82 Effectiveness, Tolerability and Impact on Quality of Life of Interventions Used for the Management of Patients with Chronic Low Back Pain [474]**
Chirag s Shah, Dipika Bansal, Babita Ghai. (India)
- 83 Anticonvulsants or Antidepressants in Combination Pharmacotherapy for the Treatment of Neuropathic Pain in Cancer Patients: A Meta-Analysis [475]**
Jia Guan, Shiro Tanaka, Koji Kawakami. (Japan)
- 84 Medication and Risk of Rehospitalization in Bipolar Disorder: A Nationwide Cohort Study [476]**
Johan Reutfors, Jari Tiihonen, Lena Brandt, Louise Scheen, Antti Tanskanen, Morten Andersen, Robert Bodén. (Sweden)
- 85 Proton-Pump Inhibitors Do Not Impair (and May Modestly Help) Metformin's Effectiveness [477]**
James H Flory, Kevin Haynes, Charles E Leonard, Sean Hennessy. (United States)
- 86 Preference-Based Instrumental Variable (IV) Methods in the Comparative Effectiveness of Osteoporosis (OP) Medications in Women with Postmenopausal Osteoporosis (PMO) Using the MarketScan Database [478]**
Jane S Der, M Alan Brookhart, Fei Xue. (United States)
- 87 Effect of Anti-Inflammatory Treatment on Depression and Side Effects: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [479]**
Ole Koehler, Michael Benros, Merete Nordentoft, Ole Mors, Jesper Krogh. (Denmark)
- 88 Comparison of Re-Hospitalization and Emergency Room Visit Patterns Among Patients with Schizophrenia Receiving Paliperidone Palmitate or Oral Atypical Antipsychotics in an Inpatient Setting [480]**
Marie-Hélène Lafeuille, Amanda Grittner, Erik Muser, John Fastenau, Mei Sheng Duh, Patrick Lefebvre. (Canada)
- 89 Above Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET) for Control of Carcinoid Syndrome Symptoms: A Multi-Center Retrospective Chart Review Study [481]**
Jonathan R Strosberg, Al B Benson, Lynn Huynh, Mei Sheng Duh, Jamie Goldman, Vaibhav Sahai, Alfred W Rademaker, Matthew H Kulke. (United States)
- 90 Vildagliptin Efficacy in Combination with Metformin for Early Treatment of Type 2 Diabetes Mellitus (VERIFY) [482]**
Wayne Huey-Herng Sheu, Stefano D Prato, James Foley, Wolfgang Kothny, Plamen Kozlovski, Päivi Paldánus, Michael Stumvoll, David R Matthews. (Taiwan)
- 91 Exploring the Factors Associated with Self-Report of Health Status among the Elderly Diagnosed with Chronic Respiratory Diseases in Taiwan [483]**
Ching-Yuan Chang, Shan-Chieh Wu, Wei-Erh Cheng, Hsiang-Wen Lin. (China)
- 92 Comparative Treatment Failure Rates of Respiratory Fluoroquinolones in the Treatment of Community-Acquired Pneumonia: An Analysis of National Representative Claims Database [484]**
Chien-Chang Lee, Meng-tse Gabriel Lee, Shih-Hao Lee, Tse-Chih Chou. (Taiwan)
- 93 Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) with Albuminuria Treated with Sitagliptin as Add-On Therapy to Metformin: A Real-World Data Study [485]**
Cheli Melzer Cohen, Gabriel Chodick, Avraham Karasik, Larry Radican, Shengsheng Yu, Bernd Voss, Offer Sharon, Noga Gadir, Kimberley Brodovicz, Varda Shalev, Harvey Katzeff, Kaan Tunceli. (Israel)
- 94 Use of High Dimensional Propensity Scores to Control for Confounding in Assessing the Association between Bone Density Screening and Hip Fracture Risk [486]**
Jie Zhang, Jeffrey R Curtis, Hong Zhao, Luqin Deng, Kenneth G Saag, Meredith L Kilgore, Paul Muntner, Nicole C Wright, Elizabeth Delzell. (United States)
- 95 On the Use of Propensity Score Method in Case of Rare Exposure [487]**
David Hajage, Yann De Rycke, Florence Tubach. (France)
- 96 Marginal Structural Model Simulation: the Effect of Omitting a Variable from the Outcome Model When It Is Present in the Numerator Model [488]**
Alan R Ellis, M Alan Brookhart. (United States)
- 97 Developing Alerting Thresholds for Active Drug Safety Monitoring [489]**
Grace Wangge, Sebastian Schneeweiss, Robert J Glynn, Joshua J Gagne. (United States)
- 98 Cognitive Health, Willingness to Live, and Social Support but Not Physical Function May Be the Source of Healthy User Bias [490]**
Soko Setoguchi, Lauren Williams, Chih-Ying Chen, Monera Wong, Melissa Clard, Winson Cheung, Edward Chia-Cheng Lai. (United States)
- 99 Value of Information Methods for Choice of Study Design [491]**
Drew G Levy, David C Norris. (United States)
- 100 Outcomes of Outpatient Integrated Medical Care Services across Times in a Medical Center [492]**
Hsiang-Wen Lin, Chih-Hsueh Lin, Chin-Kan Chang, Che-Yi Chou, Pin-Ting Chao, Chia-Nuan Hsu, Ling-Yu Chang, Yow-Wen Hsieh, Jui Sung Hung, Wen-Liang Huang, Der-Yang Cho. (Taiwan)
- 101 ENCePP-HTA Working Group 2014 Survey of Members Experience in Conducting Research to Support HTA [493]**
Kevin Blake, Massoud Toussi, Xavier Kurz, Yvonne Lis, Vera Ehrenstein, Nawab Qizilbash, Nicholas Moore. (United Kingdom)
- 102 Medication Safety Improvement in Patients Transferred from Emergency Room to Medical Wards by Initiating Medication Reconciliation [494]**
Chia-Lin Lin, Chi-Hui Lee, Chin-Lon Lin, Ning-Sheng Lai, Mei-Hua Chuang. (Taiwan)
- 103 The Effectiveness Evaluation of Lasix, Albumin, and Both Used in Liver Disease Patients with Ascites [495]**
Chiu-Ju Chen, Hey-Yu Wang. (Taiwan)

Spotlight Session- Comparative Effectiveness Research (CER) SIG

- 104 Accounting for Treatment Complexity in Propensity Score Estimation: Case Study From T2DM [496]**
Mary E Ritchey, Yong Chen, Michele L Jonsson Funk, Kimberly G Brodovicz. (United States)
- 105 A Propensity Score Matched Cohort Study to Measure the Effects of Orlistat or Bariatric Surgery on Health Outcomes in a General UK Population Sample [497]**
Ian J Douglas, Krishnan Bhaskaran, Rachel L Batterham, Liam Smeeth. (United Kingdom)

106 Indirect Comparison of Meta-Analysis Findings on Adverse Treatment Outcomes: Impact of Trial Heterogeneity and Effect Measure Selection [498]

Aaron J Katz, Michael A Kelsh, Bin Yao, Dominik D Alexander, Deborah Arrindell, Douglas L Weed. (United States)

107 Comparative Effectiveness of Contemporary Adjuvant Chemotherapy Options among Older Rectal Cancer Patients [499]

Jennifer L Lund, Hanna K Sanoff, Til Stürmer. (United States)

108 Reduced Mortality in Thai Peritoneal Dialysis Patients Using Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Propensity Score Analysis [500]

Surapon Nochaiwong, Chidchanok Ruengorn, Setthapon Panyathong, Yuraporn Kaisuwan, Sirisak Nanta. (Thailand)

109 Incidence of Diabetes Complications in Patients on Insulin Analogues Against Those on Human Insulin [501]

Rosa Gini, Giuseppe Roberto, Francesco Cipriani, Giuseppe Seghieri, Paolo Francesconi, Francesco Lapi. (Italy)

110 Radiographic and Endoscopic Diagnostic Workup around Initiation of Oral Bisphosphonates [502]

Xiaojuan Li, Yong Chen, Mugdha Gokhale, Julie Chandler, Annie McNeil, Cynthia J Girman, Til Stürmer. (United States)

111 Using Refill Information to Improve the Performance of Preference-Based Instrumental Variables [503]

Jane S Der, M Alan Brookhart, Cathy Critchlow, Vamshidar Goli, Fei Xue. (United States)

Classical Pharmacoepidemiology

112 The Impact of Insulin Glargine vs. Human Insulin Use on Cancer Incidence [504]

Anne S Geier, Ina Wellmann, Jürgen Wellmann, Jessica M Franklin, Hiltraud Kajüter, Oliver Heidinger, Georg Hempel, Hans-Werner Hense. (Germany)

113 Acute Pancreatitis in Type 2 Diabetic Patients Treated with Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: A Population-Based Nested Case-Control Study [505]

Hsin-Chun Chou, Wen-Wen Chen, Fei-Yuan Hsiao. (Taiwan)

114 Risk of Spontaneous Bacterial Peritonitis Associated with Gastric Acid Suppression [506]

Chien-Chang Lee, Yi-Hsian Lin, Shih-Hao Lee, Tzu-Ting Chen, Meng-tse Gabriel Lee. (Taiwan)

115 Negative Control Study on the Risk of Acute Myocardial Infarction Associated with the Use of Antibiotics Using a US Database [507]

Stephanie Tcherny-Lessenot, Yunxun Wang, Juhaeri Juhaeri, Xavier Kurz, Laurent Auclert, Patrick Caubel. (France)

116 Does Use of Non-Steroidal Anti-Inflammatory Drugs Affect the Risk of Incident Active Tuberculosis Disease? A Nested Case Control Study on a National Health Claim Database [508]

Shih-hao Lee, Meng-tse Gabriel Lee, Yi-Hsian Lin, Chien-Chang Lee. (Taiwan)

117 Does Systemic Corticosteroids Use Increase the Risk of Incident Active Tuberculosis Disease? A Nested Case Control Study on a National Health Claim Database [509]

Meng-tse Lee, Yi-Hsian Lin, Shih-Hao Lee, Chien-Chang Lee. (Taiwan)

118 Mortality of Hydroxyethyl Starch Versus Dextran for Resuscitation in Intensive Care [510]

Lu-Hsuan Wu, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)

119 Effect of Topical Steroids on the Eye [511]

Michael D Murray, Shanshan Li, Evgenia Teal, Corey H Whitley. (United States)

120 Severity of Stroke in Women Using Oral Contraceptives [512]

Klaus K Andersen, Tom S Olsen. (Denmark)

121 A Pilot Study on the Impact of Severe Photosensitivity Reactions Linked to Topical Ketoprofen in Europe [513]

Luigi Naldi, Simone Cazzaniga, Marie Laure Kurzinger, Laurent Auclert, Mario Gori. (Italy)

122 Bisphosphonate (BP) Treatment and Renal Impairment (RI) in Women with Postmenopausal Osteoporosis (PMO) in UK [514]

Fei Xue, Charles Wentworth, Paul Petraro. (United States)

123 Antipsychotic Drug and Seizure Risk among Patients with Psychotic or Mood Disorder in Taiwan [515]

Chi-Shin Wu, Sheng-Chang Wang, Shi-Kai Liu. (Taiwan)

124 An Observational Study of Upper Gastrointestinal Tract Bleeding Events in Patients Taking Duloxetine and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): A Case-Control Analysis [516]

Hu Li, Yingkai Cheng, Jonna Ahl, Vladimir Skljarevski. (United States)

125 Fracture Risk among Depressed Patients Initiating SNRIs vs SSRIs Antidepressants [517]

Yi-han Sheu, Amy Lanteigne, Til Stürmer, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

126 Lamotrigine and the Risk of Severe Cutaneous Adverse Drug Reactions :A Nationwide Cohort Study [518]

Chi-Hsun Chen, Edward Chia-Cheng Lai, Ching-Lan Cheng, Yea-Huei Yang Kao. (Taiwan)

127 Use of Low-Dose Aspirin and Prostate Cancer Risk [519]

Charlotte Skriver, Christian Dehlendorff, Michael Borre, Klaus Brasso, Henrik T Sørensen, Klaus K Andersen, Søren Friis. (Denmark)

128 Anti-Epileptic Drug Prescriptions and Attempted and Completed Suicide in Young Adults [520]

Jesca Brouwer, Linda Wijlaars, Irene Petersen, Irwin Nazareth. (United Kingdom)

129 Association between Inhaled Corticosteroid Use and Diabetes & Other Endpoints in Chronic Obstructive Pulmonary Disease (COPD) [521]

Robert W Flynn, Stuart Schembri, Adrian Hapca, Isla S Mackenzie, Thomas M MacDonald. (United Kingdom)

130 Comparative Safety Profiles of Bevacizumab, Ranibizumab and Pegaptanib in the Treatment of Age-Related Macular Degeneration: the Analysis of the WHO Database of Adverse Drug Reactions [522]

Chiara Biagi, Valentino Conti, Marta Bonisoli, Mauro Melis, Elena Buccellato, Anna Covezzoli, Roberta Amato, Linda Pazzi, Mauro Venegoni, Alberto Vaccheri, Domenico Motola. (Italy)

131 Upper Gastrointestinal Bleeding in Patients with Schizophrenia in the United States [523]

Nadia Foskett, Suellen Curkendall, Nicole Princic, Gregory Lenhart, Bogdan Balas, Smiljana Milosavljevic-Ristic. (United Kingdom)

132 Diabetes Drugs and Acute Pancreatitis: A Systematic Review of Observational Studies [524]

Lorna Hazell, Manel Pladevall-Vila, Lorenza Scotti, Giorgia De Berardis, Cristina Varas-Lorenzo, Susana Perez-Guttham, Miriam Sturkenboom, Saad Shakir. (United Kingdom)

133 Total Cholesterol Level and Risk of Gastrointestinal Bleeding for Patient Taking Warfarin [525]

Dahye Shin, Jin Soo Lee, Dukyong Yoon, Rae Woong Park. (Republic of Korea)

134 The Risk of Acute Asthmatic Attacks Associated with Different Dosage Forms of Non-Steroidal Anti-Inflammatory Drugs: A Self-Controlled Case Series Study [526]

Yoshinori Takeuchi, Shingo Higa, Ayumi Endo, Kazuhiro Matsui, Shinichi Watanabe. (Japan)

135 Adverse Drug Reactions in Hospitalized Patients: A Comparative Study of Intensive Care and General Care Units [527]

Joo-Hee Kim, Seung Hun Jang, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung. (Republic of Korea)

136 Potential Drug-Drug Interactions in Oncology Patients Receiving Anti-Cancer Drugs in a Tertiary Medical Centre in Taiwan [528]

Chin-Chin Ho, Chen-Chang Yang, Yueh-Ching Chou. (Taiwan)

137 Psychiatric Health Care Utilisation and Related Costs in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada) [529]

Caroline Croteau, Laurent Motttron, Marc Dorais, Jean-Éric Tarride, Sylvie Perreault. (Canada)

Pharmacovigilance

138 The Positive False Discovery Rate Method to Control the Multiplicity Problem in Pharmacovigilance: the SAFEGUARD Project [530]

Lorenza Scotti, Silvana A Romio, Antonella Zambon, Lorna Hazell, Niklas Schmedt, Miriam Sturkenboom, Giovanni Corrao. (Italy)

139 Rifampicin-Associated with Thrombocytopenia in Dose Dependent Manner during Pulmonary Tuberculosis Treatment: A Case Report [531]

Sen Mei Chen, Chen Szu Lai, Ping Ya Wang, Hao Chih Hung, Ling Hui Chen, Hua Chi Chen. (Taiwan)

140 Drug Induced Liver Injury during TB Treatment in Indonesia [532]

JA Thobari, DA Perwitasari, UA Mulyani. (Indonesia)

141 Utility of Social Media Surveillance for Drug Safety and Signal Detection Purposes [533]

Brian Dreyfus, Jaidev Dasgupta, Andres Gomez-Camirero. (United States)

142 Exploring Adverse Event Reporting Patterns of Newly Approved Anti-Cancer Drugs in the Japanese Adverse Drug Event Report (JADER) Database [534]

Shinichi Matsuda, Kenji Hamada, Kotonari Aoki. (Japan)

143 Bisphosphonate Therapy and Osteonecrosis of the Jaw: A Case/ Non-Case Study in the French National Pharmacovigilance Database [535]

Paul de Boissieu, Malak Abou Taam, Marie-Paule Roux, Lukshe Kanagaratnam, Thierry Trenque. (France)

144 Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia [536]

Samantha A Hollingworth, Treasure McGuire, David Pache, Mervyn J Eadie. (Australia)

145 Analysis of Safety Profiles between Iodinated Contrast Media and Anaphylaxis Based on Korea Adverse Event Reporting System [537]

Yeonju Woo, Sooyoun Chung, Byung-Joo Park. (Republic of Korea)

146 Knowledge, Perception Attitude About Adverse Drug Reaction (ADR) and ADR Reporting Among Pharmacy Students' in Malaysian Private University [538]

Mohamed Shukry Zawahir, Rodgne Alexius Sultan, Mohd Fadli Mohd Asmani, Eddy Yusuf. (Sri Lanka)

147 Side Effects Associated with Antiretroviral Therapy (ART) in Nepal [539]

Shyam P Lohani, Punita Rimal, Prakash Panta. (Nepal)

148 Case Review of Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents [540]

Pei-Tzu Lin, Ching-Ling Tai. (Taiwan)

149 Acute Topical β -Blocker Exposure in Asthma: Meta-Analysis of Controlled Clinical Trials [541]

Daniel R Morales, Bruce Guthrie, Brian J Lipworth, Cathy Jackson, Tobias Dreischulte. (United Kingdom)

150 Cases of Anaphylaxis Associated with the Use of Drugs: Analysis of a Pharmacovigilance Database [542]

Diogo Mendes, Carlos Alves, Francisco Batel Marques. (Portugal)

151 Medications Prescribed and Occurrence of Falls in Inpatient Setting [543]

Ming-Fen Wu, Yen-Lin Chang, Wen-Shyong Liou, Sek-Kwong Poon, Li-Yin Chang. (Taiwan)

152 Common Causative Agents of Nephrotoxicity in a Regional Pharmacovigilance Center Based on an Academic Hospital in Korea, 2009-2013 [544]

Shin-Woo Kim, Hyun-Ha Chang, Su-Jung Kim, Jong-Myung Lee. (Republic of Korea)

153 Baseline Risk Factors for Cardiovascular Events: Differences between the USA and Russia in a Study Population of Combined Oral Contraceptive Users [545]

Suzanne Reed, Klaas Heinemann, Juergen Dinger. (Germany)

154 Improving Knowledge, Attitude and Practice of Pharmacovigilance among Traditional Medicine Practitioners in Lagos State, Nigeria [546]

Ibrahim Oreagba, Khadija Ade-Abolade, Adeline Osakwe, Olayinka Ogunleye, Kazeem Oshikoya. (Nigeria)

155 Adverse Drug Event of Hospitalized Patients from Multi-Hospitals in Thailand [547]

Pramote Tragulpiankit, Narak Yeeseenpan, Thida Ninsananda, AdCoPT Working Team, Busba Chindavijak, Suvatna Chulavatnatol, Usa Chaikledkaew, Tikumpon Uaviseswong. (Thailand)

156 Analysis in Adverse Reactions of Radiocontrast Agent Using Association Rule Mining in Regional Pharmacovigilance Center [548]

Gyeong Im Yu, Yoon Nyun Kim, Chang Sik Son, Hyeok Won Jang, Sang Hyon Kim, Dong Hoon Shin. (Republic of Korea)

157 Use of Social Media in Pharmacovigilance: Testing the Waters [549]

Preciosa M Coloma, Benus Becker, Erik van Mulligen, Jan A Kors. (Netherlands)

158 A Comparison of Active Adverse Event Surveillance Systems Worldwide [550]

Yu-Lin Huang, Jinhee Moon, Jodi B Segal. (United States)

- 159 **Using New Information and Communication Technologies (ICT) in Pharmacovigilance: Results of a 2 Waves Survey Conducted in France in 2012 and 2013 [551]**
Hubert Mechin, Benoit Martinet, Nathalie Beslay. (France)
- 160 **MIHARI – Medical Information for Risk Assessment Initiative Year 5 [552]**
Chieko Ishiguro, Ayumi Endo, Kazuhiro Matsui, Shinichi Watanabe. (Japan)
- 161 **Adverse Reactions of Cardiovascular Drugs in Ukraine in 2011-2012 [553]**
Oleksandr V Matvieiev, Olena I Koniaieva, Olena V Matvieieva. (Ukraine)
- 162 **Are Patients Ready to Take Part in the Pharmacovigilance System – A Portuguese Preliminary Study Concerning Drug Reaction Reporting [554]**
Cristiano F Matos, Florence Pam van Hunsel, João J Joaquim. (Netherlands)
- 163 **Analysis of Adverse Drug Reactions in Hanyang Univ. Hospital Drug Safety Center [555]**
Won Sun Jeon, Eun Jae Park, Kyoung Ok Lee, Hye Young Kwak. (Republic of Korea)
- 164 **A Comparative Analysis of Adverse Drug Reactions: Pre- and Post Regional Pharmacovigilance Center in a Single Tertiary Hospital [556]**
Young-Hee Nam, Hee-Joo Nam, Jeong-Eun Song, Dong-Sub Jeon, Hye-Won Lee, Soo-Keol Lee. (Republic of Korea)
- 165 **Evaluation of Statistical Measures for Adverse Drug Interaction Surveillance [557]**
Kristina Juhlin, Daniel Soeria-Atmadja, Bharat Thakrar, G Niklas Norén. (Sweden)
- 166 **Study of Patients' Potential as a Source for Spontaneous Reporting Systems in Bulgaria [558]**
Hristina Lebanova, Ilko Getov. (Bulgaria)
- 167 **Sample Size Calculations for Comparative Pharmacoepidemiology Surveillance Studies in Healthcare Databases [559]**
Nicholas W Galwey, Michael C Irizarry, Ashley E Wivel, Jennifer B Christian, Marilyn A Metcalf. (United States)
- 168 **Pharmacovigilance Reporting from Saudi Hospitals: Survey of Pharmacovigilance Coordinators [560]**
Adel A Alharf, Saleh A Bawazir, Ali Alshahrani, Ghazi Saeed, Hisham Aljadhey. (Saudi Arabia)

Risk Management / Risk Minimization/Communication

- 169 **Potentially Inappropriate Medications Defined by STOPP Criteria on Nursing Home Residents of a Teaching Hospital in Taiwan [561]**
Li-Chai Chen, Pei -Yu Chen, Jian-Cheng Li, Pili Chih-Min Mao. (Taiwan)
- 170 **The Effectiveness Evaluation of CPOE Drug Alerting System in NSAIDs Prescription for Patients with Renal Impairment [562]**
Ching-Yao Cheng, Ying-Mei Liu, Wen-Shyone Liou, Ming-Ju Wu. (Taiwan)
- 171 **Evaluation of the Relationship between BMI, Body Fat Percentage and Waist to Hip Ratio in Healthy Educated Young Indians [563]**
Dipika Bansal, Paleti S Ramakrishna. (India)
- 172 **The Effectiveness of Varenicline Medication Guide for Conveying Safety Information to Patients: A 3-Year REMS Assessment Survey [564]**
Kandace L Amend, Muhammad Younus, Kenneth R Petronis, Jingping Mo, Robert Gately, Cheryl Enger. (United States)
- 173 **Real World Utilization and Management of Adverse Events in Patients Treated with Direct Acting Antivirals (DAAs) in a European Cohort of Chronic Hepatitis C (CHC) Patients [565]**
Shirin Ahmed, Stephanie Chretien, T Christopher Mast. (United States)
- 174 **Management of Drug-Drug Interaction Alerts for Clinical Decision Support in Outpatients [566]**
Chien Hao Su, Chien Ning Hsu, Shu Chen Tsai, Yu Chin Lily Wang. (Taiwan)
- 175 **Ten Years Retrospective Review of Legal Warnings in Thailand [567]**
Pakawadee Sriphiromya. (Thailand)
- 176 **Hypersensitivity Reactions to Andrographis Paniculata Reported to the Health Product Vigilance Center (HPVC) in Thailand [568]**
Wimon Suwankesawong, Surasak Saokaew, Unchalee Permsuwan, Nathorn Chaiyakunapruk. (Thailand)
- 177 **A Review on Quality Surveillance Results of Cosmetics in Taiwan [569]**
Meng-Hsuan Chung, Wei-Sheng Huang, Yu-Chang Chang, Yu-Hsuan Chen, Ming-Shin Lee, Hwei-Fang Cheng. (Taiwan)

- 178 **Conditional Approval from CHMP Is Associated with Increased Phase IV Epidemiology Study Commitments [570]**
Philip A Spearpoint, Jack O Ziomek, Wenting Zhang, Anjan K Banerjee. (United Kingdom)
- 179 **The Effect of Acquisition with the Outcome of Marketing Authorization Applications of New Active Substances Submitted to the EMA [571]**
Cornelis A Van den Bogert, Patrick C Souverein, Michelle Putzeist, Susan Janssen, Gerard H Koëter, Hubert GM Leufkens. (Netherlands)
- 180 **Case Study on a Violation of the Pharmaceutical Affairs Act: Illegal Commission of the Packing Processing of Medicinal Products to a Food Factory [572]**
Hui-Ling Chen, Yu-Ting Huang, Chyn-Liang Huang, Ming-Shin Lee, Hwei-Fang Cheng. (Taiwan)

Spotlight Session- Pregnancy SIG

- 181 **Acid-Suppressive Drug Use during Pregnancy and the Risk of Atopic Dermatitis: A Crossover Study Within the Clinical Practice Research Database [573]**
Bianca Mulder, Eelko Hak, Catharina CM Schuilng-Veninga, Tjalling W de Vries, Susan S Jick. (Netherlands)
- 182 **Association between Antibiotic Use and Birth Defects Among Women Who Had Urinary Tract Infections in the First Trimester of Pregnancy [574]**
Elizabeth Ailes, Suzanne Gilboa, Simerpal Gill, Cheryl Broussard, Krista Crider, RJ Berry, Tonia Carter, Charlotte Hobbs, Jennita Reefhuis. (United States)
- 183 **Lamotrigine Use in Pregnancy and Risk of Orofacial Cleft, an Update of EUROCAT Lamotrigine Study [575]**
Hao Wang, Maria Loane, Ester Garne, Joan Morris, Vera Nelen, Babak Khoshnood, Anke Ribmann, Awi Wiesel, Mary O'Mahony, Anna Pierini, Elisa Calzolari, Miriam Gatt, Marian Bakker, Marie-Claude Addor, David Tucker, Kari Klungsoyr, Anna Latos-Bielenska, Jan P Mejnartowicz, Karin Kallen, Ingeborg Barisic, Christine Verellen-Dumoulin, Bérénice Doray, Larraitz Arriola, Diana Wellesley, Amanda Neville, Lolkje TW de Jong-van den Berg, Helen Dolk. (Netherlands)

- 184 Selective Serotonin Reuptake Inhibitor Use in First Trimester Pregnancy and Risk of Congenital Anomalies: A Register-Based Study in 12 European Countries [576]**
Anthony Wemakor, Karen Casson, Ester Garne, Mariam Bakker, David Tucker, Babak Khoshnood, Vera Nelen, Mary O'Mahoney, Anna Pierini, Kari Klungsoyr, Mariam Gatt, Marie-Claude Addor, Anke Rissmann, Larraitz Arriola, Lolkje de Jong-van Berg, Helen Dolk. (Ghana)
- 185 Direct-from-Patient Information on Medication Use: PROTECT Pregnancy Study Results [577]**
Nancy A Dreyer, Shahrul Mt-Isa, Jonathan L Richardson, Maja Laursen, Priscilla A Zetstra-van der Woude, Lolkje de Jong-van den Berg, Ana Jamry-Dziurka, Simon HL Thomas, Stella CF Blackburn. (United States)
- 186 Discontinuation of Antipsychotic Medication in Pregnancy: A Cohort Study [578]**
Irene Petersen, Rachel L McCrea, David PJ Osborn, Vanessa Pinfold, Ruth Gilbert, Phil J Cowen, Irwin Nazareth. (United Kingdom)
- 187 Trends in the Use of Anti-Epileptic Drugs during Pregnancy in the Netherlands [579]**
Eugene van Puijenbroek, Loes de Vries, Agnes Kant. (Netherlands)
- 188 Outcomes of Opioid Use in Pregnancy: A Danish Population-Based Study [580]**
Mette Nørgaard, Sussie Antonsen, Malene S Nielsson, Deirdre J Murphy, Rikke B Nielsen, Sabine M Apelt, Henrik T Sørensen. (Denmark)

Medications in Pregnancy and Lactation

- 189 Birth Outcomes after Exposure to Mebendazole and Pyrvinium During Pregnancy – A Danish Nationwide Cohort Study [581]**
Arendse Torp-Pedersen, Espen Jimenez-Solem, Henrik E Poulsen, Jon T Andersen. (Denmark)
- 190 NSAID Use during Pregnancy: Maternal Characteristics and Prescription Patterns. A Nationwide Cohort Study [582]**
Vanja Cejvanovic, Espen Jimenez-Solem, Henrik Enghusen Poulsen, Jon Trærup Andersen. (Denmark)
- 191 Combining Adverse Perinatal and Pregnancy Outcomes Using a Latent Trait Model [583]**
Xuerong Wen, Kimford J Meador, Joseph C Delaney, Xuefeng Liu, Jeffrey Roth, Rich Segal, Robert Egerman, Abraham Hartzema. (United States)

- 193 Lithium Prescribing during Pregnancy: A UK Primary Care Database Study [585]**
Rachel L McCrea, Irwin Nazareth, David PJ Osborn, Steven Evans, Vanessa Pinfold, Phil J Cowen, Ruth Gilbert, Irene Petersen. (United Kingdom)
- 194 Parental Exposure to Folic Acid Antagonists During Reproductive Age in a National Sample [586]**
Kitaw Demissie, Matthew Cvitanovich, Bijal Balasubramanian, Tefera Gezmu. (United States)
- 195 First Results of the Nationwide pREGnant Register in the Netherlands [587]**
Eugene van Puijenbroek, Saskia Vorstenbosch, Agnes Kant. (Netherlands)
- 196 Validation of Major Congenital Malformations (MCMs) in Infants of Mothers with Chronic Inflammatory Arthritis (cIA) and Psoriasis (PsO) [588]**
Wendy J Carman, Neil A Accortt, Li Zhou, Lauren Sanders, Yessenia T Bartley, Mary S Anthony, Cheryl Enger. (United States)
- 197 Epidemiology of Pre-Existing Diabetes in Pregnancy from 2000-2006 among Medicaid Patients in 29 US States [589]**
Caitlin A Knox, Richard Segal, Almut G Winterstein. (United States)
- 198 Internet Advertisement Methods Provide Highest Levels of Recruitment to a Pilot Study of Self-Reported Medication Use and Pregnancy Outcomes [590]**
Jonathan L Richardson, Simon HL Thomas, Sally Stephens, Anna Jamry, Anna Latos-Bielenska, Priscilla A Zetstra-van der Woude, Lolkje TW de Jong-van den Berg, Maja Laursen, Shahrul Mt-Isa, Valerie Bigouret-Hliva, Nancy A Dreyer, Stella CF Blackburn. (United Kingdom)

- 199 Risks Versus Benefits of Medication Use During Pregnancy: What Do Women Perceive? [591]**
Bianca Mulder, Nynke CM Schuiling-Veninga, Leonard P Morssink, Maarten J Bijlsma, Eugene van Puijenbroek, Jan G Aarnoudse, Eelko Hak, Tjalling W de Vries. (Netherlands)
- 200 Creating a Pregnancy Register for a UK Population [592]**
Rachael Boggon, Tim Williams. (United Kingdom)
- 201 Evaluation of Medication Use During Pregnancy in the Mini-Sentinel Distributed Database [593]**
Susan Andrade, Sengwee Toh, Marilyn Pitts, Monika Houstoun, Katrina Mott, Katie Haffenreffer, Marsha Reichman. (United States)

- 202 Developing a Systematic Approach to Safer Medication Use during Pregnancy: Summary of a Centers for Disease Control and Prevention-Convended Meeting [594]**
Cheryl S Broussard, Meghan T Frey, Sonia Hernandez-Diaz, Michael F Greene, Christina D Chambers, Leyla Sahin, Beth A Collins Sharp, Margaret A Honein. (United States)
- 203 Female Kidney Transplant Patients Taking Mycophenolate Analysis in a Southern Taiwan Hospital [595]**
Pili Chih-Min Mao, Mei-Ing Chung, Eric Kin-Lap Lee, Pi-Lai Tseng. (Taiwan)
- 204 A Comparative Analysis of Signal Detection in Electronic Healthcare Databases vs. Spontaneous Reporting Databases [925]**
Alexandra C Pacurariu, Preciosa M Coloma, Gianluca Trifiro, Sabine M Straus, Martijn J Schuemie, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Johan van der Lei, Miriam C Sturkenboom. (Netherlands)

END SESSION B

Spotlight Session- Top 8 Abstracts (C)

- 1 **Combination Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study [682]**
Naseer Qayum, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 2 **Impact of a Metoprolol Shortage on Post-Myocardial Infarction beta-Blocker Utilization [683]**
Joshua J Gagne, Katsiaryna Bykov, Bo Wang, Niteesh K Choudhry. (United States)
- 3 **The Use of Oral Isotretinoin in France: Assessment of Appropriate Use as a Second Line Treatment [684]**
Aurora Tricotel, Sara Miranda, Mahmoud Zureik. (France)
- 5 **Survival of Elderly Australian Men Initiating Hormone Therapy for Prostate Cancer [686]**
Svetla Gadzanova, Libby Roughead. (Australia)
- 6 **Genomic Determinants of Prognosis in Esophageal Adenocarcinoma: Using Computational Methods to Account for Gene-Gene Interactions [687]**
Eric Morgen, Xiaowei Shen, Thomas L Vaughan, David Whiteman, Anna Wu, Marlie Gammon, Wong-Ho Chow, Daniel O Stram, Yvonne Romero, Wei Xu, Geoffrey Liu. (Canada)
- 7 **Clinical Factors Associated with Prescription Filling of Mood-Stabilizers in Bipolar Disorder – A Population-Based Cohort Study [688]**
Louise Scheen, Robert Bodén, Lena Brandt, Jari Tiihonen, Morten Andersen, Helle Kieler, Johan Reutfors. (Sweden)
- 8 **Databases in Asia: The Potential for Distributed Network Approach [689]**
Edward Chia-Cheng Lai, Nathorn Chaiyakunapruk, Yinghong Zhang, Chantelle Hardy, Kiyoshi Kubota, Elizabeth E Roughead, Byung Joo Park, Ju-Young Shin, Ian CK Wong, Jin Wen, Sawaeng Watcharathanakij, Yea-Huei Kao Yang, Soko Setoguchi. (Taiwan)

Database

- 9 **Realistic Power Estimation for New User, Active Comparator Studies: An Empirical Example [690]**
Mugdha N Gokhale, John B Buse, Til Sturmer. (United States)
- 10 **Use of Thiazolidinedione and Risk of Urothelial Cancer among Taiwan Diabetes Patients [691]**
Jo-Yen Chao, Tzu-Chieh Lin, Ming-Cheng Wang, Yea-Huei Kao Yang. (Taiwan)

- 11 **Comparing the Risk for Atrial Fibrillation in Patients with Diabetes Initiating Metformin or Sulfonylureas: A Nationwide Population-Based Cohort Study in Taiwan [692]**
Ying Ling Liu, Chi Wen Chiang, Tong Rong Tsai, Wei Chung Tsai. (Taiwan)
- 12 **Statins and Risk of Pulmonary Complications and Mortality after Gastric Bypass Surgery [693]**
Sigrid B Gribsholt, Elisabeth Svensson, Stine Skovbo, Reimar W Thomsen, Bjørn Richelsen, Henrik T Sørensen. (Denmark)
- 13 **Use of N-Methylthiotetrazole (NMTT) - Cephalosporin Antibiotics and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study [694]**
Li-Ju Chen, Fei-Yuan Hsiao, Li-Juan Shen, Shu-Wen Lin. (Taiwan)
- 14 **The Risk of Acute Liver Injury among Users of Antibiotic Medications in the PROTECT Project: The Results of a Nested Case-Control Study Using European Outpatient Healthcare Data [695]**
Ruth Brauer, Ian Douglas, Luis Alberto Garcia Rodriguez, Andrew Bate, Liam Smeeth, Robert Reynolds, Olaf Klungel, Ana Ruigomez. (United Kingdom)
- 15 **A Structured Database Approach for Addressing Pharmacoepidemiologic Research Needs Concerning Cancer [696]**
Jinghua He, Edward A Bortnichak, Mellissa Yong. (United States)
- 16 **Increasing Risks of Stroke in Oral Cancer Patients Treated with Radiotherapy or Chemotherapy: A Nationwide Cohort Study [697]**
Yu-Ting Wu, Chung-Yu Chen, Yaw-Bin Huang, Cheng-Chiun Kuo. (Taiwan)
- 17 **Algorithm to Identify Malignant Lymphoma Patients Extracted from an Electronic Hospital Database and Its Application in Japan [698]**
Sumiko Okubo, Shuko Nojiri, Stepehn Paul Motsko, Yu Yan, Masanori Taketsuna, Haru Nakasawa, Hiroya Asou, Rei Maeda. (Japan)
- 18 **The Disproportionate Analysis of Intravenous Iron-Containing Medicines Related Adverse Reactions in Taiwan [699]**
Yu Jie Huang, Wei Ming Ke, Wei I Huang, Wen Wen Chen. (Taiwan)
- 19 **Use of Antihypertensive Drugs and Risk of Skin Cancer [700]**
Sigrun A Johannesdottir, Morten Schmidt, Frank Mehnert, Stanley Lemeshow, Henrik T Sørensen. (Denmark)
- 20 **Cancer Prognosis Following the Usage of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Lung Cancer Patients with Hypertension History [701]**
Pei-Jung Sha, Jong-Rung Tsai, Kun-Pin Hsieh, Yi-Hsin Yang. (Taiwan)
- 21 **Stroke Epidemiology in China over the Past Ten Years, a Study on Subtype Distribution and Case Fatality [702]**
Lei Yan, Jiapeng Lu, Yadong Cui, Dena R Ramey, Jing Li, Lixin Jiang. (China)
- 22 **The Effect of Using Statin for Cardiovascular Prevention in Peritoneal Dialysis Patients [703]**
Ping-Hsun Wu, Yi-Ting Lin, Mei-Chuan Kuo, Yi-Wen Chiu, Hung-Chun Chen. (Taiwan)
- 23 **Statin Use and Risk of New-Onset Diabetes in the Young Population with Hyperlipidemia [704]**
Yi-Ting Lin, Ping-Hsun Wu, Tsung-Hsien Lin. (Taiwan)
- 24 **Statin Use and the Risk of Incident Diabetes Mellitus: A Population-Based Retrospective Cohort Study in Taiwan [705]**
Zhen-Fang Lin, Fe-Lin Wu Lin. (Taiwan)
- 25 **ACE-Inhibitors and the Risk of Urinary Tract Infections: Comparison of a Case-Crossover and Prescription Sequence Symmetry Design [706]**
Koen B Pouwels, Jens HJ Bos, Eelko Hak. (Netherlands)
- 26 **Discontinuation of Angiotensin Converting Enzyme Inhibitors (ACEIs) as a Potential Marker for Adverse Drug Reactions (ADRs) [707]**
Seyed Hamidreza Mahmoud Pour, Catherine E de Keyser, Patrick C Souverein, Folkert W Asselbergs, Albert Hofman, Bruno H Stricker, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)
- 27 **Epidemiology of Psoriasis in Japan: Results from a Descriptive Study Using National Database [708]**
Yukari Kamijima, Nobuhiro Ooba, Tsugumichi Sato, Kiyoshi Kubota. (Japan)
- 28 **Risk of Cardiac Valve Disorders with Use of Bisphosphonates [709]**
Preciosa M Coloma, Maria de Ridder, Peter Rijnbeek, Mees Mosseveld, Irene Bezemer, Ron MC Herings, Rosa Gini, Serena Pecchioli, Lorenza Scotti, Johan van der Lei, Gianluca Trifirò, Miriam CJM Sturkenboom. (Netherlands)

- 29 **Marginal Structural Model (MSM) to Estimate the Effect of Cumulative Osteoporosis Medication (OPM) on Serious Infection (SI) Using Claims Data [710]**
Fei Xue, Vamshidar Goli, Paul Petraro, Trevor McMullan, Eric Tchetgen Tchetgen. (United States)
- 30 **Case Report: Stevens-Johnson Syndrome Following Exposure to Valproate [711]**
Hui-Hsia Hsieh, Ching-Yi Chang, Yung-Ta Lin, Chi-Hua Chen. (China)
- 31 **Co-Morbid Medical Conditions in Vascular Dementia: A Case-Control Study [712]**
Ruby C Castilla-Puentes, Miguel E Habeych. (United States)
- 32 **Effectiveness and Safety of Aspirin in Taiwan Special Population [713]**
Chung-Yu Chen, Yaw-Bin Huang, Wen-Ter Lai, Tzu-Chi Lee. (Taiwan)
- 33 **Analysis of Adverse Drug Reactions of Antiepileptic Drugs by Using Spontaneous Reporting System in Medical Center in Taiwan [714]**
Shi-Li Wang, Chun-Ching Chiu, Sock-Ping Ng, Su-Yu Chien. (Taiwan)
- 34 **Risk of Hip Fractures Associated with Benzodiazepines: Common Methodology But Different Results in a Multi-Site Cohort Study. The PROTECT Project [715]**
Gema Requena, Consuelo Huerta, Helga Gardarsdottir, Montserrat Miret, Elisa Martin, Patrick C Souverein, Cornelia Schneider, Rocío González-González, Andrew Bate, Yolanda Alvarez, Dolores Montero, Luis A García-Rodríguez, Robert Reynolds, Raymond G Schlienger, Mark CH de Groot, Olaf H Klungel, Francisco J de Abajo. (Spain)
- 35 **No Impact of Adjusting for Lifestyle Factors or General Practice on Risk Estimates for the Association between Antidepressants and Hip/Femur Fracture [716]**
Patrick C Souverein, Mark CH De Groot, Elisa Martin, Consuelo Huerta, Gianmario Candore, Yolanda Alvarez, Jim Slattery, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Helga Gardarsdottir. (Netherlands)
- 36 **Antidepressant Use and the Risk of Hip Fracture: A Self-Controlled Case Series Approach in Two Primary Care Databases [717]**
M Sanni Ali, Mark De Groot, Giammarco Candore, Rolf HH Groenwold, Patrick C Souverein, Yolanda Alvarez, Md J Uddin, Arno W Hoes, A de Boer, Olaf H Klungel, Helga Gardarsdottir. (Netherlands)
- 37 **Evaluation of "Pre-Treated" Bipolar Disorder Patients Receiving Atypical Antipsychotics in the UK Using an Electronic Health Record Database [718]**
Mellissa Yong, Jane Liao, Herve Besson, Zhiwen Lui, Pearson Jay. (United States)
- 38 **Deprivation and Cancer Incidence in Southern Europe: A Nation-Wide Ecological Study [719]**
Maria Garcia-Gil, Josep-Maria Elorza-Ricart, Marta Banque-Navarro, Bonaventura Bolibar, Rafel Ramos, Daniel Prieto-Alhambra. (United Kingdom)
- 39 **Antidepressants and Valvular Heart Disease: A Nested Case-Control Study in Taiwan [720]**
CH Lin, FY Hsiao, FLL Wu, LJ Shen. (Taiwan)
- 40 **Distinguishing an Optimal Risk Modeling Framework for Predicting Adverse Events [721]**
Zuoyi Zhang, Xiaochun Li, Jon Duke. (United States)
- 41 **Safety of GlaxoSmithKline's Inactivated Adjuvanted (AS03) A/H1N1pdm09 Pandemic Influenza Vaccine in Solid Organ Transplant Recipients [722]**
Catherine Cohet, François Haguinet, Germano LC Ferreira, Dave Webb, John Logie, Dominique Rosillon, Vivek Shinde, Gaël Dos Santos. (Belgium)
- 42 **Comparative Safety of Antimuscarinics among Adults in the United States, 2000–2011 [723]**
Alan Kinlaw, Jennifer Wu, Mitchell Conover, Michele Jonsson Funk. (United States)
- 43 **Comparative Risk of Post-Operative Mortality between Taiwan Dialysis and Non-Dialysis Patients Receiving First-Time Surgery [724]**
Tzu Chieh Lin, Hung Chun Chen, Yen Chin Liu, Yea Huei Kao Yang. (Taiwan)
- 44 **Factors Associated with Exposure of Potential Interactions between Chinese Herbal Medicines and Western Medications [725]**
Hsin-Hui Tsai, Hsiang-Wen Lin, Chu-Ling Tsai, Yow-Wen Hsieh, Shyh-Shyan Jan, Ching-Yeh Tu. (Taiwan)
- 45 **Utilization of Immunosuppressive Drugs in Post-Heart Transplant Recipients in Taiwan [726]**
Chia-Lin Chou, Chia-Yu Chou, Yin-Yu Huang, Chia-Chen Hsu, Yueh-Ching Chou. (Taiwan)
- 46 **Association between Inhaled Long-Acting beta-2-Agonists and the Risk of Acute Myocardial Infarction: A Methodological Comparison of Two Databases [727]**
Ana SM Afonso, Sven Schmiedel, Claudia Becker, Paola Primatesa, Estel Plana, Patrick C Souverein, Joke C Korevaar, Joerg Hasford, Robert Reynolds, Mark CH de Groot, Raymond G Schlienger, Olaf H Klungel, Marietta Rottenkolber. (Netherlands)
- 47 **Long-Acting beta Agonist Containing Therapies and the Risk of Serious Adverse Events in Subjects with Persistent Asthma [728]**
Pingsheng Wu, Tebeb Gebretsadik, William D Dupont, Robert L Davis, Kelly Horan, Carlos Iribarren, Elyse O Kharbanda, Emma Larkin, Tracy Lieu, Irina Miroschnik, Edwards Mitchel, William M Vollmer, Ann C Wu, Tina Hartert. (United States)
- 48 **Concurrent Use of Chinese Herbal Products Among Hormonal Users Aged 55-79 in Taiwan: A Population-Based Study [729]**
Yueh-Ting Tsai, Jung-Nien Lai, Chien-Tung Wu, Shun-Gu Lin. (Taiwan)
- 49 **Using Oncology Electronic Medical Records in the Study of Non-Melanoma Skin Cancer in the United States: Opportunities and Challenges [730]**
Lei Chen, Yuer Yan, James A Michael, Dale Quentin Marmaduke, Yiu-Keung Lau, Nayan Acharya. (United States)
- 50 **Validating a Multiple Myeloma Algorithm Using a SEER Tumor Registry and Administrative Data [731]**
Nancy A Brandenburg, Syd Phillips, Karen E Well, Kimberley J Woodcroft, Kandace Amend, Cheryl Enger, Susan A Oliveria. (United States)
- 51 **Risk of Mortality with Venous Thromboembolism in CPRD GOLD: The Impact of Using Linked Data [732]**
Arlene M Gallagher, Tim Williams, Hubert GM Leufkens, Frank de Vries. (United Kingdom)
- 52 **Identification of Heart Failure by Diagnoses and Cardiac Tests in a U.S. Electronic Health Records Database [733]**
Hoa V Le, Chi TL Truong, Julie Priest, Julia DiBello, Carlyne Averell. (United States)

- 53 Validation of Major Adverse Cardiovascular Events (MACE) in US Claims Databases [734]**
Kevin Haynes, Melissa S Nezamzadeh, Craig W Newcomb, Jason Roy, Whitney Kite, Dena M Carbonari, Serena Cardillo, Sean Hennessy, Cristin P Freeman, Crystal N Holick, Daina B Esposito, Brian L Strom, Vincent Lo Re. (United States)
- 54 Concordance of Myocardial Infarction (MI) between Medicare & Atherosclerosis Risk in Communities (ARIC) Study [735]**
Montika Bush, Til Stürmer, Sally Stearns, Ross J Simpson, Jr, Alan Brookhart, Anna Kucharska-Newton. (United States)
- 55 Comparing the Influence of Month of Birth and Gender in Two Academic Years on Attention Deficit Hyperactivity Disorder Diagnoses (ADHD) Among Children in the Health Improvement Network (THIN) UK Data [736]**
Caroline O'Leary, Alison Bourke, David Ansell. (United Kingdom)
- 56 The Surveillance of Metoclopramide-Induced Extra-Pyramidal Symptoms and Movement Disorders Reported in Samsung Medical Center in Korea [737]**
Su Mi Lee, Ji Eun Park, Yong Seok Lee, Hu Kyung Lee, Young Mee Lee, Byung Jae Lee. (Republic of Korea)
- 57 Osteoporosis in the Community: Findings from a Novel Computerized Registry in a Large Health Organization in Israel [738]**
Inbal Goldshtein, Allison Martin Nguyen, Gabriel Chodick, Varda Shalev, Sofia Ish-Shalom, Julie Chandler. (Israel)
- 58 What Does Natural Language Processing Add to the Structured Data Available in Medical Records? [739]**
X Zhou, L Weiss, AM Walker, AN Ananthakrishnan, R Shen, R E Sobel, A Bate, R F Reynolds. (United States)
- 59 Risk of Hospitalization and HealthCare Cost Associated with Diabetic Complication Severity Index in Taiwan's National Health Insurance Research Database [740]**
Hung-Lin Chen, Fei-Yuan Hsiao. (Taiwan)
- 60 Validation of Serious Hospitalized Infection Events in US Claims Databases [741]**
Kevin Haynes, Melissa Nezamzadeh, Craig W Newcomb, Jason Roy, Whitney Kite, Dena M Carbonari, Serena Cardillo, Sean Hennessy, Cristin P Freeman, Crystal N Holick, Daina B Esposito, Strom L Brian, Lo Re Vincent. (United States)
- 61 Evaluation of Methods for Identifying Chemotherapy Induced Febrile Neutropenia among Cancer Patients in Denmark [742]**
Hairong Xu, Mette Nørgaard, Uffe Heide-Jørgensen, Lars Pedersen, John H Page, Vera Ehrenstein. (United States)
- 62 How Far Is Estimated Creatinine Clearance (eClcr) and Estimated Glomerular Filtration Rate (eGFR) from Measured Creatinine Clearance (mClcr) in Taiwanese [743]**
Yu-Hui Wu, Fe-Lin Lin Wu. (Taiwan)
- 63 A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System [744]**
Keith Altman, Renata Budny. (United States)
- 64 Socio-Economic Status and Hip Fracture Risk: A Region-Wide Ecological Study [745]**
Carlen Reyes, Maria Garcia-Gil, Josep M Elorza-Ricart, Rafael Ramos, Cyrus Cooper, Daniel Prieto-Alhambra. (United Kingdom)
- 65 Socio-Economic Status and the Risk of Developing Osteoarthritis: A Region-Wide Ecological Study [746]**
Carlen Reyes, Maria Garcia-Gil, Josep M Elorza-Ricart, Bonaventura Bolibar, Rafael Ramos, Daniel Prieto-Alhambra. (United Kingdom)
- 66 Acute Mortality among Psychiatric Patients with Acute Agitation Using a Japanese Hospital Database [747]**
Ko Nakajo, Shuko Nojiri, Meghan E Jones, Keiji Kido, Masanori Taketsuna, Rei Maeda. (Japan)
- 67 Under-Recording of Endometriosis in the Health Improvement Network (THIN) Primary Care Database: A Validation Study [748]**
Renate Schulze-Rath, Lucia Cea Soriano, Esther Lopez-Garcia, Montse Soriano-Gabarró, Luis A Garcia Rodriguez. (Germany)
- 68 Performance of an Algorithm for Identifying Primary Hypocalcemia in Commercial Health Plan Claims Data [749]**
Florence T Wang, Fei Xue, Eva Ng, Cathy W Critchlow, David D Dore. (United States)
- 69 Predicting the Need for Prolonged Mechanical Ventilation Following the First Hospital Admission Due to Chronic Obstructive Pulmonary Disease with Acute Exacerbation [750]**
Kuang-Ming Liao, Wei-Chieh Lin, Chung-Yi Li, Yea-Huei Kao Yang. (Taiwan)
- 70 Performance of an Algorithm for Identifying Serious Dermatologic Adverse Events in Commercial Health Plan Claims Data [751]**
Florence T Wang, Fei Xue, Eva Ng, Cathy W Critchlow, David D Dore. (United States)
- 71 A Normalization Method for Clinical Laboratory Test Results between Distributed Electronic Healthcare Databases [752]**
Dukyong Yoon, Man Young Park, Eun Kyoung Ahn, Martijn J Schuemie, Rae Woong Park, on Behalf of the Surveillance of Health Care in Asian Network (SCAN) project. (Republic of Korea)
- 72 The Predictive Values in Validation Studies: Misleading Statistics? [753]**
Hairong Xu, Yanli Li, John H Page. (United States)
- 73 A Novel Broadly Applicable Risk Score for Predicting Mortality of Patients with Circulatory System Diseases Within Hospitalization Duration [754]**
Zhi Qu, Jingchen Song, Siyan Zhan, Xiemin Ma. (China)
- 74 Applying STROBE in Renal Journals, Is There Any Difference in the Quality of Reporting Observational Studies? [755]**
Mahmoud E Elrggal, Abdulhaseeb M Hanif. (Saudi Arabia)
- 75 An Evaluation of Sequential Analysis Methods for Active Drug Safety Surveillance Using Observational Data [756]**
Xiaofeng Zhou, Warren Bao, Mike Gaffney, Rongjun Shen, Sara Young, Andrew Bate. (United States)
- 76 Considerations for Using Electronic Medical Record Data for Pharmacoepidemiology [757]**
Scott L DuVall, Corinne H Halls, Olga V Patterson. (United States)
- 77 Impact of Varying Control Moment Selection in a Case-Crossover (CCO) Study on Antidepressant Drug (AD) Use and Hip/Femur Fracture (HFF) in PROTECT [758]**
Mark CH de Groot, Svetlana V Belitser, Patrick C Souverein, Rolf HH Groenwold, Gianmario Candore, Yolanda Alvarez, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Helga Gardarsdottir. (Netherlands)
- 78 Study Designs in Pharmacoepidemiologic Studies on Electronic Healthcare Databases: A Systematic Review [759]**
Nathalie Gault, Stéphanie Foulon, Sylvie Guillo, Florence Tubach. (France)

- 79 **RCT Participants and Real Life Drug Users: A Population-Based Cohort Study [760]**
Daniel Prieto-Alhambra, M Kassim Javaid, Tjeerd Van Staa, Cyrus Cooper, Adolfo Diez-Perez. (Spain)
- 80 **MM Optimization in Massive Observational Analysis [761]**
Trevor R Shaddox, Kenneth L Lange, David Madigan, Marc A Suchard. (United States)
- 81 **Understanding of the Clinical Course of Breast Cancer in Japanese Women Using Health Insurance Claims Database [762]**
Kenji Hamada, Terumi Nakayama. (Japan)
- 82 **Simvastatin and Its Potential Drug Interactions: An Analysis of Safety Signal Based on FDA AERS Database [763]**
Amarsinh M Desai, Teresa M Cavanaugh, Christina ML Kelton, Pamela C Heaton, Jeff J Guo. (United States)
- 83 **Validity of Coding and Descriptive Epidemiology of Rheumatoid Arthritis in Catalonia, Spain: A Population-Based Cohort Study [764]**
Francesc Fina-Aviles, Bonaventura Bolibar, Daniel Prieto-Alhambra. (Spain)
- 84 **Lessons Learned from a Survey for Hospitalized Influenza Using a Japanese Administrative Database [765]**
Tomomi Kimura. (Japan)
- 85 **The Association of Neovascular Age-Related Macular Degeneration with Cardiovascular Diseases: A Study Using the NHIRD in Taiwan [766]**
Wan-ju Lee, Yea-Huei Kao Yang, Ching-lan Cheng, Yi-sheng Willis Chang, Chung-yi Li. (Taiwan)
- 86 **Race-Specific Prevalence and Risk Factors for Cutaneous Psoriasis in a U.S. Population-Based Cohort [767]**
Hoa V Le, Chi TL Truong, Julie Priest, Carlyne Averell, Charlotte Carroll, Martin Crane. (United States)
- 87 **Interactive Web-Based Tool for Cohort Creation and Disease Outcome Feasibility [768]**
Scott L Du Vall, Aaron WC Kamaau, Jonathan R Nebeker. (United States)
- 88 **Comorbidities in Patients with Thyroid Cancer Evaluated Using US Administrative Claims Data [769]**
Ceri Hirst, James Ryan, Ozgur Tunceli, Siting Zhou, Kern David. (United Kingdom)
- 89 **Suspected Adverse Drug Reactions Caused by Herb Ephedrae Case Study [770]**
Ju-Hui Chen, Tsung-Hsiu Wu, Lih-Chi Chen. (Taiwan)
- 90 **A Comparison between Chinese and US Electronic Health Records Database Structures [771]**
Anokhi J Kapasi, Varinder Singh, Sharmila A Kamani, Bao Nguyen-Khoa, Judith K Jones. (United States)
- 91 **Reducing the Manual Burden of Medical Record Review through Informatics [772]**
Scott L Du Vall, Tyler B Forbush, Ryan C Cornia, Thomas Ginter, Brad Adams, Miland N Palmer, Olga V Patterson, Jonathan R Nebeker. (United States)
- 92 **Use of Hydroxyethyl Starch Solutions in Taiwan [773]**
Wei-I Huang, Wei-Ming Ke, Wen-Wen Chen. (Taiwan)
- 93 **Impact of Subgroup Analyses and Adjustment by Stratification on Safety Signal Detection for Individual Case Reports [774]**
Suzie Seabroke, Kristina Juhlin, Gianmario Candore, Antoni Wisniewski, Naashika Quarcoo, Jeffery L Painter, Daniel Soeria-Atmadja, Phil Tregunno, G Niklas Norén, Jim Slattery. (Sweden)
- 94 **Structured Assessment for Prospective Identification of Potential Safety Signals in Electronic Health Records [775]**
Susanna Cederholm, Alex Asiimwe, Andrew Bate, Fatima Bhayat, Gunnar Brobert, Geraldine Hill, Kristina Star, G Niklas Norén. (Sweden)
- Spotlight Session- Database SIG**
- 95 **Evaluating Survival Outcome for Chemotherapy in Advanced Lung Cancer Patients [776]**
PeiYi Lin, MeiFan Lin. (Taiwan)
- 97 **Incidence of Intussusception in Early Childhood in the Netherlands as a Baseline to the Introduction of New Rotavirus Vaccines [778]**
Kartini Gadroen, Silvia Pérez-Vilar, Daniel Weibel, Sabine Straus, Jeanet Kemmeren, Noline van der Maas, Hester de Melker, Miriam Sturkenboom. (Netherlands)
- 98 **Identification of Drug-Induced Liver Injury in Medical Information Databases Using the Japanese Diagnostic Scale [779]**
Tadaaki Hanatani, Kimie Sai, Masahiro Tohkin, Katsunori Segawa, Michio Kimura, Katsuhito Hori, Junichi Kawakami, Yoshiro Saito. (Japan)
- 99 **Validation of Diagnostic Algorithms to Identify AIDS Status, Hepatitis C Infection, Alcohol Abuse and Illicit Drug Use in HIV Positive Individuals in the Database of the Regie de l'Assurance-Maladie du Quebec [780]**
Madeleine Durand, Yishu Wang, François Venne, Jason R Guertin, Cécile L Tremblay, Michal Abrahamovicz. (Canada)
- 100 **Signal Detection for Potential Drug-Drug Interactions Using Inpatient Electronic Health Records with Laboratory Data [781]**
Rae Woong Park, Man Young Park, Dukyong Yoon, Eun Kyoung Ahn, Martijn Schuemie, Sean Hennessy. (United States)
- 101 **Flumazenil as Trigger Tool for Measuring Adverse Drug Events [782]**
Sock Ping Ng, Hsiu Ling Wu, Alan Ronaldmp Talbot, Su Yu Chien. (Taiwan)
- 102 **Clinical Burden of ANCA Associated Vasculitis [783]**
Scott L Du Vall, Stephen Agbor, Andrew Wilson, Aaron WC Kamaau, Thomas Ginter, Tyler Forbush, Tmirah Haselkorn, Pavel Napalkov, Iain D Tatt, Curry K Koening. (United States)
- Measurements/Validation Studies**
- 103 **Is Information on Medication Use and Occurrence of Drug Related Problems Obtained by Means of a Patient Questionnaire Useful When Conducting Clinical Medication Reviews in Older Patients? [784]**
Floor Willeboordse, Lucienne Grundeken, Lisanne van den Eyckel, Petra JM Elders, Francois G Schellevis, Jacqueline G Hugtensburg. (Netherlands)
- 104 **Performance of Claims-Based Algorithms for Identifying Thyroid Cancer in Commercial Health Plan Enrollees Receiving Antidiabetic Therapies [785]**
Donnie P Funch, Douglas S Ross, Betsey M Gardstein, Heather S Norman, Lauren A Sanders, Atheline Major-Pedersen, Sofia II Kring, David D Dore. (United States)
- 105 **Predictive Analysis for Identifying Post Stroke Spasticity Patients in UK Primary Care Data [786]**
Jerome Dinet, Andrew P Cox, Mireia Raluy, Sylvie Gabriel, Meng Wang, Abdel Magid O Bakheit, A Peter Moore. (United Kingdom)
- 106 **The Feasibility of Using Administrative Claims Data to Study Pure Red Cell Aplasia (PRCA) in a Cohort of Chronic Hepatitis C (CHC) Patients [787]**
Vinay Mehta, Scott Quinlan, Shirin Ahmed, Jennifer Hawes, Chris Mast, Dan Mines, Nancy Santanello. (United States)

- 107 Validation of Diagnosis of Age-Related Macular Degeneration in a Computer Database of Primary Care [788]**
Zdravko P Vassilev, Luis A García Rodríguez, Montse Soriano-Gabarró, Ana Ruigómez. (United States)
- 108 Validation of Health Insurance Claims in Identification of Sudden Cardiac Death or Hospitalized Myocardial Infarction (MI) Death through US National Death Index (NDI) Search [789]**
Caihua Liang, C Robin Clifford, Alexander M Walker. (United States)
- 109 A Comparison of Disproportionality Analysis Methods in National Adverse Drug Reaction Databases of China [790]**
Jia He, Yongfang Hou, Xiaofei Ye, Guizhi Wu, Gang Cheng, Xiaoxi Du. (China)
- 110 Signal Detection from Spontaneous Reporting System: An Evaluation of Disproportionality Analysis in China [791]**
Jia He, Yongfang Hou, Xiaofei Ye, Guizhi Wu, Gang Cheng, Xiaoxi Du. (China)
- 111 Feasibility of Alternative Methods for Health Outcomes of Interest Algorithm Validation [792]**
Wan-Ju Lee, Todd A Lee, Simon Pickard, Azadeh Shoaibi, Glen T Schumock. (United States)
- 112 Validation of Clinical Diagnoses, Medication Use, and Health System Utilization in Taiwan's National Health Insurance Research Database [793]**
Chi-Shin Wu, Mei-Shu Lai, Susan Shur-Fen Gau, Sheng-Chang Wang, Hui-Ju Tsai. (Taiwan)
- 113 What Can Affect the Agreement between Patient and General Practitioner Data on Medicine Use? [794]**
Hélène Peyrouzet, Sylvie Blazejewski, Julien Bezin, Jean-Louis Montastruc, Marie-Laure Laroche, Nicholas Moore. (France)
- 114 Agreement between Patient and General Practitioner Data on Medicine Use [795]**
Hélène Peyrouzet, Sylvie Blazejewski, Julien Bezin, Jean-Louis Montastruc, Marie-Laure Laroche, Nicholas Moore. (France)
- 115 Beyond Crude Cohort Designs: Large-Scale Adjustment Approaches for Pharmacoepidemiology [796]**
Marc Suchard, Martijn Schuemie, Patrick Ryan. (United States)
- 116 Refill Variables in Administrative Claims Data – Potential Implications for Defining New Medication User Cohorts [797]**
Jane S Der, M Alan Brookhart, Fei Xue. (United States)
- 117 How to Combine Evidence in a Database Network [798]**
Martijn J Schuemie, Rave Harpaz, Patrick B Ryan, William DuMouchel, David Madigan, Marc A Suchard. (United States)
- 118 Measuring Frailty Using Claims Data for Pharmacoepidemiologic Studies of Mortality in Older Adults: Evidence and Recommendations [799]**
Dae Hyun Kim, Sebastian Schneeweiss. (United States)
- 119 A Critical Review of Pharmacoepidemiological Observational Post-Authorisation Safety Study (PASS) Design Used in the European Union and Its Applicability in Latin America (LA) [800]**
Pedro A Lima-Filho, David Brown, Deborah Layton. (United Kingdom)
- 120 Bayesian Computation on Graphics Processing Units Expands the Reach and Practicability of Bayesian Methods in Pharmacoepidemiology [801]**
David C Norris. (United States)
- 121 Feasibility of Adjusted Parametric Methods to Model Survival Data as a Tool for Signal Strengthening: An Example in Modified Prescription-Event Monitoring (M-PEM) [802]**
Deborah Layton, Alan C Kimber. (United Kingdom)
- 122 Calibration of Statistics from Observational Studies Using Control Drug-Outcome Pairs: Incorporating Uncertainty about Controls [803]**
Martijn J Schuemie, Sander Greenland, Patrick B Ryan, Marc A Suchard, William DuMouchel, David Madigan. (United States)
- 123 Use of a Bayesian Approach to Design and Evaluation of NCE2 [804]**
Lien-Cheng Chang, Ming-Kung Yeh, Min-Shung Lin, Chin-Fu Hsiao. (Taiwan)
- 124 Reporting of Confounding Bias in Observational Intervention Studies: Are We Making Progress? [805]**
Koen B Pouwels, Eelko Hak. (Netherlands)
- 125 Withdrawn By Author**
- 126 Validation of Indonesian Version of Short Formulary-36 Questionnaire in Hypertension Patients [807]**
Yuli Rahmawati, Dyah A Perwitasari. (Indonesia)
- 127 Association between Hospitalizations Due to Cardiovascular and/or Neurologic Diseases and Exposure of High Alert Chinese Medications: Nested Case-Control Study [808]**
Hsiang-Wen Lin, Hsin-Hui Tsai, Chu-Ling Tsai, Yow-Wen Hsieh, Sheng-Shing Lin, Wen-Ling Lin, Shyh-Shyan Jan, Ching-Yeh Tu, Kun-Lung Chang. (Taiwan)
- 128 Assessment of Affect of Geriatric Conditions on Activities of Daily Living in the Elderly [809]**
Krishna Undela, Ancy Varghese, Parthasarathi Gurumurthy, Narahari Mg. (India)
- 129 The Risk of Geriatric Conditions in Patient with Diabetes Mellitus and Hypertension [810]**
Parthasarathi Gurumurthy, Ancy Varghese, Krishna Undela, Narahari Mg, Krishna Undela. (India)
- 130 The Effectiveness and Safety of Febuxostat for Chronic Kidney Disease Patients with Gout and Hyperuricemia [811]**
Chien-Huei Huang, Ming-Cheng Wang, Chi-Tai Yen, Ching-Lan Cheng, Pheng-Ying Yeh Liu, Hui-Jen Chang. (Taiwan)
- 131 Non-Prescription Medicine Purchasing Behavior Among Community Pharmacy Patrons in Malaysia [812]**
Abdul Haniff Bin Mohamad Yahaya, Mohamed Azmi Bin Hassali, Asrul Akmal Bin Shafie. (Malaysia)
- 132 Outcomes of Earlier Use of Inhaled Corticosteroids among Patients Diagnosed with Moderate Chronic Obstructive Pulmonary Diseases [813]**
Shan-Chieh Wu, Wei-Erh Cheng, Hsiang-Wen Lin, Yow-Wen Hsieh. (China)
- 133 Assessment on the Risk of Pneumonia Associated with Inhaled Corticosteroids in COPD Patients in Taiwan [814]**
Ya-Chuan Chang, Tzu-Chieh Lin, Jih-Shuin Jerng, Yea-Huei Kao Yang. (Taiwan)
- 134 The Prescription Analysis of Sedative Hypnotics in Nursing Home of Hospital [815]**
Meei Shure Kuo, Huei Ming Pan, Wen Ching Lin. (China)
- 135 Assessment of Diabetic Care Pay-for-Performance Program [816]**
Mei-Chieh Chen, Yea-Huei Kao Yang, Shwu-Juan Sheu. (Taiwan)
- 136 Common Data Model Conversion in AsPEN for SCAN Project [817]**
Yinghong Zhang, Edward Chia Cheng Lai, Chantelle Hardy, Li Lin, Paul Stang, Patrick Ryan, Martijn Schuemie, Soko Setoguchi. (United States)

Methods Potpourri

Pharmacoepidemiology in Asia

- 137 **Evaluation of Drug Safety Monitoring System in the Republic of Armenia [818]**
Naira Romanova, Albert Sahakyan. (Armenia)
- 138 **Framework Proposal for Post-Marketing Surveillance (PMS) from Taiwan National ADR Reporting Center [819]**
Pi-Hui Chao, Wen-Wen Chen, Tsui-Min Tsai, Wei-Ming Ke. (Taiwan)

Spotlight Session- Asian Pharmacoepidemiology Network (AsPEN) SIG

- 139 **The Association between Oral Fluoroquinolones and Incident Seizure Event [820]**
Celine SL Chui, Esther W Chan, Ian CK Wong. (Hong Kong)
- 140 **Trastuzumab-Related Cardiotoxicity Among Breast Cancer Patients in Taiwan [821]**
Hsu-Chih Chien, Yea-Huei Kao Yang, Jane PF Bai. (Taiwan)
- 141 **Withdrawn By Author**
- 142 **Comparative Risk of Oral Ulcerations among Antipsychotic Users with Schizophrenia or Bipolar Disorder [823]**
Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Soko Setoguchi, Yea-Huei Kao Yang. (Taiwan)
- 143 **The Utilization of Pharmacovigilance Databases for the Safety of Health Products: A Systematic Review [824]**
Nathorn Chaiyakunapruk, Surasak Saokaew, Unchalee Permsuwan, Piyameth Dilokthornsakul, Mingkwan Na Takuathung, Gary Oderda, Wimon Suwanakesawong. (Malaysia)
- 144 **Adverse Drug Reactions Leading to Hospital Admissions: A Prospective Study [825]**
Anand Kunchanur, Gurumurthy Parthasarathi. (India)
- 145 **Baseline Characteristics of COPD Clinical Trial Subjects: An Inter-Ethnic Comparison [826]**
Christine S Clifton, Sophie L Stocker, Jaeyeon Shin, Annette S Gross. (Australia)
- 146 **Pharmacoepidemiology Studies in China: Are There Gaps in Databases, Training Programs or Both? [827]**
Hu Li, Natasha Stohlman, Lei Chen, Ken Hornbuckle. (United States)

Cardiovascular Outcome

- 147 **Psoriasis and the Risk of Myocardial Infarction: A Population-Based Cohort Study Using the Clinical Practice Research Datalink [828]**
Rosa Parisi, Martin K Rutter, Mark Lunt, Helen S Young, Deborah PM Symmons, Christopher EM Griffiths, Darren M Ashcroft. (United Kingdom)
- 148 **Psoriasis and the Risk of Stroke: A Population-Based Cohort Study Using the Clinical Practice Research Datalink (CPRD) [829]**
Rosa Parisi, Martin K Rutter, Mark Lunt, Helen S Young, Deborah PM Symmons, Christopher EM Griffiths, Darren M Ashcroft. (United Kingdom)
- 149 **Spontaneous Reports of Thromboembolic Events Associated with Cyproterone/Ethinylestradiol after Media Attention [830]**
Florence van Hunsel, Eugene van Puijenbroek, Agnes Kant. (Netherlands)
- 150 **Bisphosphonate and Adverse Cardiovascular Events: Meta-Analysis of Randomized Placebo-Controlled Trials [831]**
Dae Hyun Kim, James R Rogers, Lisa A Fulchino, Daniel H Solomon, Seoyoung C Kim. (United States)
- 151 **Potential Signals for Cardiovascular-Related Adverse Events with COX Inhibitor Use: Analysis of the WHO Global ICSR Database System (VigiBase) [832]**
David Prieto-Merino, Joseph Kim, Stephen JW Evans. (United Kingdom)
- 152 **Temporal Changes in the Prescribing Propensity Following Safety Warnings [833]**
Elizabeth M Garry, John B Buse, Virginia Pate, Til Sturmer. (United States)
- 153 **A Comparison of Cardiac Event Rates in Patients with or Without Multiple Myeloma in the US [834]**
Kristin D Kistler, Brian Murphy, Jill Kalman, Gagan Sahni, Winifred Werther, Kanya Rajangam, Ajai Chari. (United States)
- 155 **Comparative Safety of NSAIDs on Myocardial Infarction According to the COX-2 Selectivity [836]**
Sun-Young Jung, Eunmi Choi, Hyun-Joo Jung, Byung-Joo Park. (Republic of Korea)
- 156 **Risk of Aortic Aneurysm or Aortic Dissection Associated with Fluoroquinolone Therapy [837]**
Chien-Chang Lee, Yueh-Sheng Chen, Shih-Hao Lee, Meng-tse Gabriel Lee, Yi-Hsian Lin, Tse-Chih Chou. (Taiwan)
- 157 **Ranibizumab Associated with Increased Risk of Ischaemic Stroke but Not Myocardial Infarct: A Self-Controlled Case Series Analysis [838]**
Nicole Pratt, Emmae Ramsay, Anna Kemp, Lisa Kalisch Ellett, Sepehr Shakib, Gillian Caughey, Philip Ryan, Stephen Graves, Elizabeth Roughton. (Australia)
- 158 **Methods and Guidelines for Integrity of Multivariable Analysis of Real World (observational) Data [839]**
Drew G Levy, David C Norris, Aaron WC Kamau, Andrew Wilson. (United States)
- 159 **Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: REGARDS Study Linked with Medicare Claims [840]**
Hiraku Kumamaru, Suzanne E Judd, Jeffrey R Curtis, Rekha Ramachandran, N Chantelle Hardy, J David Rhodes, Monika M Safford, Brett M Kissela, George Howard, Jessica J Jalbert, Thomas G Brott, Soko Setoguchi. (United States)
- 160 **Performance of ICD-10 Codes in a Computerized Hospital Database for Identification of Acute Coronary Syndrome [841]**
Julien Bezin, Paul Ferreira, Maëlys Touya, Véronique Gilleron, Sahondra Rambelomanana, Pierre-Olivier Girodet, Nicholas Moore, Antoine Pariente. (France)
- 161 **Prevalence of Cardiovascular Risk Factors and Estimated 10 Year Cardiovascular Risk for Patients in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [842]**
Claudine G Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 162 **Cardiovascular Risk Management of Patients in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [843]**
Claudine G Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 163 **Incidence of Heart Failure: A Population-Based Study in General Practice Setting [844]**
Ana Ruigomez, Luis A Garcia Rodriguez, Alexander Michel. (Germany)

- 164 Risk of Death in a Cohort of Newly Diagnosed Heart Failure Patients [845]**
Ana Ruigomez, Luis A Garcia Rodriguez, Alexander Michel. (Germany)
- 165 Cardiac Dysfunction among Soft Tissue Sarcoma Patients in Denmark [846]**
Sumitra Shantakumar, Morten Olsen, Mette Norgaard, Lars Pedersen. (Singapore)
- 166 Risk of QT Prolongation Induced by Atypical Antipsychotics: A Case-Control Study [847]**
Nam-Kyong Choi, Joongyub Lee, Bo Ram Yang, Ye-Jee Kim, Mi-Sook Kim, Xue-Mei Jin, Jungmee Kim, Rae Woong Park, Jin-Ho Lee, Byung-Joo Park. (Korea)
- 167 Cardiac Adverse Events Associated with Macrolide and Fluoroquinolone Antibiotics [848]**
Yizhou Ye, Aisling R Caffrey. (United States)
- 168 Pulse Pressure and Stroke Risk: Development and Validation of a New Stroke Risk Model [849]**
Francis Vekeman, Rajeev Ayyagari, Patrick Lefebvre, Siew Hwa Ong, Elizabeth Faust, Alex Trahey, Gerardo Machnicki, Mei Sheng Duh. (Canada)

Cardiovascular Therapeutics

- 169 Impact of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy on Recurrent Myocardial Infarction: A Population-Based Case Cross-Over Study [850]**
Ye-Jee Kim, Nam-Kyong Choi, Jong-Mi Seong, Joongyub Lee, Mi-Sook Kim, Ju-Young Shin, Sun-Young Jung, Hong-Ji Song, Byung-Joo Park. (Republic of Korea)
- 170 Long-Term Evaluation of the Effectiveness of Warfarin Interactions Prescription Warning System in a Medical Center [851]**
Pili Chih-Min Mao, Mei-Ing Chung, Eric Kin-Lap Lee, Pi-Lai Tseng. (Taiwan)
- 171 Use of Warfarin and Risk of Stroke and Mortality in Chronic Dialysis Patients with Atrial Fibrillation in Taiwan [852]**
Chiu-Ying Chen, Tzu-Chieh Lin, Yea-Huei Kao Yang. (Taiwan)
- 172 Risk of Peripheral Neuropathy for Dronedronone Compared to Other Antiarrhythmics [853]**
Chuntao Wu, Stephanie Tcherny-Lessenot, Wanju Dai, Yunxun Wang, Hayet Kechemir, Laurent Auclert, Jasmanda Wu, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 173 Risk of New-Onset Diabetes in Users of Lipid Lowering Drugs (LLDs) [854]**
Nobuhiro Ooba, Soko Setoguchi, Tsugumichi Sato, Kiyoshi Kubota. (Japan)

- 174 Development of a Collaborative European Post-Authorization Safety Study (PASS) Program Examining Rivaroxaban Use in Routine Clinical Practice [855]**
Luis Garcia Rodriguez, Edeltraut Garbe, Irene Bezemer, Deborah Layton, Kiliana Suzart-Woischnik, Gunnar Brobert, Jesse Alderson, Christopher Winchester, Ron Herings, Kathrin Jobski, Tania Schink, Saad Shakir, Montse Soriano-Gabarró, Mari-Ann Wallander. (Germany)
- 175 Comparative Safety of New Oral Anticoagulants in Nonvalvular Atrial Fibrillation – A Single Medical Center Experience [856]**
Ying-Hsuan Lai, Chien-Huei Huang, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 176 Minor Bleedings and Associated Risk Factors Within Patients Initiating Warfarin Therapy: Population-Based Study [857]**
Stéphanie Dumas, Payman Shahabi, Étienne Rouleau-Mailloux, Jean-Claude Tardif, Sylvie Perreault, Marie-Pierre Dubé. (Canada)
- 177 Clinical Outcomes of Pharmacists Providing Medication Education to Inpatients New on Warfarin Therapy [858]**
Yu-Chun Hwang, Chuei-Fen Yee, Kuei-Ju Cheng, YF Lee, YT Tsai, KL Chu, Cy Chen. (Taiwan)
- 178 Comparing Individual Angiotensin-Converting Enzyme Inhibitors with Angiotensin Receptor Blockers on the Risk of Pneumonia: A Nationwide Cohort Study [859]**
Sheng-Yuan Ruan, Chia-Hsuei Chang, Yen-Chieh Lee, Li-Chiu Wu, Mei-Shu Lai. (Taiwan)
- 179 Does Use of Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Decrease the Risk of Incident Active Tuberculosis Disease? A Nested Case-Control Study on a National Health Claim Database [860]**
Meng-tse Gabriel Lee, Shih-Hao Lee, Yi-Hsian Lin, Chien-Chang Lee. (Taiwan)
- 180 Does Use of Calcium Channel Blockers Affect the Risk of Incident Active Tuberculosis Disease? A Nested Case Control Study on a National Health Claim Database [861]**
Meng-tse Gabriel Lee, Yi-Hsian Lin, Shih-Hao Lee, Chien-Chang Lee. (Taiwan)
- 181 Is Statin Use Associated with Reduced Risk of Incident Active Tuberculosis? A Population-Based Nested Case-Control Study [862]**
Chien-Chang Lee, Shih-Hao Lee, Yi-Hsian Lin, Meng-tse Gabriel Lee. (United States)

- 182 Impact of Diuretic Use on Serum Urate Level in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [863]**
Robert W Flynn, Claudine G Jennings, Isla S Mackenzie, George Nuki, Ian Ford, Thomas M MacDonald. (United Kingdom)
- 183 Is There Less Interaction with Atorvastatin and Rosuvastatin? [864]**
Baptiste Demailly, Malak Abou Taam, Marie-Laure Duchenois, François Krabansky, Marie-Paule Roux, Thierry Trenque. (France)

Biologics

- 184 Early Intervention of Skin Toxicities by Panitumumab and Clinical Outcomes in the Clinical Setting [865]**
Hagit Bergman, Tara Walton, Ryan Del Bel, Jack Seki, Wei Xu, Gideon Koren, Neil Shear, Monika Krzyzanowska, Doris Howell, Geoffrey Liu. (Canada)
- 185 Do Pharmaceutical Claims Accurately Reflect Oncology Prescribing Practice: Evidence from an Australian HER2+ Early Breast Cancer Cohort (HER2EBC) [866]**
Carole Harris, Benjamin Daniels, Robyn Ward, Sallie-Anne Pearson. (Australia)
- 186 Analysis of Human Recombinant Somatotropins, Erythropoietins and Granulocyte Colony Stimulating Factors in Pharmaceutical Formulations [867]**
Jia-Chuan Hsu, Bo-Yin Lai, Der-Yuan Wang, Daniel Yang-Chih Shih. (Taiwan)
- 187 Hepatotoxicity with Pazopanib for Renal Cell Carcinoma in the Post-Approval Setting [868]**
Sumitra Shantakumar, Beth Nordstrom, Luc Djousse, Susan A Hall, Myrthe van-Herk Sukel, Kathy Fraeman, David R Gagnon, Karen Chagin, Jeanne J Nelson. (Singapore)

Spotlight Session-Biologics SIG

- 188 A Systematic Review of Progressive Multifocal Leukoencephalopathy Case Reports Associated with Monoclonal Antibody Treatment [869]**
Alicia Brunssen, Niklas Schmedt, Edeltraut Garbe. (Germany)
- 189 Adverse Reactions Associated To Biologics for Psoriasis in Brazil [870]**
Luciane Cruz Lopes, Miriam Sanches Silveira, Claudia Garcia Serpa Osorio-De-Castro, Tatiana Chama Borges, Gordon Henry Guyatt. (Brazil)

- 190 HER2 Positive Early Breast Cancer (HER2EBC): An Australian Patterns of Care Study [871]**
Carole Harris, Sallie-Anne Pearson, Ben Daniels, Robyn Ward. (Australia)
- 191 Bypassing Agents and Risk of Thromboembolic Events in Patients with Hemophilia and Inhibitors [872]**
Katsiaryna Bykov, Rhonda L Bohn, Bruce M Ewenstein, Jerry Avorn, John D Seeger. (United States)
- 192 Factors Associated with Denosumab Initiation among Postmenopausal Osteoporosis Patients in Medicare [873]**
Huifeng Yun, Rui Chen, Nicole C Wright, Robert Matthews, Torun Arora, Ashley N Milford, Fei Xue, Elizabeth Delzell, Jeffrey R Curtis. (United States)
- 193 Safety Profile of Ophthalmic Biologics: Review of Safety Data [874]**
Ana Penedones, Carlos Alves, Francisco Batel Marques. (Portugal)
- 194 Characteristics of Rheumatoid Arthritis Patients Initiating Abatacept Therapy [875]**
Veena Thyagarajan, Teresa A Simon, Nan Liu, Nancy D Lin. (United States)
- 195 Utilization Pattern of Tumor Necrosis Factor alpha Inhibitors among Patients with Rheumatologic Arthritis in Korea [876]**
Joongyub Lee, Nam-Kyong Choi, Bo Ram Yang, Xue-Mei Jin, Byung-Joo Park. (Korea)

Potpourri

- 196 Drug Safety Evaluation of Linezolid Injection Inducing Thrombocytopenia [877]**
Mei-Ying Lu, Chih-I Lee, Yao-Jen Yang, Li-Hsiang Liao. (Taiwan)
- 197 Challenges of a Post-Authorisation Safety Study (PASS) in an Orphan Oncology Indication [878]**
Jane B Porter, Matthew Desmond, Marie O'Donnell, Patrick McNamara, Manfred Lehnert, Bingxia Wang, Hnin Hnin Ko. (United States)
- 198 Assessment of Patient Characteristics of Selective Serotonin Reuptake Inhibitor (SSRI) Plus Add-On Treatment Users in a United States Claims Database [879]**
Meghan E Jones, Elsie Grace, Dale Marmaduke, James Martinez, Mark Bangs. (United States)
- 199 Types of Adverse Reactions of Non-Steroidal Anti-Inflammatory Drugs. Multiclassification Approach [880]**
Oleksandr V Matvieiev, Oleksandr Y Ezeritskiy. (Ukraine)

- 200 Effectiveness of Multidisciplinary Care for Chronic Kidney Disease Stage I to IV: An Experience of CCPC-CKD Program [881]**
Yi-Shan Wang, Yuan-Ting Yang, Ping-Fang Chiu, Sock-Ping Ng, Su-Yu Chien. (Taiwan)
- 201 Pharmacist Role in Diabetes Clinical Care Program Certification (CCPC-DM) [882]**
Shui-Mu Lin, Li-Hsuan Kuo, Yi-Shan Wang, Sock-Ping Ng, Su-Yu Chien. (Taiwan)
- 202 Characterization of Patients with Type 1 and Type 2 Diabetes and Availability of Clinical Measures Within the Humedica Research Database [883]**
Anthony P Nunes, Donnie P Funch, Yan Ding, Robin C Clifford, Jing Yang, Michael C Doherty, Jeanne Loughlin. (United States)
- 203 The Impact of Clinical Pharmacist on the Medicine Expenditure in the Surgical Intensive Care Unit [884]**
Pei-Tzu Lin, Ching-Ling Tai. (Taiwan)
- 204 Cost-Effectiveness Analysis between Rocephin® and Ceftriaxone® in Hospitalized Patient with Community-Acquired Pneumonia [885]**
Min-Hsin Chao, Shun-Jin Lin. (Taiwan)
- 205 Teaching Pharmacoepidemiology in the GCC Countries: Survey of Pharmacy Schools [886]**
Hisham Aljadhey, Mohamed Izham Ibrahim, Nouf Almeshal, Yasser Albogami. (Saudi Arabia)
- 206 Experience of Joint Post-Authorization Safety Studies (PASS) through an Example [887]**
Marie-Laure Kurzinger, Juhaeri Juhaeri, Cristina Chang, Laurent Auclert. (France)
- 207 Safety Practices of Compounded Sterile Parenteral Preparations: An International Cross-Sectional Study [888]**
Hisham Aljadhey, Nouf Al-Fadel, Rabih Dabliz, Osama Tabbara, Mansour A Mahmoud. (Saudi Arabia)
- 208 An Assessment of the Current Medication Safety Practices in the Primary Care Settings in Riyadh, Saudi Arabia [889]**
Hisham Aljadhey, Rawan Alenizi, Mansour A Mahmoud, Mohamed Azmi Hassali. (Saudi Arabia)
- 209 Compounding Training in Singapore: Are Final Year Pharmacy Students Ready in Ensuring Quality and Safety of Compounded Medications? [890]**
Yuen-Teng Choo, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

- 210 We've Got Your Clinical Data – What's in It for Clinicians? [891]**
Nancy Huang, Isla Hains, Jane London, Clare Delaney, Margaret Williamson, Malcolm B Gillies, Catherine Marshall. (Australia)
- 211 Analysis of Barriers to Patient Recruitment: A Poster Advertising Campaign for Two Online-Only Clinical Studies [892]**
David A Rorie, Rob Flynn, Lewis McConnachie, Tom M MacDonald, Isla Mackenzie, Claudine Jennings. (United Kingdom)

Devices

- 212 A Novel Approach to Pharmacogenomic and Pharmacoepidemiologic Evidence Synthesis for Predictive Analysis and Regulatory Decision-Making on Medical Device Performance [893]**
Yelizaveta Torosyan, Danica Marinac-Dabic. (United States)
- 213 Impact, in Real Life Conditions, of the Use of a Purifier Spray on Allergy Care in Dust Mite Allergic Subjects [894]**
Charles Taieb, Christophe Ripoll. (France)
- 214 Comparative Safety of Endovascular and Open Surgical Repair of Abdominal Aortic Aneurysms in Low-Risk Patients [895]**
Jeffrey J Siracuse, Darren B Schneider, Peter H Connolly, Art Sedrakyan, Andrew J Meltzer. (United States)
- 215 Cardiac Resynchronization Devices with and Without Defibrillation: A Quantitative Systematic Review and Assessment of National Use [896]**
Art Sedrakyan, Jennifer E Moon, Lauren Kuntz, Sharon-Lise T Normand, Abby J Isaacs, Bethany Roell, Denica Marinac-Dabic. (United States)
- 216 Comparative Safety and Effectiveness of Robotic-Assisted Mitral Valve Repair [897]**
Subroto Paul, Abby J Isaacs, Jessica J Jalbert, Art Sedrakyan. (United States)
- 217 The Selection of Prosthetic Aortic Valves for Elderly Medicare Patients from 2006 to 2011 – A Population Based Cross-Sectional Study [898]**
Dongyi(Tony) Du, Stephen McKean, Jeffrey Kelman, John Laschinger, Chris Johnson, Rob Warnock, Chris Worrall, Thomas E MaCurdy, Hector Izurieta. (United States)
- 218 Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries [899]**
Bilal Chughtai, Abby J Isaacs, Art Sedrakyan. (United States)

- 219 **Trend, Utilization, and Outcomes of Male Incontinence Devices [900]**
Bilal Chughtai, Abby J Isaacs, Jialin Mao, Art Sedrakyan. (United States)
- 220 **Comparative Effectiveness of Robotic Device Assisted vs. Thoracoscopic Lobectomy [901]**
Subroto Paul, Abby J Isaacs, Jessica Jalbert, Art Sedrakyan. (United States)
- 221 **Taiwan Post-Market Surveillance of Medical Devices in Recent 5 Years [902]**
Ya-Hui Cheng, Ming-Chan Sung, Pei-Weng Tu, Ming-Kung Yeh, Tsui-Min Tsai, Yi-You Huang. (Taiwan)

Spotlight Session- Device SIG

- 222 **Anti-Coagulation After Hip or Knee Joint Replacement: Assessment of the Benefits and Risks in an Elderly Cohort [903]**
Nicole Pratt, Stephen Graves, Kara Cashman, Gillian Caughey, Elizabeth Roughton. (Australia)
- 223 **12-Year Implantation and Survival Rates of Patients with Implantable Cardioverter-Defibrillator in Routine Clinical Practice Compared with the Background Population, and the Prognostic Impact of Age, Sex, and Comorbidity: A Danish Nationwide Population-Ba [904]**
Morten Schmidt, Susanne B Pedersen, Dorá K Farkas, Søren P Hjortshøj, Hans E Bøtker, Jens C Nielsen, Henrik T Sørensen. (Denmark)
- 224 **Comparative Effectiveness of Peripheral Vascular Stents and Surgical Bypass for Critical Limb Ischemia in the Vascular Study Group of Greater New York [905]**
Andrew J Meltzer, Abby J Isaacs, Art Sedrakyan. (United States)
- 225 **How Do Routine Care Carotid Artery Stenting Patients Fare Compared to Those Enrolled in Trials? [906]**
Jessica J Jalbert, Louis L Nguyen, Marie D Gerhard-Herman, Michael R Jaff, John D Seeger, Hiraku Kumamaru, Lauren A Williams, Jun Liu, Chih-Ying Chen, Soko Setoguchi. (United States)
- 226 **Use of Optional ICD-9-CM Articulating Surface Codes for Total Hip Arthroplasty in US Claims Data [907]**
Jonathan Schelfhout, Chao Chen, Abraham Hartzema. (United States)
- 227 **Hospital Volume and Outcomes for Total Hip Arthroplasty [908]**
Chao Chen, Efe Eworuke, Jonathan Schelfhout, Abraham Hartzema. (United States)

- 228 **Evaluation of Implant Stabilization and Mobility in Total Knee Arthroplasty [909]**
Art Sedrakyan, Elixabeth W Paxton, Steven E Graves, Guy Cafri, Abby J Isaacs, Barbara Bordini, Otto Robertsson, Alejandro Allepuz, Ove Furnace, Denica Marinac-Dabic. (United States)
- 229 **Creation and Use of a "Lag Time" Variable for Comparative Effectiveness Research Using Claims Data [910]**
Sarah R Hoffman, Nilsa Loyo-Berrios, Megan Gatski, Manuel Bayona, Veronica Price. (United States)

Late Breaking

- 230 **Identifying Important Sensitivity Analyses Empirically for Pre-Specification in CER Protocols [911]**
Cynthia J Girman, Douglas Faries, Patrick Ryan, Matt Rotelli, Mark Belger, Bruce Binkowitz, Robert O'Neill. (United States)
- 231 **Withdrawn By Author**
- 232 **Risk of Spontaneous Abortion in Young Women Exposed to Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in the United Kingdom: An Observational Cohort Study [913]**
Laurence Baril, Dominique Rosillon, Corinne Willame, Maria-Genalin Angelo, Julia Zima, Judith H van den Bosch, Tjeerd van Staa, Rachel Boggon, Eveline Bunge, Sonia Hernandez-Diaz, Christina Chambers. (Belgium)
- 233 **Withdrawn By Author**
- 234 **Risk of Microscopic Colitis during Use of PPIs, NSAIDs, beta-Blockers and Other Drugs [915]**
Gwen MC Masclee, Preci M Coloma, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)
- 235 **A Descriptive Analysis to Compare the Occurrence of Myocardial Infarction (MI) in Testosterone-Treated and Untreated Hypogonadal Males and PDE5-Inhibitor Users [916]**
Hu Li, Karin Benoit, James Michael, Stephen Motsko.
- 236 **Risk of Sudden Sensorineural Hearing Loss in Adults Using Phosphodiesterase Type 5 Inhibitors [917]**
Wei Liu, Patrick J Antonelli, Philipp Dahm, Tobias Gerhard, Joseph AC Delaney, Richard Segal, Stephen Crystal, Almut G Winterstein. (United States)

- 237 **An Innovative Approach to Benefit-Risk Assessment Addressing Quality and Efficiency with Transformative Technology: Insights and Lessons from a Pilot Initiative [918]**
Mondira Bhattacharya, Tobias Sayre, Jeff Frimpter, Scott Snyder. (United States)
- 238 **Educational Intervention to Improve the Practice of Pharmacovigilance among Traditional Medicine Practitioners [919]**
Ibrahim Oreagba, Iwalewa Ogunleye. (Nigeria)
- 239 **Natural Language Processing of Clinical Notes in Electronic Health Records to Improve Capture of Hypoglycemia [920]**
Anthony P Nunes, Shengsheng Yu, Karen Kurtyka, Cynthia Senerchia, Jeffrey Hill, Kimberly G Brodovicz, Larry Radican, Samuel S Engel, Sean R Calvo, David D Dore. (United States)
- 240 **Incidence Rate of Microscopic Colitis in the Netherlands [921]**
Gwen MC Masclee, Preci M Coloma, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)
- 241 **The Positive Impact of Pharmacist on Appropriateness of Ambulatory Prescriptions in Medical Center [922]**
Wen Chuan Lin, Hwei Chuan Lee, Wen Liang Lin, Shu Hua Tai, Feng Ying Yeh, Hui Hui-Jen Chang.
- 242 **Risk of Diabetes among Patients Exposed to Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer [923]**
Hwei-Ting Tsai, Nancy L Keating, Marianne Ulcickas Yood, Stephen K Van Den Eeden, Reina Haque, Andrea E Cassidy-Bushrow, Matthew R Smith, Arnold L Potosky. (United States)
- 243 **Study of Ursodeoxycholic Acid Influence on Efficacy and Safety of Statin Therapy in Patients with Liver, Gall Bladder and/or Biliary Tract Diseases (the RAKURS Study) [924]**
Sergey Martsevich, Nataly Kutishenko, Lyubov Drozdova, Olga Lerman. (Russian Federation)

END SESSION C

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SATURDAY, OCTOBER 25, 2014				
All About Statins				
1		10:30 am	201BC	Oral
2		10:45 am	201BC	Oral
3		11:00 am	201BC	Oral
4		11:15 am	201BC	Oral
5		11:30 am	201BC	Oral
6		11:45 am	201BC	Oral
Biologics Bouillabaisse				
7		10:30 am	201AF	Oral
8		10:45 am	201AF	Oral
9		11:00 am	201AF	Oral
10		11:15 am	201AF	Oral
11		11:30 am	201AF	Oral
12		11:45 am	201AF	Oral
Continuing the Discussion on Antipsychotic Safety				
13		10:30 am	201DE	Oral
14		10:45 am	201DE	Oral
15		11:00 am	201DE	Oral
16		11:15 am	201DE	Oral
17		11:30 am	201DE	Oral
18		11:45 am	201DE	Oral
Improving Strength and Balance				
19		10:30 am	4 th Floor VIP	Oral
20		10:45 am	4 th Floor VIP	Oral
21		11:00 am	4 th Floor VIP	Oral
22		11:15 am	4 th Floor VIP	Oral
23		11:30 am	4 th Floor VIP	Oral
24		11:45 am	4 th Floor VIP	Oral
The Good, the Bad, and the Ugly of Anti-Infectives				
25		10:30 am	103	Oral
26		10:45 am	103	Oral
27		11:00 am	103	Oral
28		11:15 am	103	Oral
29		11:30 am	103	Oral
30		11:45 am	103	Oral
Women's Health				
31		10:30 am	102	Oral
32		10:45 am	102	Oral
33		11:00 am	102	Oral
34		11:15 am	102	Oral
35		11:30 am	102	Oral
36		11:45 am	102	Oral
Antibiotics and Other Exposures in Pregnancy				
37		1:30 pm	102	Oral
38		1:45 pm	102	Oral
39		2:00 pm	102	Oral
40		2:15 pm	102	Oral
41		2:30 pm	102	Oral
42		2:45 pm	102	Oral
Cancer Care Continuum				
43		1:30 pm	201DE	Oral
44		1:45 pm	201DE	Oral
45		2:00 pm	201DE	Oral

Abstract #	Poster #	Presentation Time	Room	Format
46		2:15 pm	201DE	Oral
47		2:30 pm	201DE	Oral
48		2:45 pm	201DE	Oral
CER and Safety in CV TX/Care				
49		1:30 pm	201BC	Oral
50		1:45 pm	201BC	Oral
51		2:00 pm	201BC	Oral
52		2:15 pm	201BC	Oral
53		2:30 pm	201BC	Oral
54		2:45 pm	201BC	Oral
Pseudorandom Exposures				
55		1:30 pm	4 th Floor VIP	Oral
56		1:45 pm	4 th Floor VIP	Oral
57		2:00 pm	4 th Floor VIP	Oral
58		2:15 pm	4 th Floor VIP	Oral
59		2:30 pm	4 th Floor VIP	Oral
60		2:45 pm	4 th Floor VIP	Oral
Understanding Antidepressant Use and Safety				
61		1:30 pm	103	Oral
62		1:45 pm	103	Oral
63		2:00 pm	103	Oral
64		2:15 pm	103	Oral
65		2:30 pm	103	Oral
66		2:45 pm	103	Oral
Watch Closely				
67		1:30 pm	201AF	Oral
68		1:45 pm	201AF	Oral
69		2:00 pm	201AF	Oral
70		2:15 pm	201AF	Oral
71		2:30 pm	201AF	Oral
72		2:45 pm	201AF	Oral
A Guide to Guidelines. A Symposium Sponsored by the ISPE Public Policy Committee				
73		5:00 - 6:30 pm	201DE	Sympos.
Academic Detailing: Putting Pharmacoepidemiology into Practice				
74		5:00 - 6:30 pm	103	Sympos.
Biospecimens from Asia in Pharmacoepidemiology Research: Opportunities and Challenges in a Global Environment				
75		5:00 - 6:30 pm	4 th Floor VIP	Sympos.
Challenges in Risk Minimization Evaluation: CIOMS Working Group IX Consensus and Recent Field Experience				
76		5:00 - 6:30 pm	102	Sympos.
Gender Differences in Pharmacoepidemiology				
77		5:00 - 6:30 pm	201BC	Sympos.
Impact of Methodological Choices on Findings from Pharmacoepidemiological Studies: Final Results of the IML-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) Project				
78		5:00 - 6:30 pm	Plenary Hall, 3 rd Fl.	Sympos.
The New ISPE Vaccine Special Interest Group (VAXSIG): Helping to Advance the Global Vaccine Agenda				
79		5:00 - 6:30 pm	201AF	Sympos.

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SATURDAY, OCTOBER 25 CONTINUED				
POSTER SESSION A				
Spotlight Session- Top 8 Abstracts				
80	1	8:00 am – 6:00 pm		Poster
81	2	8:00 am – 6:00 pm		Poster
82	3	8:00 am – 6:00 pm		Poster
83	4	8:00 am – 6:00 pm		Poster
84	5	8:00 am – 6:00 pm		Poster
85	6	8:00 am – 6:00 pm		Poster
86	7	8:00 am – 6:00 pm		Poster
87	8	8:00 am – 6:00 pm		Poster
Burden of Disease/Epidemiology of Illness				
88	9	8:00 am – 6:00 pm		Poster
89	10	8:00 am – 6:00 pm		Poster
90	11	8:00 am – 6:00 pm		Poster
91	12	8:00 am – 6:00 pm		Poster
92	13	8:00 am – 6:00 pm		Poster
93	14	8:00 am – 6:00 pm		Poster
94	15	8:00 am – 6:00 pm		Poster
95	16	8:00 am – 6:00 pm		Poster
96	17	8:00 am – 6:00 pm		Poster
97	18	8:00 am – 6:00 pm		Poster
98	19	8:00 am – 6:00 pm		Poster
99	20	8:00 am – 6:00 pm		Poster
100	21	8:00 am – 6:00 pm		Poster
101	22	8:00 am – 6:00 pm		Poster
102	23	8:00 am – 6:00 pm		Poster
103	24	8:00 am – 6:00 pm		Poster
104	25	8:00 am – 6:00 pm		Poster
105	26	8:00 am – 6:00 pm		Poster
106	27	8:00 am – 6:00 pm		Poster
107	28	8:00 am – 6:00 pm		Poster
108	29	8:00 am – 6:00 pm		Poster
Spotlight Session- Drug Utilization/Health Services Research SIG				
109	30	8:00 am – 6:00 pm		Poster
110	31	8:00 am – 6:00 pm		Poster
111	32	8:00 am – 6:00 pm		Poster
112	33	8:00 am – 6:00 pm		Poster
113	34	8:00 am – 6:00 pm		Poster
114	35	8:00 am – 6:00 pm		Poster
115	36	8:00 am – 6:00 pm		Poster
116	37	8:00 am – 6:00 pm		Poster
Drug Utilization/Health Services Research SIG				
117	38	8:00 am – 6:00 pm		Poster
118	39	8:00 am – 6:00 pm		Poster
119	40	8:00 am – 6:00 pm		Poster
120	41	8:00 am – 6:00 pm		Poster
121	42	8:00 am – 6:00 pm		Poster
122	43	8:00 am – 6:00 pm		Poster
123	44	8:00 am – 6:00 pm		Poster
124	45	8:00 am – 6:00 pm		Poster
125	46	8:00 am – 6:00 pm		Poster
126	47	8:00 am – 6:00 pm		Poster
127	48	8:00 am – 6:00 pm		Poster
128	49	8:00 am – 6:00 pm		Poster
129	50	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
130	51	8:00 am – 6:00 pm		Poster
131	52	8:00 am – 6:00 pm		Poster
132	53	8:00 am – 6:00 pm		Poster
133	54	8:00 am – 6:00 pm		Poster
134	55	8:00 am – 6:00 pm		Poster
135	56	8:00 am – 6:00 pm		Poster
136	57	8:00 am – 6:00 pm		Poster
137	58	8:00 am – 6:00 pm		Poster
138	59	8:00 am – 6:00 pm		Poster
139	60	8:00 am – 6:00 pm		Poster
140	61	8:00 am – 6:00 pm		Poster
141	62	8:00 am – 6:00 pm		Poster
142	63	8:00 am – 6:00 pm		Poster
143	64	8:00 am – 6:00 pm		Poster
144	65	8:00 am – 6:00 pm		Abstract Withdrawn by Author
145	66	8:00 am – 6:00 pm		Poster
146	67	8:00 am – 6:00 pm		Poster
147	68	8:00 am – 6:00 pm		Poster
148	69	8:00 am – 6:00 pm		Poster
149	70	8:00 am – 6:00 pm		Poster
150	71	8:00 am – 6:00 pm		Poster
151	72	8:00 am – 6:00 pm		Poster
152	73	8:00 am – 6:00 pm		Poster
153	74	8:00 am – 6:00 pm		Poster
154	75	8:00 am – 6:00 pm		Poster
155	76	8:00 am – 6:00 pm		Poster
156	77	8:00 am – 6:00 pm		Poster
157	78	8:00 am – 6:00 pm		Poster
158	79	8:00 am – 6:00 pm		Poster
159	80	8:00 am – 6:00 pm		Poster
160	81	8:00 am – 6:00 pm		Poster
161	82	8:00 am – 6:00 pm		Poster
162	83	8:00 am – 6:00 pm		Poster
163	84	8:00 am – 6:00 pm		Poster
164	85	8:00 am – 6:00 pm		Poster
165	86	8:00 am – 6:00 pm		Poster
166	87	8:00 am – 6:00 pm		Poster
167	88	8:00 am – 6:00 pm		Poster
168	89	8:00 am – 6:00 pm		Poster
169	90	8:00 am – 6:00 pm		Poster
170	91	8:00 am – 6:00 pm		Poster
171	92	8:00 am – 6:00 pm		Poster
172	93	8:00 am – 6:00 pm		Poster
173	94	8:00 am – 6:00 pm		Poster
174	95	8:00 am – 6:00 pm		Poster
175	96	8:00 am – 6:00 pm		Poster
176	97	8:00 am – 6:00 pm		Poster
177	98	8:00 am – 6:00 pm		Poster
178	99	8:00 am – 6:00 pm		Poster
179	100	8:00 am – 6:00 pm		Poster
180	101	8:00 am – 6:00 pm		Poster
181	102	8:00 am – 6:00 pm		Poster
182	103	8:00 am – 6:00 pm		Poster
183	104	8:00 am – 6:00 pm		Poster
184	105	8:00 am – 6:00 pm		Poster
185	106	8:00 am – 6:00 pm		Poster
186	107	8:00 am – 6:00 pm		Poster

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SATURDAY, OCTOBER 25 CONTINUED				
187	108	8:00 am – 6:00 pm		Poster
188	109	8:00 am – 6:00 pm		Poster
189	110	8:00 am – 6:00 pm		Poster
190	111	8:00 am – 6:00 pm		Poster
191	112	8:00 am – 6:00 pm		Poster
192	113	8:00 am – 6:00 pm		Poster
193	114	8:00 am – 6:00 pm		Poster
194	115	8:00 am – 6:00 pm		Poster
195	116	8:00 am – 6:00 pm		Poster
196	117	8:00 am – 6:00 pm		Poster
197	118	8:00 am – 6:00 pm		Poster
198	119	8:00 am – 6:00 pm		Poster
199	120	8:00 am – 6:00 pm		Poster
200	121	8:00 am – 6:00 pm		Poster
201	122	8:00 am – 6:00 pm		Poster
202	123	8:00 am – 6:00 pm		Poster
203	124	8:00 am – 6:00 pm		Poster
204	125	8:00 am – 6:00 pm		Poster
205	126	8:00 am – 6:00 pm		Poster
206	127	8:00 am – 6:00 pm		Poster
207	128	8:00 am – 6:00 pm		Poster
208	129	8:00 am – 6:00 pm		Poster
209	130	8:00 am – 6:00 pm		Poster
210	131	8:00 am – 6:00 pm		Poster
211	132	8:00 am – 6:00 pm		Poster
212	133	8:00 am – 6:00 pm		Poster
213	134	8:00 am – 6:00 pm		Poster
214	135	8:00 am – 6:00 pm		Poster
215	136	8:00 am – 6:00 pm		Poster
216	137	8:00 am – 6:00 pm		Poster
217	138	8:00 am – 6:00 pm		Poster
218	139	8:00 am – 6:00 pm		Poster
219	140	8:00 am – 6:00 pm		Poster
220	141	8:00 am – 6:00 pm		Poster
221	142	8:00 am – 6:00 pm		Poster
222	143	8:00 am – 6:00 pm		Poster
223	144	8:00 am – 6:00 pm		Poster
224	145	8:00 am – 6:00 pm		Poster
225	146	8:00 am – 6:00 pm		Poster
226	147	8:00 am – 6:00 pm		Poster
227	148	8:00 am – 6:00 pm		Poster
228	149	8:00 am – 6:00 pm		Poster
229	150	8:00 am – 6:00 pm		Poster
230	151	8:00 am – 6:00 pm		Poster
231	152	8:00 am – 6:00 pm		Poster
232	153	8:00 am – 6:00 pm		Poster
233	154	8:00 am – 6:00 pm		Poster
234	155	8:00 am – 6:00 pm		Poster
235	156	8:00 am – 6:00 pm		Poster
236	157	8:00 am – 6:00 pm		Poster
237	158	8:00 am – 6:00 pm		Poster
238	159	8:00 am – 6:00 pm		Poster
239	160	8:00 am – 6:00 pm		Poster
240	161	8:00 am – 6:00 pm		Poster
241	162	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
242	163	8:00 am – 6:00 pm		Poster
243	164	8:00 am – 6:00 pm		Poster
244	165	8:00 am – 6:00 pm		Poster
245	166	8:00 am – 6:00 pm		Poster
246	167	8:00 am – 6:00 pm		Poster
247	168	8:00 am – 6:00 pm		Poster
248	169	8:00 am – 6:00 pm		Poster
249	170	8:00 am – 6:00 pm		Poster
251	172	8:00 am – 6:00 pm		Poster
252	173	8:00 am – 6:00 pm		Poster
253	174	8:00 am – 6:00 pm		Poster
254	175	8:00 am – 6:00 pm		Poster
255	176	8:00 am – 6:00 pm		Poster
256	177	8:00 am – 6:00 pm		Poster
257	178	8:00 am – 6:00 pm		Poster
258	179	8:00 am – 6:00 pm		Poster
259	180	8:00 am – 6:00 pm		Poster
260	181	8:00 am – 6:00 pm		Poster
261	182	8:00 am – 6:00 pm		Poster
262	183	8:00 am – 6:00 pm		Poster
263	184	8:00 am – 6:00 pm		Poster
264	185	8:00 am – 6:00 pm		Poster
265	186	8:00 am – 6:00 pm		Poster
Spotlight Session- Methods				
266	187	8:00 am – 6:00 pm		Poster
267	188	8:00 am – 6:00 pm		Poster
268	189	8:00 am – 6:00 pm		Poster
269	190	8:00 am – 6:00 pm		Poster
270	191	8:00 am – 6:00 pm		Poster
271	192	8:00 am – 6:00 pm		Poster
Analytic Methods				
272	193	8:00 am – 6:00 pm		Poster
273	194	8:00 am – 6:00 pm		Poster
274	195	8:00 am – 6:00 pm		Poster
275	196	8:00 am – 6:00 pm		Poster
276	197	8:00 am – 6:00 pm		Poster
277	198	8:00 am – 6:00 pm		Poster
278	199	8:00 am – 6:00 pm		Poster
279	200	8:00 am – 6:00 pm		Poster
280	201	8:00 am – 6:00 pm		Poster
281	202	8:00 am – 6:00 pm		Poster
Spotlight Session- Pediatrics SIG				
282	203	8:00 am – 6:00 pm		Poster
283	204	8:00 am – 6:00 pm		Poster
284	205	8:00 am – 6:00 pm		Poster
285	206	8:00 am – 6:00 pm		Poster
286	207	8:00 am – 6:00 pm		Poster
287	208	8:00 am – 6:00 pm		Poster
288	209	8:00 am – 6:00 pm		Poster
289	210	8:00 am – 6:00 pm		Poster
Pediatrics				
290	211	8:00 am – 6:00 pm		Poster
291	212	8:00 am – 6:00 pm		Poster
292	213	8:00 am – 6:00 pm		Poster
293	214	8:00 am – 6:00 pm		Poster

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SATURDAY, OCTOBER 25 CONTINUED				
294	215	8:00 am – 6:00 pm		Poster
295	216	8:00 am – 6:00 pm		Poster
296	217	8:00 am – 6:00 pm		Poster
297	218	8:00 am – 6:00 pm		Poster
298	219	8:00 am – 6:00 pm		Poster
299	220	8:00 am – 6:00 pm		Poster
Vaccines				
300	221	8:00 am – 6:00 pm		Poster
301	222	8:00 am – 6:00 pm		Poster
302	223	8:00 am – 6:00 pm		Poster
303	224	8:00 am – 6:00 pm		Poster
304	225	8:00 am – 6:00 pm		Poster
Spotlight Session- Vaccine SIG				
305	226	8:00 am – 6:00 pm		Poster
306	227	8:00 am – 6:00 pm		Poster
307	228	8:00 am – 6:00 pm		Poster
308	229	8:00 am – 6:00 pm		Poster
309	230	8:00 am – 6:00 pm		Poster
310	231	8:00 am – 6:00 pm		Poster
311	232	8:00 am – 6:00 pm		Poster
312	233	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
SUNDAY, OCTOBER 26				
Antidepressants During Pregnancy and Diverse Outcomes				
313		8:00 am	103	Oral
314		8:15 am	103	Oral
315		8:30 am	103	Oral
316		8:45 am	103	Oral
317		9:00 am	103	Oral
584		9:15 am	103	Oral
Diabetes and Cancers: The Double Whammy				
319		8:00 am	201BC	Oral
320		8:15 am	201BC	Oral
321		8:30 am	201BC	Oral
322		8:45 am	201BC	Oral
323		9:00 am	201BC	Oral
324		9:15 am	201BC	Oral
Equity, Elderly & Ecclecticism				
325		8:00 am	201AF	Oral
326		8:15 am	201AF	Oral
327		8:30 am	201AF	Oral
328		8:45 am	201AF	Oral
329		9:00 am	201AF	Oral
330		9:15 am	201AF	Oral
How Thin is Your Blood?				
331		8:00 am	201DE	Oral
332		8:15 am	201DE	Oral
333		8:30 am	201DE	Oral
334		8:45 am	201DE	Oral
335		9:00 am	201DE	Oral
336		9:15 am	201DE	Oral

Abstract #	Poster #	Presentation Time	Room	Format
Sticks and Stones May Break My Bones				
337		8:00 am	102	Oral
338		8:15 am	102	Oral
339		8:30 am	102	Oral
340		8:45 am	102	Oral
341		9:00 am	102	Oral
342		9:15 am	102	Oral
Well Adjusted by Design				
343		8:00 am	4 th Floor VIP	Oral
344		8:15 am	4 th Floor VIP	Oral
345		8:30 am	4 th Floor VIP	Oral
346		8:45 am	4 th Floor VIP	Oral
347		9:00 am	4 th Floor VIP	Oral
348		9:15 am	4 th Floor VIP	Oral
Diverse Topics in Pediatric Populations				
349		10:00 am	103	Oral
350		10:15 am	103	Oral
351		10:30 am	103	Oral
352		10:45 am	103	Oral
353		11:00 am	103	Oral
354		11:15 am	103	Oral
Don't Go Breaking My Heart				
355		10:00 am	201BC	Oral
356		10:15 am	201BC	Oral
357		10:30 am	201BC	Oral
358		10:45 am	201BC	Oral
359		11:00 am	201BC	Oral
360		11:15 am	201BC	Oral
How Sick We Are				
361		10:00 am	102	Oral
362		10:15 am	102	Oral
363		10:30 am	102	Oral
835		10:45 am	102	Oral
365		11:00 am	102	Oral
366		11:15 am	102	Oral
Not All Diabetes Are Alike: Issues of Diagnosis				
367		10:00 am	201DE	Oral
368		10:15 am	201DE	Oral
369		10:30 am	201DE	Oral
370		10:45 am	201DE	Oral
371		11:00 am	201DE	Oral
372		11:15 am	201DE	Oral
PS or What???				
373		10:00 am	4 th Floor VIP	Oral
374		10:15 am	4 th Floor VIP	Oral
375		10:30 am	4 th Floor VIP	Oral
376		10:45 am	4 th Floor VIP	Oral
377		11:00 am	4 th Floor VIP	Oral
378		11:15 am	4 th Floor VIP	Oral
To Use or Not to Use Psychotropic Medications				
379		10:00 am	201AF	Oral
380		10:15 am	201AF	Oral
381		10:30 am	201AF	Oral
250		10:45 am	201AF	Oral

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SUNDAY, OCTOBER 26 CONTINUED				
383		11:00 am	201AF	Oral
384		11:15 am	201AF	Oral
Plenary Session: Edlavitch Award				
385		1:00 - 2:30 pm	Plenary Hall	Plenary
Adherence to Drug Treatment: A Practical Look at Complex Measurement Issues				
386		4:30 - 6:00 pm	201DE	Symposia
Databases in China: Are We Ready Yet?				
387		4:30 - 6:00 pm	201AF	Symposia
Evaluating the Drug Regulatory System: Lessons from the Escher Project				
388		4:30 - 6:00 pm	103	Symposia
Guidelines and Recommendations for Comparative Effectiveness Research (CER) Methods: International Assessment and Exchange				
389		4:30 - 6:00 pm	Plenary Hall	Symposia
Leveraging Electronic Health Data for Medical Device Epidemiology: Approaches to Post-Market Surveillance of Joint Replacement Surgery				
390		4:30 - 6:00 pm	102	Symposia
Primary Data Collection in Pharmacoepidemiology: Design, Practical, and Methodologic Considerations				
391		4:30 - 6:00 pm	201BC	Symposia
Tracking of Adverse Drug Reactions in Social Media: Current Status of Requirements, Best Practices, Methods and Tools				
392		4:30 - 6:00 pm	4 th Floor VIP	Symposia
POSTER SESSION B				
Top 8 Abstracts (Day 2) Spotlight Session				
393	1	8:00 am – 6:00 pm		Poster
394	2	8:00 am – 6:00 pm		Poster
395	3	8:00 am – 6:00 pm		Poster
396	4	8:00 am – 6:00 pm		Poster
397	5	8:00 am – 6:00 pm		Poster
398	6	8:00 am – 6:00 pm		Poster
399	7	8:00 am – 6:00 pm		Poster
400	8	8:00 am – 6:00 pm		Poster
Adherence				
401	9	8:00 am – 6:00 pm		Poster
402	10	8:00 am – 6:00 pm		Poster
403	11	8:00 am – 6:00 pm		Poster
404	12	8:00 am – 6:00 pm		Poster
405	13	8:00 am – 6:00 pm		Poster
406	14	8:00 am – 6:00 pm		Poster
407	15	8:00 am – 6:00 pm		Poster
408	16	8:00 am – 6:00 pm		Poster
409	17	8:00 am – 6:00 pm		Poster
410	18	8:00 am – 6:00 pm		Poster
411	19	8:00 am – 6:00 pm		Poster
412	20	8:00 am – 6:00 pm		Poster
413	21	8:00 am – 6:00 pm		Poster
414	22	8:00 am – 6:00 pm		Poster
415	23	8:00 am – 6:00 pm		Poster
Spotlight Session Adherence SIG				
416	24	8:00 am – 6:00 pm		Poster
417	25	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
418	26	8:00 am – 6:00 pm		Poster
419	27	8:00 am – 6:00 pm		Poster
420	28	8:00 am – 6:00 pm		Poster
421	29	8:00 am – 6:00 pm		Poster
422	30	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
423	31	8:00 am – 6:00 pm		Poster
Benefit Risk Assessment, Communication and Evaluation				
424	32	8:00 am – 6:00 pm		Poster
425	33	8:00 am – 6:00 pm		Poster
426	34	8:00 am – 6:00 pm		Poster
427	35	8:00 am – 6:00 pm		Poster
428	36	8:00 am – 6:00 pm		Poster
429	37	8:00 am – 6:00 pm		Poster
430	38	8:00 am – 6:00 pm		Poster
431	39	8:00 am – 6:00 pm		Poster
432	40	8:00 am – 6:00 pm		Poster
433	41	8:00 am – 6:00 pm		Poster
434	42	8:00 am – 6:00 pm		Poster
435	43	8:00 am – 6:00 pm		Poster
436	44	8:00 am – 6:00 pm		Poster
437	45	8:00 am – 6:00 pm		Poster
438	46	8:00 am – 6:00 pm		Poster
439	47	8:00 am – 6:00 pm		Poster
440	48	8:00 am – 6:00 pm		Poster
441	49	8:00 am – 6:00 pm		Poster
442	50	8:00 am – 6:00 pm		Poster
443	51	8:00 am – 6:00 pm		Poster
444	52	8:00 am – 6:00 pm		Poster
445	53	8:00 am – 6:00 pm		Poster
446	54	8:00 am – 6:00 pm		Poster
447	55	8:00 am – 6:00 pm		Poster
448	56	8:00 am – 6:00 pm		Poster
449	57	8:00 am – 6:00 pm		Poster
Spotlight Session- Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG				
450	58	8:00 am – 6:00 pm		Poster
451	59	8:00 am – 6:00 pm		Poster
452	60	8:00 am – 6:00 pm		Poster
453	61	8:00 am – 6:00 pm		Poster
454	62	8:00 am – 6:00 pm		Poster
455	63	8:00 am – 6:00 pm		Poster
456	64	8:00 am – 6:00 pm		Poster
457	65	8:00 am – 6:00 pm		Poster
Comparative Effectiveness Research				
458	66	8:00 am – 6:00 pm		Poster
459	67	8:00 am – 6:00 pm		Poster
460	68	8:00 am – 6:00 pm		Poster
461	69	8:00 am – 6:00 pm		Poster
462	70	8:00 am – 6:00 pm		Poster
463	71	8:00 am – 6:00 pm		Poster
464	72	8:00 am – 6:00 pm		Poster
465	73	8:00 am – 6:00 pm		Poster
466	74	8:00 am – 6:00 pm		Poster
467	75	8:00 am – 6:00 pm		Poster
468	76	8:00 am – 6:00 pm		Poster
469	77	8:00 am – 6:00 pm		Poster

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SUNDAY, OCTOBER 26 CONTINUED				
470	78	8:00 am – 6:00 pm		Poster
471	79	8:00 am – 6:00 pm		Poster
472	80	8:00 am – 6:00 pm		Poster
473	81	8:00 am – 6:00 pm		Poster
474	82	8:00 am – 6:00 pm		Poster
475	83	8:00 am – 6:00 pm		Poster
476	84	8:00 am – 6:00 pm		Poster
477	85	8:00 am – 6:00 pm		Poster
478	86	8:00 am – 6:00 pm		Poster
479	87	8:00 am – 6:00 pm		Poster
480	88	8:00 am – 6:00 pm		Poster
481	89	8:00 am – 6:00 pm		Poster
482	90	8:00 am – 6:00 pm		Poster
483	91	8:00 am – 6:00 pm		Poster
484	92	8:00 am – 6:00 pm		Poster
485	93	8:00 am – 6:00 pm		Poster
486	94	8:00 am – 6:00 pm		Poster
487	95	8:00 am – 6:00 pm		Poster
488	96	8:00 am – 6:00 pm		Poster
489	97	8:00 am – 6:00 pm		Poster
490	98	8:00 am – 6:00 pm		Poster
491	99	8:00 am – 6:00 pm		Poster
492	100	8:00 am – 6:00 pm		Poster
493	101	8:00 am – 6:00 pm		Poster
494	102	8:00 am – 6:00 pm		Poster
495	103	8:00 am – 6:00 pm		Poster
Spotlight Session- Comparative Effectiveness Research (CER) SIG				
496	104	8:00 am – 6:00 pm		Poster
497	105	8:00 am – 6:00 pm		Poster
498	106	8:00 am – 6:00 pm		Poster
499	107	8:00 am – 6:00 pm		Poster
500	108	8:00 am – 6:00 pm		Poster
501	109	8:00 am – 6:00 pm		Poster
502	110	8:00 am – 6:00 pm		Poster
503	111	8:00 am – 6:00 pm		Poster
Classical Pharmacoepidemiology				
504	112	8:00 am – 6:00 pm		Poster
505	113	8:00 am – 6:00 pm		Poster
506	114	8:00 am – 6:00 pm		Poster
507	115	8:00 am – 6:00 pm		Poster
508	116	8:00 am – 6:00 pm		Poster
509	117	8:00 am – 6:00 pm		Poster
510	118	8:00 am – 6:00 pm		Poster
511	119	8:00 am – 6:00 pm		Poster
512	120	8:00 am – 6:00 pm		Poster
513	121	8:00 am – 6:00 pm		Poster
514	122	8:00 am – 6:00 pm		Poster
515	123	8:00 am – 6:00 pm		Poster
516	124	8:00 am – 6:00 pm		Poster
517	125	8:00 am – 6:00 pm		Poster
518	126	8:00 am – 6:00 pm		Poster
519	127	8:00 am – 6:00 pm		Poster
520	128	8:00 am – 6:00 pm		Poster
521	129	8:00 am – 6:00 pm		Poster
522	130	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
523	131	8:00 am – 6:00 pm		Poster
524	132	8:00 am – 6:00 pm		Poster
525	133	8:00 am – 6:00 pm		Poster
526	134	8:00 am – 6:00 pm		Poster
527	135	8:00 am – 6:00 pm		Poster
528	136	8:00 am – 6:00 pm		Poster
529	137	8:00 am – 6:00 pm		Poster
Pharmacovigilance				
530	138	8:00 am – 6:00 pm		Poster
531	139	8:00 am – 6:00 pm		Poster
532	140	8:00 am – 6:00 pm		Poster
533	141	8:00 am – 6:00 pm		Poster
534	142	8:00 am – 6:00 pm		Poster
535	143	8:00 am – 6:00 pm		Poster
536	144	8:00 am – 6:00 pm		Poster
537	145	8:00 am – 6:00 pm		Poster
538	146	8:00 am – 6:00 pm		Poster
539	147	8:00 am – 6:00 pm		Poster
540	148	8:00 am – 6:00 pm		Poster
541	149	8:00 am – 6:00 pm		Poster
542	150	8:00 am – 6:00 pm		Poster
543	151	8:00 am – 6:00 pm		Poster
544	152	8:00 am – 6:00 pm		Poster
545	153	8:00 am – 6:00 pm		Poster
546	154	8:00 am – 6:00 pm		Poster
547	155	8:00 am – 6:00 pm		Poster
548	156	8:00 am – 6:00 pm		Poster
549	157	8:00 am – 6:00 pm		Poster
550	158	8:00 am – 6:00 pm		Poster
551	159	8:00 am – 6:00 pm		Poster
552	160	8:00 am – 6:00 pm		Poster
553	161	8:00 am – 6:00 pm		Poster
554	162	8:00 am – 6:00 pm		Poster
555	163	8:00 am – 6:00 pm		Poster
556	164	8:00 am – 6:00 pm		Poster
557	165	8:00 am – 6:00 pm		Poster
558	166	8:00 am – 6:00 pm		Poster
559	167	8:00 am – 6:00 pm		Poster
560	168	8:00 am – 6:00 pm		Poster
Risk Management / Risk Minimization/Communication				
561	169	8:00 am – 6:00 pm		Poster
562	170	8:00 am – 6:00 pm		Poster
563	171	8:00 am – 6:00 pm		Poster
564	172	8:00 am – 6:00 pm		Poster
565	173	8:00 am – 6:00 pm		Poster
566	174	8:00 am – 6:00 pm		Poster
567	175	8:00 am – 6:00 pm		Poster
568	176	8:00 am – 6:00 pm		Poster
569	177	8:00 am – 6:00 pm		Poster
570	178	8:00 am – 6:00 pm		Poster
571	179	8:00 am – 6:00 pm		Poster
572	180	8:00 am – 6:00 pm		Poster
Spotlight Session- Pregnancy SIG				
573	181	8:00 am – 6:00 pm		Poster
574	182	8:00 am – 6:00 pm		Poster
575	183	8:00 am – 6:00 pm		Poster

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
SUNDAY, OCTOBER 26 CONTINUED				
576	184	8:00 am – 6:00 pm		Poster
577	185	8:00 am – 6:00 pm		Poster
578	186	8:00 am – 6:00 pm		Poster
579	187	8:00 am – 6:00 pm		Poster
580	188	8:00 am – 6:00 pm		Poster
Medications in Pregnancy and Lactation				
581	189	8:00 am – 6:00 pm		Poster
582	190	8:00 am – 6:00 pm		Poster
583	191	8:00 am – 6:00 pm		Poster
585	193	8:00 am – 6:00 pm		Poster
586	194	8:00 am – 6:00 pm		Poster
587	195	8:00 am – 6:00 pm		Poster
588	196	8:00 am – 6:00 pm		Poster
589	197	8:00 am – 6:00 pm		Poster
590	198	8:00 am – 6:00 pm		Poster
591	199	8:00 am – 6:00 pm		Poster
592	200	8:00 am – 6:00 pm		Poster
593	201	8:00 am – 6:00 pm		Poster
594	202	8:00 am – 6:00 pm		Poster
595	203	8:00 am – 6:00 pm		Poster
925	204	8:00 am – 6:00 pm		Poster

MONDAY, OCTOBER 27				
Kids Up and Down and All Around				
596		8:30 am	103	Oral
597		8:45 am	103	Oral
598		9:00 am	103	Oral
599		9:15 am	103	Oral
600		9:30 am	103	Oral
601		9:45 am	103	Oral
On or Off Course				
602		8:30 am	201BC	Oral
603		8:45 am	201BC	Oral
604		9:00 am	201BC	Oral
605		9:15 am	201BC	Oral
606		9:30 am	201BC	Oral
607		9:45 am	201BC	Oral
Steroids With a Twist!				
608		8:30 am	201DE	Oral
609		8:45 am	201DE	Oral
610		9:00 am	201DE	Oral
611		9:15 am	201DE	Oral
612		9:30 am	201DE	Oral
613		9:45 am	201DE	Oral
Strings Making Sense (SMS) Harvesting Data				
614		8:30 am	201AF	Oral
615		8:45 am	201AF	Oral
616		9:00 am	201AF	Oral
617		9:15 am	201AF	Oral
618		9:30 am	201AF	Oral
619		9:45 am	201AF	Oral

Abstract #	Poster #	Presentation Time	Room	Format
Translating Policy into Practice				
620		8:30 am	102	Oral
621		8:45 am	102	Oral
622		9:00 am	102	Oral
623		9:15 am	102	Oral
624		9:30 am	102	Oral
625		9:45 am	102	Oral
Treatment of Diabetes: Is It Safe Enough?				
626		8:30 am	4 th Floor VIP	Oral
627		8:45 am	4 th Floor VIP	Oral
628		9:00 am	4 th Floor VIP	Oral
629		9:15 am	4 th Floor VIP	Oral
630		9:30 am	4 th Floor VIP	Oral
631		9:45 am	4 th Floor VIP	Oral
Comparative and Clinical Effectiveness Studies Based on Taiwan National Health Insurance Research Database				
632		10:30 am - Noon	201BC	Symposia
Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharmacoepidemiology (PE) Studies				
633		10:30 am - Noon	402	Symposia
Drugs and Devices: Challenges and Opportunities for the Evaluation of Combination Medical Products				
634		10:30 am - Noon	201DE	Symposia
HOT, HOT, HOT and Getting HOTTER? – Climate Change and Pharmacoepidemiology				
635		10:30 am - Noon	102	Symposia
How Do We Overcome Challenges of Diverse Views in Multi-Disiplinary Collaboration on CER?				
636		10:30 am - Noon	4 th Floor VIP	Symposia
Improving the Science of Regulatory Decision-Making – Advances in 2013/2014				
637		10:30 am - Noon	201AF	Symposia
International Collaboration on Pharmacogenomics in Epidemiology Research				
638		10:30 am - Noon	103	Symposia
From Epilepsy to Dementia				
639		1:30 pm	201BC	Oral
640		1:45 pm	201BC	Oral
641		2:00 pm	201BC	Oral
642		2:15 pm	201BC	Oral
643		2:30 pm	201BC	Oral
644		2:45 pm	201BC	Oral
Gain on Pain				
645		1:30 pm	201AF	Oral
685		1:45 pm	201AF	Oral
647		2:00 pm	201AF	Oral
648		2:15 pm	201AF	Oral
649		2:30 pm	201AF	Oral
650		2:45 pm	201AF	Oral
Probably a Good Link				
651		1:30 pm	201DE	Oral
652		1:45 pm	201DE	Oral
653		2:00 pm	201DE	Oral
654		2:15 pm	201DE	Oral
655		2:30 pm	201DE	Oral
656		2:45 PM	201DE	Oral

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, OCTOBER 27 CONTINUED				
The Answer is Not Clear				
657		1:30 PM	4 th Floor VIP	Oral
658		1:45 PM	4 th Floor VIP	Oral
659		2:00 PM	4 th Floor VIP	Oral
660		2:15 PM	4 th Floor VIP	Oral
661		2:30 PM	4 th Floor VIP	Oral
662		2:45 PM	4 th Floor VIP	Oral
World War V: Vaccines and Viruses				
663		1:30 PM	102	Oral
664		1:45 PM	102	Oral
665		2:00 PM	102	Oral
666		2:15 PM	102	Oral
667		2:30 PM	102	Oral
668		2:45 PM	102	Oral
For Better or for Worse				
669		1:30 PM	103	Oral
670		1:45 PM	103	Oral
671		2:00 PM	103	Oral
672		2:15 PM	103	Oral
673		2:30 PM	103	Oral
674		2:45 PM	103	Oral
Common Data Model vs. Common Protocol – Can We Identify Gold Standards for Multi-Database Drug Effect Studies?				
675		4:30 - 6:00 pm	201DE	Symposia
Comparisons in Pharmacoepidemiology: New Challenges and Limitations of Current Approaches				
676		4:30 - 6:00 pm	4 th Floor VIP	Symposia
How to Bridge the Gap between Requirements of Regulatory and Health Technology Assessment Authorities for Post Authorization Studies? Examples from Europe and Asia				
677		4:30 - 6:00 pm	103	Symposia
Multi-National Pharmacoepidemiological Studies in Asia – Methodological Challenges and Potential Cross-Continental Collaboration				
678		4:30 - 6:00 pm	201BC	Symposia
Special Issues in Pharmacovigilance in Emerging Countries				
679		4:30 - 6:00 pm	402	Symposia
The Patient's Voice in the Heart of BRACE (Benefit-Risk Assessment, Communication and Evaluation)				
680		4:30 - 6:00 pm	201AF	Symposia
Using Pharmaceutical Data for Evaluating Medicines Policy and Informing Quality Use of Medicines				
681		4:30 - 6:00 pm	102	Symposia
POSTER SESSION C				
Top 8 Abstracts (Day 3) Spotlight Session				
682	1	8:00 am – 6:00 pm		Poster
683	2	8:00 am – 6:00 pm		Poster
684	3	8:00 am – 6:00 pm		Poster
686	5	8:00 am – 6:00 pm		Poster
687	6	8:00 am – 6:00 pm		Poster
688	7	8:00 am – 6:00 pm		Poster
689	8	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Database				
690	9	8:00 am – 6:00 pm		Poster
691	10	8:00 am – 6:00 pm		Poster
692	11	8:00 am – 6:00 pm		Poster
693	12	8:00 am – 6:00 pm		Poster
694	13	8:00 am – 6:00 pm		Poster
695	14	8:00 am – 6:00 pm		Poster
696	15	8:00 am – 6:00 pm		Poster
697	16	8:00 am – 6:00 pm		Poster
698	17	8:00 am – 6:00 pm		Poster
699	18	8:00 am – 6:00 pm		Poster
700	19	8:00 am – 6:00 pm		Poster
701	20	8:00 am – 6:00 pm		Poster
702	21	8:00 am – 6:00 pm		Poster
703	22	8:00 am – 6:00 pm		Poster
704	23	8:00 am – 6:00 pm		Poster
705	24	8:00 am – 6:00 pm		Poster
706	25	8:00 am – 6:00 pm		Poster
707	26	8:00 am – 6:00 pm		Poster
708	27	8:00 am – 6:00 pm		Poster
709	28	8:00 am – 6:00 pm		Poster
710	29	8:00 am – 6:00 pm		Poster
711	30	8:00 am – 6:00 pm		Poster
712	31	8:00 am – 6:00 pm		Poster
713	32	8:00 am – 6:00 pm		Poster
714	33	8:00 am – 6:00 pm		Poster
715	34	8:00 am – 6:00 pm		Poster
716	35	8:00 am – 6:00 pm		Poster
717	36	8:00 am – 6:00 pm		Poster
718	37	8:00 am – 6:00 pm		Poster
719	38	8:00 am – 6:00 pm		Poster
720	39	8:00 am – 6:00 pm		Poster
721	40	8:00 am – 6:00 pm		Poster
722	41	8:00 am – 6:00 pm		Poster
723	42	8:00 am – 6:00 pm		Poster
724	43	8:00 am – 6:00 pm		Poster
725	44	8:00 am – 6:00 pm		Poster
726	45	8:00 am – 6:00 pm		Poster
727	46	8:00 am – 6:00 pm		Poster
728	47	8:00 am – 6:00 pm		Poster
729	48	8:00 am – 6:00 pm		Poster
730	49	8:00 am – 6:00 pm		Poster
731	50	8:00 am – 6:00 pm		Poster
732	51	8:00 am – 6:00 pm		Poster
733	52	8:00 am – 6:00 pm		Poster
734	53	8:00 am – 6:00 pm		Poster
735	54	8:00 am – 6:00 pm		Poster
736	55	8:00 am – 6:00 pm		Poster
737	56	8:00 am – 6:00 pm		Poster
738	57	8:00 am – 6:00 pm		Poster
739	58	8:00 am – 6:00 pm		Poster
740	59	8:00 am – 6:00 pm		Poster
741	60	8:00 am – 6:00 pm		Poster
742	61	8:00 am – 6:00 pm		Poster
743	62	8:00 am – 6:00 pm		Poster
744	63	8:00 am – 6:00 pm		Poster
745	64	8:00 am – 6:00 pm		Poster

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, OCTOBER 27 CONTINUED				
746	65	8:00 am – 6:00 pm		Poster
747	66	8:00 am – 6:00 pm		Poster
748	67	8:00 am – 6:00 pm		Poster
749	68	8:00 am – 6:00 pm		Poster
750	69	8:00 am – 6:00 pm		Poster
751	70	8:00 am – 6:00 pm		Poster
752	71	8:00 am – 6:00 pm		Poster
753	72	8:00 am – 6:00 pm		Poster
754	73	8:00 am – 6:00 pm		Poster
755	74	8:00 am – 6:00 pm		Poster
756	75	8:00 am – 6:00 pm		Poster
757	76	8:00 am – 6:00 pm		Poster
758	77	8:00 am – 6:00 pm		Poster
759	78	8:00 am – 6:00 pm		Poster
760	79	8:00 am – 6:00 pm		Poster
761	80	8:00 am – 6:00 pm		Poster
762	81	8:00 am – 6:00 pm		Poster
763	82	8:00 am – 6:00 pm		Poster
764	83	8:00 am – 6:00 pm		Poster
765	84	8:00 am – 6:00 pm		Poster
766	85	8:00 am – 6:00 pm		Poster
767	86	8:00 am – 6:00 pm		Poster
768	87	8:00 am – 6:00 pm		Poster
769	88	8:00 am – 6:00 pm		Poster
770	89	8:00 am – 6:00 pm		Poster
771	90	8:00 am – 6:00 pm		Poster
772	91	8:00 am – 6:00 pm		Poster
773	92	8:00 am – 6:00 pm		Poster
774	93	8:00 am – 6:00 pm		Poster
775	94	8:00 am – 6:00 pm		Poster
Spotlight Session- Database SIG				
776	95	8:00 am – 6:00 pm		Poster
778	97	8:00 am – 6:00 pm		Poster
779	98	8:00 am – 6:00 pm		Poster
780	99	8:00 am – 6:00 pm		Poster
781	100	8:00 am – 6:00 pm		Poster
782	101	8:00 am – 6:00 pm		Poster
783	102	8:00 am – 6:00 pm		Poster
Measurement/Validation Studies				
784	103	8:00 am – 6:00 pm		Poster
785	104	8:00 am – 6:00 pm		Poster
786	105	8:00 am – 6:00 pm		Poster
787	106	8:00 am – 6:00 pm		Poster
788	107	8:00 am – 6:00 pm		Poster
789	108	8:00 am – 6:00 pm		Poster
790	109	8:00 am – 6:00 pm		Poster
791	110	8:00 am – 6:00 pm		Poster
792	111	8:00 am – 6:00 pm		Poster
793	112	8:00 am – 6:00 pm		Poster
794	113	8:00 am – 6:00 pm		Poster
795	114	8:00 am – 6:00 pm		Poster
Methods Potpourri				
796	115	8:00 am – 6:00 pm		Poster
797	116	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format	
798	117	8:00 am – 6:00 pm		Poster	
799	118	8:00 am – 6:00 pm		Poster	
800	119	8:00 am – 6:00 pm		Poster	
801	120	8:00 am – 6:00 pm		Poster	
802	121	8:00 am – 6:00 pm		Poster	
803	122	8:00 am – 6:00 pm		Poster	
804	123	8:00 am – 6:00 pm		Poster	
805	124	8:00 am – 6:00 pm		Poster	
Pharmacoepidemiology in Asia					
806	125	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>		
807	126	8:00 am – 6:00 pm		Poster	
808	127	8:00 am – 6:00 pm		Poster	
809	128	8:00 am – 6:00 pm		Poster	
810	129	8:00 am – 6:00 pm		Poster	
811	130	8:00 am – 6:00 pm		Poster	
812	131	8:00 am – 6:00 pm		Poster	
813	132	8:00 am – 6:00 pm		Poster	
814	133	8:00 am – 6:00 pm		Poster	
815	134	8:00 am – 6:00 pm		Poster	
816	135	8:00 am – 6:00 pm		Poster	
817	136	8:00 am – 6:00 pm		Poster	
818	137	8:00 am – 6:00 pm		Poster	
Spotlight Session- Asian Pharmacoepidemiology Network (AsPEN) SIG					
820	139	8:00 am – 6:00 pm			Poster
821	140	8:00 am – 6:00 pm		Poster	
822	141	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>		
823	142	8:00 am – 6:00 pm		Poster	
824	143	8:00 am – 6:00 pm		Poster	
825	144	8:00 am – 6:00 pm		Poster	
826	145	8:00 am – 6:00 pm		Poster	
827	146	8:00 am – 6:00 pm		Poster	
Cardiovascular Outcome					
828	147	8:00 am – 6:00 pm			Poster
829	148	8:00 am – 6:00 pm			Poster
830	149	8:00 am – 6:00 pm			Poster
831	150	8:00 am – 6:00 pm		Poster	
832	151	8:00 am – 6:00 pm		Poster	
833	152	8:00 am – 6:00 pm		Poster	
834	153	8:00 am – 6:00 pm		Poster	
836	155	8:00 am – 6:00 pm		Poster	
837	156	8:00 am – 6:00 pm		Poster	
838	157	8:00 am – 6:00 pm		Poster	
839	158	8:00 am – 6:00 pm		Poster	
840	159	8:00 am – 6:00 pm		Poster	
841	160	8:00 am – 6:00 pm		Poster	
842	161	8:00 am – 6:00 pm		Poster	
843	162	8:00 am – 6:00 pm		Poster	
844	163	8:00 am – 6:00 pm		Poster	
845	164	8:00 am – 6:00 pm		Poster	
846	165	8:00 am – 6:00 pm		Poster	
847	166	8:00 am – 6:00 pm		Poster	
848	167	8:00 am – 6:00 pm		Poster	
849	168	8:00 am – 6:00 pm		Poster	

30th ICPE Abstract Index

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, OCTOBER 27 CONTINUED				
Cardiovascular Therapeutics				
850	169	8:00 am – 6:00 pm		Poster
851	170	8:00 am – 6:00 pm		Poster
852	171	8:00 am – 6:00 pm		Poster
853	172	8:00 am – 6:00 pm		Poster
854	173	8:00 am – 6:00 pm		Poster
855	174	8:00 am – 6:00 pm		Poster
856	175	8:00 am – 6:00 pm		Poster
857	176	8:00 am – 6:00 pm		Poster
858	177	8:00 am – 6:00 pm		Poster
859	178	8:00 am – 6:00 pm		Poster
860	179	8:00 am – 6:00 pm		Poster
861	180	8:00 am – 6:00 pm		Poster
862	181	8:00 am – 6:00 pm		Poster
863	182	8:00 am – 6:00 pm		Poster
864	183	8:00 am – 6:00 pm		Poster
Biologics				
865	184	8:00 am – 6:00 pm		Poster
866	185	8:00 am – 6:00 pm		Poster
867	186	8:00 am – 6:00 pm		Poster
868	187	8:00 am – 6:00 pm		Poster
Spotlight Session-Biologics SIG				
869	188	8:00 am – 6:00 pm		Poster
870	189	8:00 am – 6:00 pm		Poster
871	190	8:00 am – 6:00 pm		Poster
872	191	8:00 am – 6:00 pm		Poster
873	192	8:00 am – 6:00 pm		Poster
874	193	8:00 am – 6:00 pm		Poster
875	194	8:00 am – 6:00 pm		Poster
876	195	8:00 am – 6:00 pm		Poster
Potpourri				
877	196	8:00 am – 6:00 pm		Poster
878	197	8:00 am – 6:00 pm		Poster
879	198	8:00 am – 6:00 pm		Poster
880	199	8:00 am – 6:00 pm		Poster
881	200	8:00 am – 6:00 pm		Poster
882	201	8:00 am – 6:00 pm		Poster
883	202	8:00 am – 6:00 pm		Poster
884	203	8:00 am – 6:00 pm		Poster
885	204	8:00 am – 6:00 pm		Poster
886	205	8:00 am – 6:00 pm		Poster
887	206	8:00 am – 6:00 pm		Poster
888	207	8:00 am – 6:00 pm		Poster
889	208	8:00 am – 6:00 pm		Poster
890	209	8:00 am – 6:00 pm		Poster
891	210	8:00 am – 6:00 pm		Poster
892	211	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Devices				
893	212	8:00 am – 6:00 pm		Poster
894	213	8:00 am – 6:00 pm		Poster
895	214	8:00 am – 6:00 pm		Poster
896	215	8:00 am – 6:00 pm		Poster
897	216	8:00 am – 6:00 pm		Poster
898	217	8:00 am – 6:00 pm		Poster
899	218	8:00 am – 6:00 pm		Poster
900	219	8:00 am – 6:00 pm		Poster
901	220	8:00 am – 6:00 pm		Poster
902	221	8:00 am – 6:00 pm		Poster
Spotlight Session- Device SIG				
903	222	8:00 am – 6:00 pm		Poster
904	223	8:00 am – 6:00 pm		Poster
905	224	8:00 am – 6:00 pm		Poster
906	225	8:00 am – 6:00 pm		Poster
907	226	8:00 am – 6:00 pm		Poster
908	227	8:00 am – 6:00 pm		Poster
909	228	8:00 am – 6:00 pm		Poster
910	229	8:00 am – 6:00 pm		Poster
Late Breaking				
911	230	8:00 am – 6:00 pm		Poster
912	231	8:00 am – 6:00 pm	Abstract Withdrawn by Author	
913	232	8:00 am – 6:00 pm		Poster
914	233	8:00 am – 6:00 pm	Abstract Withdrawn by Author	
915	234	8:00 am – 6:00 pm		Poster
916	235	8:00 am – 6:00 pm		Poster
917	236	8:00 am – 6:00 pm		Poster
918	237	8:00 am – 6:00 pm		Poster
919	238	8:00 am – 6:00 pm		Poster
920	239	8:00 am – 6:00 pm		Poster
921	240	8:00 am – 6:00 pm		Poster
922	241	8:00 am – 6:00 pm		Poster
923	242	8:00 am – 6:00 pm		Poster
924	243	8:00 am – 6:00 pm		Poster

Official Journal of the International Society for Pharmacoepidemiology

Editor-In-Chief: Professor Brian L. Strom, FISPE

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

* Free online access for ISPE members via the society website

Congratulations to The Ronald D. Mann Best Article of 2013 Awards Winners



Best paper:

Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control

Adriana M. Hung, Christianne L. Roumie, Robert A. Greevy, Xulei Liu, Carlos G. Grijalva, Harvey J. Murff and Marie R. Griffin Volume 22, Issue 6, June 2013, Pages: 623–631

Honorable mention:

Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years

Shahed Iqbal, John P. Barile, William W. Thompson and Frank DeStefano Volume 22, Issue 12, December 2013, Pages: 1263–1270

Honorable mention:

Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study

Carlos Iribarren, Alfred D. Round, Jonathan A. Peng, Meng Lu, Jonathan G. Zaroff, Taylor J. Holve, Amit Prasad and Paul Stang Volume 22, Issue 11, November 2013, Pages: 1222–1232

Honorable mention:

Use of case–time–control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly

Sylvie D. Price, C. D'Arcy J. Holman, Frank M. Sanfilippo and Jon D. Emery Volume 22, Issue 11, November 2013, Pages: 1159–1170

For more information on these top papers and other journal features, please visit

www.pdsjournal.org

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2014 Volume: 23 • Frequency: Monthly

WILEY


TICC 1F Floor Plan




TICC 2F Floor Plan



TICC 3F Floor Plan



TICC 4F Floor Plan



ACCESS ICPE ABSTRACTS ON
YOUR MOBILE DEVICE




www.abstracts2view.com/ispe

- Online only Abstract Supplement
- Free WiFi is provided for you to access this tool

Join the conversation
#ICPEtaipei

30th Final Program ICPE

INTERNATIONAL CONFERENCE ON
PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT



OCT 24-27, 2014

TAIPEI INTERNATIONAL CONVENTION CENTER
TAIPEI, TAIWAN

Jointly Sponsored by:



International Society for
Pharmacoepidemiology



Institute of Clinical Pharmacy &
Pharmaceutical Sciences, National
Cheng Kung University



National Taiwan University